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Abstract 
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia 
in the Western world, characterised by the accumulation of mature B-cells. 
The disease has a heterogeneous course whereby some patients do not 
require treatment for several years while others follow a more aggressive 
disease progression and require early therapeutic action.  Although several 
prognostic markers have been described, it is still difficult to predict the 
prognosis of the disease at diagnosis or to explain the diversity associated 
with the disease. The goal of this thesis was therefore, to characterise the 
genomic complexity and molecular drivers of clonal expansion and 
maintenance of CLL using targeted next generation sequencing (NGS) and 
high resolution single nucleotide polymorphism (SNP) array.   
 
NGS analysis of the immunoglobulin variable heavy-chain (IgHV) in 497 pre-
treatment CLL patients found IgHV subclones in 18.5%, far higher than 
previously reported. SNP array analysis in 411 CLL patients refined the 
minimally overlapping regions (MOR) on del(6q) to the ATG5 and PRDM1 
genes. Further autophagy related genes were also found to be present in 
other MORs. Analysis of the autophagy pathway at the protein level 
showed higher autophagy activity in primary CLL cells compared with age-
matched controls. 
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NGS-IgHV enabled the existing Sanger-sequencing based prognostic system 
to be refined. Correlation to the clinical outcome data showed that this 
new classification was prognostically significant. Furthermore, the 
identification of IgHV subclones imply that the leukaemia initiating event in 
CLL takes place prior to recombination. Concurrently, the detection of 
altered autophagy levels suggests a role for autophagy in CLL. Collectively 
these data provide new insights into the pathogenesis of CLL. 
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Chapter 1  Introduction 
 
1.1 Chronic Lymphocytic Leukaemia 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the 
UK. There are over 3400 new diagnoses every year representing around 
38% of all leukaemias and 1% of total cancer. CLL incidence is strongly 
associated with age since over 70% of new diagnoses occur in the 65 years 
and over age-group. Males are more likely to develop the disease, having 
an incidence rate of 4.9 per 100,000 versus 2.6 in females (Cancer Research 
UK 2016a). Of interest, CLL is more common in those of a white racial 
background, particularly in comparison to Asian populations where CLL 
accounts for less than 10% of all leukaemias (Dores et al 2007), although 
this may also be due to a decrease in early diagnoses in these populations 
(Gross et al 2008, Yang et al 2015). 
 
CLL is a haematological malignancy affecting B lymphocytes, a type of 
white blood cell. The CLL cells have increased proliferation as well as a 
decreased apoptosis rate, leading to their accumulation in the blood and 
bone marrow. Patients are typically asymptomatic at diagnosis, the disease 
having been detected through a routine full blood count showing a high 
white cell count, although some patients may present with anaemia, 
abnormal bleeding or suffer from infection due to the abnormal CLL cells 
2 
 
overwhelming the normal blood cells, preventing them from functioning 
normally. 
 
Table 1.1. Staging systems in CLL. Adapted from Rai et al. (1975) and Binet et al. (1981). 
Stage Features Median 
Survival (yrs) 
Binet et al (1981) 
A Involvement with <3 lymphoid areas >10 
B Involvement with ≥3 lymphoid areas 5 
C Haemoglobin < 100g/l and/or platelet count < 
100 x 109/l 
2 
Rai et al (1975) 
0 Lymphocyte count > 15 x 109/l 12 
I Lymphadenopathy 9 
II Lymphocyte count > 15 x 109/l with 
splenomegaly or hepatomegaly 
7 
III Haemoglobin < 110 g/l 1-2 
IV Platelet count < 100 x 109/l 1-2 
 
Currently there is no cure for CLL aside from a haematopoietic stem cell 
transplantation which is not usually suitable for those over 65 years of age. 
The disease has a very heterogeneous course whereby some patients have 
a life expectancy comparable to the general population (Parikh et al 2014, 
Rossi, Rasi, et al 2013) whereas others follow a more aggressive disease 
progression requiring early therapeutic action. Consequently, there is great 
diversity in the survival time with advanced stage (Binet stage C) patients 
having an overall survival (OS) of 1-3 years whilst Binet stage A patients 
have an OS of over 10 years (Table 1.1) (Binet et al 1981, Rai et al 1975, 
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Zenz et al 2010). For some patients their disease will transform to an 
aggressive lymphoma know as Richter syndrome (RS) which has a median 
overall survival (OS) of only 8-19 months (Eyre et al 2016, Rossi et al 2011). 
 
Patients are not treated until they display symptoms (CLL Trialists’ 
Collaborative Group 1999), therefore most patients remain untreated for 
several years with 30% never requiring therapeutic intervention (Bachow 
and Lamanna 2016). Once symptoms develop, patients are assessed for 
fitness based on their age, existing co-morbidities and susceptibility to 
infection. Patients deemed fit are treated with the chemo-immunotherapy 
regime of fludarabine, cyclophosphamide and rituximab (FCR) (Oscier et al 
2012). Patients for whom this treatment is unsuitable are treated instead 
with chlorambucil with either ofatumumab or obinotuzumab (Goede et al 
2014, Hillmen et al 2015), or alternatively with bendamustine and 
rituximab (Gentile, Zirlik, et al 2016). However, most patients will 
eventually relapse and the disease follows a chronic relapsing pattern. 
 
1.2 B Lymphocytes 
B cell lymphocytes are a subset of white blood cells that form part of the 
adaptive immune system. Adaptive immunity is highly specific towards a 
certain pathogen in comparison to the innate immune response which 
provides a more generic response. In addition, the adaptive system can 
remember a pathogen and improve its response on each subsequent 
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encounter with the same pathogen, thereby providing life-long immunity. 
The adaptive immune system’s diverse specificity comes from genetic 
manipulation during the cells' development through V(D)J recombination 
and somatic hypermutation (SHM) (Murphy and Weaver 2016a).  
 
The principle function of the B-lymphocyte is to produce immunoglobulins 
(Ig). Ig are Y-shaped proteins (Figure 1.1) that recognise and bind to a 
distinct target called an antigen which can be a protein expressed on the 
cellular surface of the pathogen or a toxin that it produces. A site in the 
antigen, known as the epitope, binds to the tip of the Ig in a region called 
the paratope. Each B-lymphocyte produces a unique paratope which will 
only have specificity for a single epitope. There are five different types or 
classes of Ig, known as isotypes. The isotypes have different functions but 
express the same paratope as their parent B-cell. Membrane-bound Ig 
form part of the B-cell receptor (BCR) which triggers cell activation upon 
antigen binding (Murphy and Weaver 2016).  
 
1.2.1 VDJ Recombination 
The Ig is composed of two heavy chains (IgH) and two light chains (IgL). 
Each chain has a variable region at its N terminus and a constant region at 
its C terminus. The constant region controls for the class of the Ig whereas 
the variable region contains the paratope. The paratope is composed of 
three hypervariable regions known as the complementary determining 
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regions (CDR) held together by four relatively conserved framework 
regions (FR) (Figure 1.1). Although all three CDRs interact directly with the 
attacking antigen, the CDR3 has been shown to be the crucial factor for 
antigen specificity recognition (Xu and Davis 2000) . 
 
 
Figure 1.1 Immunoglobulin structure. Adapted from Hwang et al. (2014). 
 
The gene for the heavy chain is located on chromosome 14 and diversity of 
the variable region is coded for through the composition of three types of 
genes; the diverse (D), joining (J) and variable (V) regions. The light chain 
can be either an Ig kappa or Ig lambda genes for which are 
located on chromosomes 2 and 22, respectively, and are composed of a V 
and J gene. Together these genes can be rearranged to produce 2 x 106 
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different combinations (Figure 1.2). Additionally, modifications are 
introduced into the rearranged genes during the recombination process 
through the addition and removal of nucleotides. Diversity is further 
increased by SHM, a process of extremely high mutation rate that is at 
least 105 times greater than the normal rate of mutation.  
 
 
Figure 1.2. The IgH locus undergoes VDJ recombination during B-cell development. The D and J genes 
are rearranged first followed by the V gene. Adapted from Roth (2014). 
 
The site of recombination is demarcated by the recombination signal 
sequence (RSS) which is composed of a conserved heptamer and nonamer 
region separated by either a 12bp or 23bp spacer sequence.  
Recombination typically occurs between RSSs of different spacer lengths 
known as the 12/23 rule. Consequently, within the IgL, 
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have 23bp spacers whilst the Vκ and Jλ have 12bp spacers. Similarly, in the 
IgH the VH-gene and JH-gene segments both have spacers of 23bp whereas 
the DH-gene segment has a 12bp spacer on both sides (Ramsden et al 
1994). Therefore, following the 12/23 rule, the amalgamation of Vλ-Jλ, Vκ-
Jκ, DH-JH and VH-DH are permitted whilst the direct combination of the 
VH- and JH-genes are prevented.  
 
Recombination can occur using both deletional and inversional 
rearrangement (Figure 1.3). In the more common deletional 
recombination, both gene segments are in the same transcriptional 
orientation. The DNA forms a loop enabling the 12bp spacer and 23bp 
spacer to come into alignment. During this type of recombination, the loop 
containing the signalling ends is excised when the coding ends are joined 
together. Inversional rearrangement takes place less frequently and occurs 
when the segments are in opposing orientations. To get the spacers into 
the correct position, the DNA forms a coil. In this instance the signalling 
ends are also incorporated into the DNA strand. 
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Figure 1.3. VDJ recombination uses deletional or inversional rearrangement. The left side of the 
figure shows deletional recombination used when the gene segments are in the same transcriptional 
orientation. The DNA forms a loop which is excised. The right side shows inversional recombination 
used when the gene segments are in opposing transcriptional orientations. In this instance, the DNA 
forms a coil which is retained following recombination. Blue box – V-gene, orange box – D-gene, 
green box – J-gene, yellow triangle – 23bp RSS, purple triangle – 12bp RSS. Adapted from Murphy 
and Weaver (2016). 
 
 
The recombination activating gene (RAG) complex guides alignment of the 
opposing RSSs. This complex is comprised of a heterotetramer of the 
lymphocyte-specific proteins RAG1 and RAG2 (Lapkouski et al 2015), with a 
DNA-bending protein which can be either high mobility group box 1 or 2 
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(HMGB1 or 2) (Grundy et al 2009, Kim et al 2015). The RAG complex binds 
to the RSS sequence through the nonmer binding domain (NBD) on RAG1 
then recruits the opposing RSS into the complex (Jones and Gellert 2002) 
bringing the gene pairs together. The RAG complex then cuts a single 
strand of the DNA between the RSS and the coding region of the gene 
segment. A 3’OH group is generated by this cut which then undergoes 
transesterification with the opposing strand, thereby creating a hairpin 
loop on the coding ends. The ends are then repaired using the 
nonhomologous end joining (NHEJ) pathway. The repair proteins, Ku70 and 
Ku80, bind to both the signalling and coding ends and recruit the DNA-
dependant protein kinase catalytic subunit (DNA-PKcs) to the coding ends. 
The DNA-PKcs initiates the enzyme Artemis to randomly open the hairpin 
coding ends through hydrolysis of their phosphodiester bonds. The 
haphazard nature of this action has the potential to create overhanging 
ends which introduce further modifications through the addition of 
palindromic nucleotides (P) that are complementary to the overhanging 
end. Further alterations in the sequence can be made by the removal of 
nucleotides through exonuclease activity and through the insertion of non-
template nucleotides (N) by the template-independent DNA polymerase 
terminal deoxynucleotidyltransferase (TdT).  Finally, DNA ligase IV in 
combination with XRCC4 and the Cernunnos protein ligates the ends 
together (Figure 1.4) (Helmink and Sleckman 2012, Roth 2014, Schatz and 
Swanson 2011, Teng and Schatz 2015).  
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Figure 1.4. Process of V(D)J recombination. The RAG complex brings the gene pairs into alignment 
then cleaves the RSS leaving a hairpin loop. Ku70 and Ku80 recruit Artemis and DNA-PKcs to initiate 
random opening of the hairpin loops. P and/or N nucelotides are inserted, before the ends are ligated 
by DNA ligase IV. Blue box – V-gene, orange box – D-gene, green box – J-gene, yellow triangle – 23bp 
RSS, purple triangle – 12bp RSS, yellow box- newly inserted nucleotides, P- palindromic. N-non-
template, TdT- terminal deoxynucleotidyltransferase. Adapted from Murphy and Weaver (2016). 
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The rearranged DNA must code for a functioning protein, otherwise the cell 
will undergo apoptosis (Lam et al 1997). To be functional, the recombined 
DNA must be (1) in-frame; that is, in multiples of three, so as to be 
compatible with protein synthesis; (2) have no stop codons which would 
result in a truncated protein; (3) contain only functional genes - that is, 
they must not have base alterations in their splice sites, recombination 
signalling sites, regulatory elements or in conserved amino acids important 
for correct protein folding; and (4) the protein produced through 
recombination must be able to pair with the protein of the second chain to 
produce a complete Ig (Belessi 2009). Due to the imprecise nature of the 
junctional joining, it is estimated that only a third of recombination 
produces a functional rearrangement. Therefore, there is a high level of 
wastage in this process. It is possible for some cells to undergo receptor 
editing which enables a second V-gene to replace the one in the non-
functioning rearrangement. This is more common in the Igκ, but has also 
been described in the IgH and the Igλ (Luning Prak et al 2011). 
 
V(D)J recombination takes place during the development of the B-cell in an 
ordered fashion and allows for multiple attempts at producing a 
functioning protein. The IgH gene rearranges first during the pro-B cell 
phase. DJ recombination occurs on both alleles in the early pro-B cell 
followed by the joining of the V gene to one of the DJ in the late pro-B cell 
(Alt et al 1984). If the resulting rearrangement is productive, it feeds back 
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to prevent the appendage of the V-gene to the DJ on the second allele in a 
process called allelic exclusion. If the rearrangement is out-of-frame, then 
the second allele undergoes V recombination. Once a productive IgH 
rearrangement has been generated, the heavy chain is associated with a 
surrogate light chain to form a pre-BCR which is expressed on the cell 
surface. Expression of the pre-BCR triggers proliferation and facilitates 
differentiation to the pre-B cell. In the pre-B cell, the light chain undergoes 
VJ rearrangement (Hesslein and Schatz 2001, Melchers 2005), with the Igκ, 
typically undergoing recombination before the Igλ. This was first implicated 
by the κ:λ ratio of 3:1, that is commonly found in the human B-cell 
repertoire (Gorman et al 1996, Takeda et al 1996). Secondly, it has been 
shown that cells expressing Igλ often have had rearranged Igκ, whereas the 
Igλ has not undergone recombination in Igκ expressing cells. This is not 
always the case however as there are some instances whereby Igλ 
expressing cells have been found to have unrearranged Igκ genes (Berg et 
al 1990).  
 
Traditionally in genetics, allelic exclusion is monoallelic, in that only one 
allele is expressed whilst the other is silenced. In the Ig genes, in contrast, 
both Ig allele transcripts are expressed; therefore, allelic exclusion occurs 
through the generation of a non-functioning, unproductive or 
dysfunctional transcript on one allele. The stochastic model of allelic 
exclusion proposes that since the method of producing a functioning, 
13 
 
pairing-compatible rearrangement is so inefficient, it is highly improbable 
for the second allele to be able to replicate the process to produce a 
second functioning transcript. Nonetheless, the likelihood of dual 
expressing B-cell has been estimated to be as high as 20% based on this 
model (Wabl and Steinberg 1992). Studies using flow cytometry have 
demonstrated that in actuality this phenomenon occurs in less than 1 in 
10000 of B-cells (Barreto and Cumano 2000), suggesting that there must be 
some feedback regulating allelic exclusion.  
 
In the feedback inhibition model, the process of allelic exclusion occurs in 
response to the proliferation that is triggered when the pre-BCR is 
expressed on the cell surface. Proliferation is associated with increased 
signalling through the interleukin-7 receptor (Il-7R) pathway. The Il-7R 
pathway activates the signal transducer and activator of transcription 
(STAT)5 proteins whilst repressing the forkhead box protein O (FOXO) 
transcription factors. FOXO induces transcription of Rag1 and Rag2 (Amin 
and Schlissel 2008), whereas STAT5 repositions the Rag locus to the 
repressive nuclear environment of the pericentrometric heterochromatin 
(PCH). Therefore, the increase in activated STAT5 as well as a decrease in 
FOXO leads to decreased levels of RAG1 and RAG2 (Bertolino et al 2005, 
Johnson et al 2012). In addition, RAG2 is further reduced during the cell 
cycle since it is rapidly degraded during the G1 to S transition (Jiang et al 
2005, Lee and Desiderio 1999). 
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Allelic exclusion has also been shown to occur during recombination. The 
ataxia telangiectasia mutated (ATM) kinase is activated in response to DNA 
double-stranded breaks (DSB), such as those generated by the Rag 
complex.  This has been shown to prevent recombination from taking place 
on the second allele following Rag-mediated DNA cleavage on the first 
allele. ATM repositions the second un-cleaved allele to the PCH where it is 
inaccessible to the recombinase (Hewitt et al 2009). Indeed  mice deficient 
for ATM have been shown to have an increased frequency of bi-allelic B-
cells in their repertoire (Steinel et al 2013, 2014). 
 
In terms of antibody diversity, the capacity of a B-cell to produce multiple 
functioning antibodies may at first appear beneficial. However, this can 
lead to problems with tolerance, the system that prevents the production 
of autoreactive Ig. Indeed, in the autoimmune disease systemic lupus 
erythematous (SLE), a disorder whereby antibodies are targeted towards 
the patient’s own DNA and nucleoproteins, deficiencies have been 
reported in the kappa deleting element (KDE), whose function it is to 
remove unwanted Igκ rearrangements, leading to the dual expression of a 
functional Igκ and Igλ (Fraser et al 2015). 
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1.2.2 Somatic Hypermutation 
Following successful V(D)J recombination, the immature B-lymphocyte 
expresses the IgM on its cell surface as its BCR, and migrates to the 
germinal centres (GC) so that it may encounter a compatible antigen. The 
compatible antigen activates the B-cell through binding of the BCR. Once 
activated, the B-cell undergoes a process called somatic hypermutation 
(SHM) whereby multiple single point mutations are introduced to the V(D)J 
and its flanking DNA.  SHM occurs most commonly in the region coding for 
the CDRs of the Ig thereby affecting the strength of the interaction 
between the B-cell and the antigen (Wilson et al 1998). 
 
SHM is initiated by the activation induced deaminase (AID) enzyme in the 
first stage of a two-step process (Figure 1.5). The AID enzyme only acts on 
single stranded DNA; therefore, it is only functional on DNA that is actively 
being transcribed.  AID works by deaminating a cytidine to a uridine which 
creates a mismatch with the pairing guanidine as well as introducing a 
foreign nucleoside to the DNA strand. Replication of the strand at this 
stage leads to a transition mutation at this site. Alternatively, the uridine 
stimulates the second step of SHM through the initiation of the DNA repair 
pathways including the mismatch repair (MMR) and the base-excision 
repair (BER) pathways.  The BER pathway utilises uracil-DNA-glycosylase 
(UNG) to excise the uracil thereby creating an abasic site in the DNA. 
Provided there are no further modifications, the DNA polymerase Rev1 will 
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insert a deoxycytidine opposite this abasic site resulting in a C:G 
transversion (Nelson et al 1996, Prakash et al 2005). Another option is for 
the mismatch to be detected by the MSH2-MHS6 heterodimer from the 
MMR pathway. The mismatch and its bordering DNA are then removed by 
EXO1. The resulting patch is then filled in by the low fidelity polymerase 
the surrounding sequence  (Rada et al 2004). 
 
 
Figure 1.5. Mechanisms of somatic hypermutation. AID deaminases the cytosine to a uracil. a. the 
uracil is replicated to a thymidine. b. The uracil is excised by the UNG enzyme, then a cytosine 
incorporated in the opposite strand during replication. c. The surrounding DNA is excised by the EXO1 
enzyme, then repaired with the low fidelity Pol
(2006). 
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Another method of repairing the error is through a process called gene 
conversion. In this instance, following excision of the uracil by Uracil-DNA 
glycosylase (UNG), the surrounding DNA is also removed by the enzyme 
apurinic/apyrimidinic endonuclease 1 (APE1). The resulting gap is then 
repaired using the neighbouring genes as templates. While gene 
conversion is a common mechanism of diversification in birds, it is not 
thought to be used in humans. However, there is some evidence that it 
may have role in receptor editing (Darlow and Stott 2006), a process that 
initiates a secondary rearrangement in a functioning rearranged V(D)J in 
order to remove an autoreactive BCR (Luning Prak et al 2011).  
 
1.3 The IgH in CLL 
CLL is a neoplasm affecting B-lymphocytes, resulting in the increase of 
mature B-cells. Since these are cells that have left the bone marrow, their 
IgH locus would have undergone differentiation. Additionally, as a cancer is 
the uncontrolled growth of clonal cell, and as each B cell expresses a single 
IgH rearrangement, the IgH locus could act as a clonal marker of CLL. Initial 
analysis of the IgH locus in CLL led to the assumption that CLL cells were 
antigen naïve as early studies only demonstrated germline IgHV sequences 
(Kipps et al. 1989). However, a literature review in the early 90’s of VDJ 
transcripts in CLL found that 39 of 75 VH sequences differed significantly 
from the germline indicating that these cells had undergone SHM 
(Schroeder & Dighiero 1994).  
18 
 
1.3.1 IgHV Mutational Status 
The finding that some patients with CLL had a mutated IgHV (Fais et al 
1998) fuelled further analysis of the region. This lead to the breakthrough 
discovery that IgHV mutation status was an important prognostic marker. 
Two studies independently identified that patients could be divided into 
two groups based on those whom had undergone SHM and those that had 
not. In both studies, an unmutated (UM) IgHV region, defined as greater 
than 98% homology to the germline sequence, was found to be associated 
with a worse prognosis than those found to be hypermutated (M), with the 
UM patients having a median survival of 9 years compared to over 17 years 
for the M patients (Damle et al 1999, Hamblin et al 1999). 
 
The 98% cut-off that is used to distinguish the UM and M groups is an 
arbitrary value chosen to take into account germline polymorphisms and 
possible sequencing error (Ghia et al 2007), thereby alleviating the need 
for germline sequencing of the IgHV. Therefore, caution should be used 
when interpreting borderline case as there are studies which suggest that 
the greater the level of mutation the better the prognosis (Tobin et al 
2005). Furthermore it has been shown that, in terms of prognosis, 97% is 
equivalent to 98% (Davis et al 2016), and a cut-off of 96% homology has 
been proposed as a better discriminating factor (Kröber et al 2002). 
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The distinction between the M and UM groups is reflected on a protein 
level with the two groups showing biological differences.  Patients with an 
UM IgHV have a higher expression of ZAP-70 (Crespo et al 2003, Rassenti et 
al 2004, Rosenwald et al 2001, Wiestner et al 2003), a protein tyrosine 
kinase involved in BCR signalling (Chen et al 2002).  The UM group have 
also been found to have higher levels of cells expressing CD38 (Damle et al 
1999, 2002, Kröber et al 2002, Matrai et al 2001), a cell surface marker that 
is detectable on immature B-cells, but lost once the cells have left the GC 
(Hamblin 2003). They also express high  levels of lipoprotein lipase (LPL) 
(Oppezzo et al 2008), beta-2-microglobulin (Oscier et al 2010) and serum 
thymidine kinase (Magnac et al 2003).  
 
Genetic differences have also been reported; telomeres are shorter in UM 
CLL compared with M CLL (Damle et al. 2003) and the two groups have 
been shown to have different gene expression profiles (Klein et al 2001, 
Rosenwald et al 2001). Furthermore, the groups are known to correlate 
with certain genomic abnormalities since genotypes associated with a 
poorer prognosis are more recurrently described in the UM subgroup, such 
as the poor prognosis cytogenetic abnormalities the 17q and 11p deletions 
(Section 1.4.2) (Kröber et al 2002). Additionally KRAS mutations have been 
found exclusively in UM-CLL (Herling et al 2016). 
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1.3.1.1 The IGHV3-21 Gene 
Even though the IgHV mutational status has been repeatedly 
demonstrated to correlate with prognosis (Kröber et al 2002, Oscier et al 
2010), there are exceptions, the most reported of which is found in 
patients expressing IGHV3-21. This has been reported as M and UM yet 
these patients are known to have an inferior survival (Lin et al 2003, Tobin 
et al 2002) as well as a shorter time to first treatment (TTFT) then M-CLL 
(Ghia et al 2008) regardless of their mutational status.  IGHV3-21-CLL share 
characteristics with UM-CLL, such as elevated expression of ZAP-70 and 
CD38 as well an increased incidence of poor prognostic cytogenetics 
(Kienle et al 2013, Thorselius et al 2006). It was speculated that these cases 
may in fact be UM-CLL that appeared mutated due to polymorphisms in 
the IGHV3-21 gene (Nollet et al 2002). However, this was not confirmed by 
germline analysis of M-IGHV3-21 cases, and further analysis of these 
mutations found that around half occurred in the hypermutation hotspots, 
suggesting they were caused by SHM (Tobin et al 2003). Furthermore, gene 
expression studies have shown that patients with IGHV3-21 
rearrangements have a distinct gene expression profile that differs from 
both M- and UM-CLL (Falt et al 2005, Kienle et al 2006). Interestingly, 
IGHV3-21 has an higher incidence in Northern Europe - of around 11% (Lin 
et al 2003, Tobin et al 2002, 2003) - compared to Southern Europe where it 
is found in around 3% of CLL cases (Ghia et al 2005). 
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1.3.2 Stereotyping 
Although B-cells can produce an extraordinary diverse catalogue of 
immunoglobulins, the repertoire identified in CLL cells has been found to 
be skewed with overrepresentation of selected heavy chain genes that are 
inconsistent with the repertoire in age-matched controls (Potter et al. 
2003; Fais et al. 1998). Over 35% of CLL cases express either IGHV1-69, 
IGHV4-34, IGHV3-7 or IGHV3-23 (Fais et al 1998, Murray et al 2008, 
Stamatopoulos et al 2005). Additionally, certain V-genes correlate with 
mutational status, since around a quarter of all UM-CLL express IGHV1-69, 
whereas the IGHV3-family are found in nearly 60% of M-CLL (Murray et al 
2008). This selection bias is also seen with the IgHJ, whereby IGHJ4 is 
overrepresented in M-CLL and IGHJ6 is more frequently reported in UM-
CLL (Stamatopoulos et al 2007). The IgL has also been shown to be biased 
in its usage in CLL and is frequently found to have the same mutation 
status as its heavy chain counterpart (Stamatopoulos et al 2005). 
 
Bias has also been reported in the V(D)J gene combinations. A large-scale 
study of 1220 patients with CLL noted that there was restricted use of the 
IgHJ and IgHD genes rearranged with some IgHV genes, leading to the 
creation of VH CDR3s with conserved amino acid sequences. In particular, 
1% of the cases analysed had an IGHV1-69/IGHD3-16/IGHJ3 
rearrangement. Furthermore, these cases also used the same IgLV gene, 
IgκV3-20 (also known as A27) (Widhopf et al 2004). Another study reported 
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a recurrent IGHV4-39/IGHD6-13/IGHJ5 rearrangement in a fifth of its 
cohort. As with the previous study, the cases all utilised the same IgLV gene 
- in this instance the IgκV1-39 (Ghiotto et al 2004). Restricted IgL usage has 
also been described in the IGHV3-21 rearrangement whereby the IGλV3-21 
(Vλ2-14) is reported in around 75% of cases (Ghia et al 2008, Thorselius et 
al 2006, Tobin et al 2003). These recurrent features all implied that there 
were similarities in the BCR in many unrelated cases of CLL.  
 
Analysis of the BCR sequence in 30 patients with a functional IGHV3-21 
rearrangement showed that 40% of them had homologous heavy chain 
variable region complementary determining region 3 (VH-CDR3) (Figure 
1.1). For seven of these patients, the amino acid sequence in the VH-CDR3 
was identical, and a further five differed by a single amino acid (Tobin et al 
2003). Another study of 255 patients identified five subsets of VH-CDR3 
sequences that had over 60% amino acid identity. The authors termed this 
phenomenon as stereotypy and were able to classify 8% of their cohort 
into one of these five subsets (Messmer et al 2004). Larger scale studies 
found that stereotyped VH-CDR3s were present in up to a third of CLL 
cases. Restricted Ig gene usage was a feature of stereotyped BCRs as non-
stereotyped had a more diverse Ig gene repertoire. This implies that these 
two classifications of CLL may have different ontogeny and may therefore 
have different features and potentially require different therapies 
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(Agathangelidis et al 2012, Darzentas et al 2009, Stamatopoulos et al 
2007).  
In the largest stereotyping study to date of over 7000 CLL cases, the 
authors revised the criteria for determining stereotypy in the BCR to make 
it more stringent. Additionally, since the different IgHV genes are known to 
originate from three ancestral clans (Kirkham et al 1992), stereotyped BCRs 
had to contain IgHV genes from the same clan since these have 
phylogenetically similar sequences. Therefore, BCRs were classified as 
stereotyped if they had: 
 
• ≥50% amino acid identity i.e. at least 50% of the amino acid 
sequence matched precisely 
• ≥70% amino acid similarity i.e. at least 70% of the amino acid 
sequence had similar amino acids based on their physiochemical 
properties 
• IgHV genes belonged to the same clan 
• Identical VH-CDR3 length 
• Identical sequence pattern offsets i.e. sequence patterns were at 
the exact same location in the VH-CDR3 
 
 
 
 
Table 1.2. Characteristics of the major stereotyped subsets. AA- amino acid. Adapted from Agathangelidis et al (2012). 
Subset 
No 
Freq in 
CLL (%)  
Freq in 
stereotyped 
CLL (%)  
IGHV gene(s) IGHJ 
gene(s) 
VH-CDR3 
AA 
length 
VH-CDR3 AA sequence pattern 
#2 2.8 9.2 V3-21 J6 9 [AVLI]x[DE]xxxM[DE]x 
#1 2.4 8.0 Clan I genes J4 13 ARx[NQ]W[AVLI]xxxxFDx 
#4 1.0 3.2 V4-34 J6 20 [AVLI]RGxxxxxxx[KRH]RYYYYGx[DE]x 
#6 0.9 2.9 V1-69 J3 21 ARGGxYDY[AVLI]WGSYRxx[DE][AVLI]FDx 
#5 0.7 2.3 V1-69 J6 20 ARxxxxxx[AVLI]xxxYYYYxMDx 
#3 0.6 1.8 V1-69 J6 22 Axxxxx[AVLI][AVLI]VxxAxxxxYYGMDx 
#8 0.5 1.5 V4-39 J5 19 AxxxxYSSSWxxxxNWFDP 
#31 0.4 1.3 Clan III genes J6 21 ARxxxxxxxxxxxxYYYxMDx 
#16 0.3 1.1 V4-34 J6 24 AxRFYCxGxxCxxxxxxYYxGxDx 
#77 0.3 1.1 V4 (V4-4, V4-59) Various 14 [AVLI]RGxxx[ST]GWxxxxx 
#7C 0.3 1.0 V1-69 J6 24 AxxxxxxDFW[ST]GYxxxxYYYxxDx 
#28A 0.3 1.0 V1 (V1-2) J6 17 ARxxxGxxYYYYYGMDx 
#201 0.3 1.0 V4-34 J3 17 ARRxxxWxxxxxDxxDx 
#59 0.3 1.0 Clan I genes Various 12 AxxxDFWSGxxx 
#12 0.3 1.0 V1-2, V1-46 J4 19 ARDxxYYDSSGYY[ST]xxxDx 
#14 0.3 0.9 V4 (V4-4) J4 10 x[KRH]GGxWxFDx 
#64B 0.3 0.9 V3 (V3-48) J6 21 A[KRH][DE]xx[AVLI]VVxxx[AVLI]xYYYYGMDx 
#99 0.3 0.9 Clan I genes J4 14 ARxQWLxxxxxFDx 
#202 0.3 0.9 Clan III genes J3, J4 14 A[KRH]xxxGxx[AVLI]xxxDx 
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Using these criteria, 952 different BCR sequences were detected that were 
quasi-identical in at least two cases. Of these, the authors identified 19 
major subsets (Table 1.2) that were found in 12% of the overall cohort and 
41% of stereotyped cases, with subset #1, #2 and #4 comprising half of 
those (20% overall) (Agathangelidis et al 2012). These subsets have been 
found to share clinical and molecular features in addition to BCR 
similarities. 
 
Subset #2 is the most commonly occurring subset, found in 2.8% of all CLL 
cases. It is associated with poor prognosis similar to that of UM-CLL despite 
the majority having undergone some level of SHM (Bomben et al 2009, 
Ghia et al 2005, Stamatopoulos et al 2007) The inferior survival reported in 
patients expressing IGHV3-21 has been confirmed to be a feature of subset 
#2, as non-subset #2 IGHV3-21 behave in a similar manner to their 
respective counterparts depending on their mutation status (Baliakas, 
Agathangelidis, et al 2015, Bomben et al 2009). Subset #2 patients  have a 
higher incidence of SF3B1 mutations, especially in comparison to the other 
major subsets #1 and #8 (Strefford et al 2013), as well as being enriched for 
11q deletions (Thorselius et al 2006) and ATM mutations (Navrkalova et al 
2016). 
 
Subset #1 is the next most common, found in 2.4% of CLL cases 
(Agathangelidis et al 2012). The IgHV in these patients are found to be 
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exclusively UM. They are reported to have an inferior median survival of 84 
months compared to 234 months in the non-subset # 1 cohort, a group of 
patients expressing the same UM-IgHV genes as the subset #1 patients but 
without the stereotyped BCR (Bomben et al 2009, Stamatopoulos et al 
2007). Subset #1 patients have been found to have an increased frequency 
of NOTCH1 mutations which is found in around 40% of the cohort (Rossi, 
Spina, et al 2013). 
 
Patients in subset #4 are typically younger with a median age of 43 years at 
diagnosis. These patients are reported to have an indolent disease and the 
median survival is yet to be determined (Stamatopoulos et al 2007). This is 
supported by an absence of unfavourable molecular markers such as poor 
prognostic cytogenetics, UM-IgHV and mutations in TP53, SF3B1 and 
NOTCH1 (Maura et al 2015, Rossi, Spina, et al 2013). 
 
The other 16 major subsets combined make up 20% of stereotyped cases 
of CLL.  Within these subsets #6, #5, #3, #8, #31, #7C, #28A, #59, #12, #64B, 
#99 and #202 are usually UM whereas #16, #77, #201, and #14 are 
generally M (Agathangelidis et al 2012). The UM subsets have a 
substantially shorter TTFT than the M subsets (Baliakas et al 2014). Subset 
#8 is associated with a particularly poor prognosis with patients having a 
high risk of transformation to RS (Rossi et al 2009).  
27 
 
 
The findings that some patients with CLL had undergone SHM as well as 
the identification of stereotyping in the BCR of CLL cells has given rise to 
the theory that antigens/superantigens may drive pathogenesis in CLL 
(Stamatopoulos et al 2007). The hypothesis proposes that these antigens 
stimulate cell proliferation through activation of the BCR, although 
whether this is limited to the stage at which malignant transformation 
takes place or if this is ongoing throughout the disease has yet to be 
established. 
 
1.4 Prognostic Markers in CLL 
In addition to the IgHV mutation status there have been other genetic 
aberrations that have been identified in CLL that have been found to be 
predictive of prognosis. These include large copy number alterations (CNA) 
that can be detected in the chromosomes as well as single nucleotide 
variations (SNV) and small insertion/deletion (indel) mutations in recurrent 
genes. 
 
1.4.1 Abnormalities affecting the TP53 gene 
TP53 is a vital tumour suppressor gene which codes for the protein p53. 
The p53 protein is a key regulator of cell division that acts by triggering 
various pathways involved in preventing the proliferation of aberrant DNA. 
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It does this through arresting the cell cycle and initiating DNA repair or 
apoptosis in response to cellular stress (Lane 1992). Abnormalities in the 
TP53 gene have been described in many cancers including CLL (Olivier et al 
2010, Rivlin et al 2011). In all cancers, defective TP53 is associated with 
poorer prognosis and treatment resistance (Petitjean et al 2007).  TP53 
defects occur in ~10% of pre-treated CLL and are associated with 
significantly shorter TFS and OS (Dohner et al 1995, Gonzalez et al 2011, 
Landau et al 2013, Zenz et al 2010).  
 
TP53 is located on the p-arm of chromosome 17. In CLL, both deletions of 
the 17p locus as well as mutations in the gene itself have been described. 
Additionally, the identification of one type of TP53 mutation is strongly 
associated with presence of another i.e. patients with a 17p deletion often 
have a mutation in the remaining TP53 gene (Zenz et al 2008). TP53 
mutations are known to cause refractoriness to traditional CLL 
chemotherapy as most conventional chemotherapy agents operate 
through the TP53 pathway. However TP53 mutated patients have been 
shown to respond to treatment with novel therapies, such as Idelalisib and 
ibrutinib, that by-pass the TP53 pathway and instead target the B-cell 
receptor pathway to prevent the proliferation of B-cells (Burger et al 2014, 
Byrd et al 2014, Farooqui et al 2015, Furman et al 2014). 
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1.4.2 Chromosomal Aberrations 
Around 80% of CLL patients have chromosomal aberrations (Dohner et al 
2000). Of these, there are four key chromosomal abnormalities that have 
been identified as commonly occurring in CLL. These are the 13q14 
deletion which is associated with good prognosis, trisomy 12 which is 
thought to be an intermediary marker and the 11q23 and17p deletions 
which confer a poorer prognosis. Other abnormalities have also been 
detected, such as the 6q deletion, but these occur at a lower frequency 
(Dohner et al 1999).  
 
The 13q14 deletion is the most common cytogenetic abnormality found in 
up to 61% of CLL cases (Dohner et al 2000, Edelmann et al 2013). It is 
thought to be a favourable prognostic marker when found in isolation with 
patients having a median TTFT of 6 years and OS of over 12 years (Van 
Dyke et al 2016). However, it has also been associated with a reduced 
progression free survival (PFS) time when found in greater than 65% of 
nuclei and also when associated with the more severe 17p deletion (Van 
Dyke et al 2009). Furthermore, it has also been found that patients with 
larger deletions of the 13q have a shorter TTFT of under 3 years (Parker et 
al 2011). 
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Extensive characterisation over several large cohort studies have defined 
the predominant minimally overlapping region (MOR) in the 13q deletion 
as containing DLEU1, DLEU2 and the microRNAs miR15a and miR16-1 
(Knight et al 2012, Ouillette, Collins, Shakhan, Li, Li, et al 2011, Parker et al 
2011).  This is consistent with studies that have shown that patients with 
13q deletions have reduced expression of miR15a and miR16-1 (Calin et al 
2002, Ouillette, Collins, Shakhan, Li, Li, et al 2011). However more recent 
data have suggested that only DLEU1 and the first 2 exons of DLEU2 are 
involved in the MOR (Edelmann et al 2013). There is evidence that DLEU2 
acts as a promotor for the microRNAs (Kasar et al 2014, Lerner et al 2009), 
therefore defects in DLEU2 alone may still cause their downregulation. 
 
The prognostic significance of trisomy 12 is uncertain. In isolation it is 
considered an intermediate marker with patients having a similar TTFT and 
OS as those with normal karyotype (Dohner et al 2000, Van Dyke et al 
2016). However, its role in disease progression is still undetermined as 
although it is not an indicator of aggressive disease (Catovsky et al 2007), 
nor does its frequency increase over time (Gunnarsson et al 2011), it does 
have associations with transformation to RS (Chigrinova et al 2013). In 
keeping with this, trisomy 12 is reported to be in 87% of subset #8 patients 
who also have a high incidence of Richter transformation (Rossi, Spina, et 
al 2013). Furthermore, NOTCH1 mutated trisomy 12 CLL has a more 
31 
 
aggressive disease course reducing OS by over a third (Balatti et al 2012, 
Del Giudice et al 2012). 
 
 
11q23 deletions are found in up to 27% of CLL cases and are more common 
in patients with an early disease onset as well as those with a marked 
lymphadenopathy (Byrd et al 2004, Edelmann et al 2013, Hernández et al 
2015).  These patients have a shorter remission period when treated with 
chemotherapy alone (Catovsky et al 2007). However, since the introduction 
of the immunotherapy drug rituximab as a standard therapy, the number 
of patients having a PFS of over 3 years has doubled (Fischer et al 2016, 
Hallek et al 2010). The MOR has been refined to the ATM gene (Edelmann 
et al 2013) which was previously found to be downregulated in patients 
with 11q deletions (Kienle et al 2005). The ATM gene is important in cell 
cycle regulation and can induce apoptosis in response to DNA damage 
(Bredemeyer et al 2006) as well as having a role in V(D)J recombination 
(Section 1.2.1 above). In addition to deletions of the 11q, mutations in ATM 
have been reported in 12% of CLL cases and are associated with a reduced 
OS (Austen et al 2005). Furthermore ATM mutations on the residual allele 
have been reported in 36% of patients with 11q deletions (Austen et al 
2007). Patients with biallelic inactivation of ATM have been shown to have 
shorter TTFT, an inferior response to treatment as well as an increased risk 
of disease progression and shorter OS comparable with TP53 mutated CLL 
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(Austen et al 2007, Hurtado et al 2015, Lozano-Santos et al 2016, 
Skowronska et al 2012).   
 
Array technologies have been shown to be a powerful tool which can be 
used to identify genetic aberrations in cancers. Comparative genomic 
hybridization (CGH) arrays operate by comparing the copy numbers of 
differentially labelled test and reference DNA samples (Barrett et al. 2004). 
Single nucleotide polymorphism (SNP) arrays are composed of 
oligonucleotide probes which correspond to the allelic variants of selected 
SNPs. SNP arrays have the added advantage of being able to detect copy 
neutral loss of heterozygosity (cnLOH) which is when a cell contains two 
copies of the same allele (Gunderson et al. 2005). 
 
CGH arrays have been found to have a high concordance with fluorescent 
in-situ hybridisation (FISH) analysis in the detection of chromosomal 
abnormalities in CLL, although are unable to detect abnormalities at low 
levels (Schwaenen et al. 2004; Tyybakinoja et al. 2007) despite detection 
sensitivity having improved from 53% of the total cell population down to 
around 25% (Patel et al. 2007). Studies using CGH arrays identified novel 
recurring regions of interest such as small deletions on areas of 
chromosomes 8 and 2 (Grubor et al. 2009). The long arm of chromosome 
22 has also been reported to have recurrent deletions particularly in a 
region containing the PRAME gene (Gunn et al. 2008). However, recent 
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evidence suggests that this is an artefact of Igλ rearrangement and not 
pathogenic in nature (Mraz et al 2013). 
 
Genome analysis of CLL patients using SNP arrays have identified a 
previously undescribed gain of the 2p16 locus which contains the REL and 
BCL11A oncogenes. These gains occurred in patients with UM-IGHV and are 
more frequent in patients with a 17p deletion (Pfeifer et al. 2007; Forconi 
et al. 2008). Later studies identified 78 SNPs that were implicated in PFS 
(Sellick et al. 2008), six novel risk loci (Di Bernardo et al. 2008) and a novel 
MOR on chromosome 15 (Edelmann et al 2013). Furthermore, it has been 
demonstrated that elevated numbers of CNAs are associated with 
progressive disease and shorter survival (Knight et al 2012, Kujawski et al 
2008, Ouillette, Collins, Shakhan, Li, Peres, et al 2011). 
 
1.4.3 Other Genetic Markers 
In addition to chromosomal abnormalities, genome-wide screening 
technologies such as whole genome (WGS) and whole exome sequencing 
(WES) have identified further genetic aberrations that are recurrent in CLL, 
including mutations in the NOTCH1, SF3B1, BIRC3 and MYD88 genes 
(Baliakas et al 2014, Landau et al 2013, Schuh et al 2012). Although these 
genes are mutated at a low frequency in cohorts of untreated patients with 
CLL (<10%) (Foà et al 2013), there have been many reported associations 
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with refractory disease and inferior survival rates (Jethwa et al 2013, 
Nadeu et al 2016, Wang et al 2011). 
 
Notch1 is a transmembrane receptor that upon activation undergoes 
cleavage of the Notch intercellular domain (NICD). NICD translocates to the 
nucleus where it associates with the CSL DNA-binding complex to initiate 
transcription  (Kopan and Ilagan 2009). Mutations in the NOTCH1 gene are 
reported in up to 12% of pre-treated CLL (Chiaretti et al 2014, Jethwa et al 
2013, Pozzo et al 2015, Puente et al 2011, Rossi, Rasi, et al 2012) with their 
frequency increasing in patients with advanced disease (Jethwa et al 2013, 
Villamor et al 2013). These mutations, predominately a 2-bp frameshift 
deletion (c.7544_7545delCT) in exon 34, are all predicted to disrupt the 
PEST domain (Chiaretti et al 2014, Puente et al 2011, 2015, Rossi, Rasi, et al 
2012), preventing the degradation of NICD by F-box and WD repeat 
containing protein 7 (FBXW7) leading to  the accumulation of NICD in the 
nucleus. NOTCH1 mutations are enriched in trisomy 12 patients (Balatti et 
al 2012, Del Giudice et al 2012) as well as in the subset #8 cohort (Rossi, 
Spina, et al 2013). Mutations in FBXW7 have also been reported in CLL, 
often in  association with trisomy 12 (Jeromin et al 2014, Wang et al 2011). 
Interestingly, recent data have demonstrated that patients with a NOTCH1 
mutation do not benefit from treatment with rituximab (Bo et al 2014, 
Stilgenbauer et al 2014). 
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Mutations in splicing factor 3B subunit 1 (SF3B1) are reported in around 
10% of pre-treated CLL cases and are considered to be a poor prognostic 
marker as they are associated with a short TTFT and OS (Jeromin et al 
2014, Nadeu et al 2016, Wang et al 2011). Similar to NOTCH1, their 
mutation frequency increases over time and in relapse cohorts (Baliakas, 
Hadzidimitriou, et al 2015, Guièze et al 2015, Jethwa et al 2013). SF3B1 
mutations are strongly correlated with subset #2 (Rossi, Rasi, et al 2013, 
Strefford et al 2013) as well as deletions in 11q (Jeromin et al 2014). The 
SF3B1 protein is a component of the small nuclear ribonucleoprotein 
complex that functions in the initiating phases of RNA splicing (Shin and 
Manley 2004). Patients with mutations in SF3B1 in CLL have been shown to 
have aberrant splicing (Quesada et al 2012, Wang et al 2011). As with 
NOTCH1, mutations have also been reported in CLL in genes that operate 
downstream to SF3B1, including XPO1 (Quesada et al 2012) and DDX3X 
(Landau et al 2015, Wang et al 2011). 
 
Mutations have also been recurrently described at frequencies of less than 
5% in pre-treatment CLL in baculoviral IAP repeat containing 3 (BIRC3) and 
myeloid differentiation primary response 88 (MYD88) (Puente et al 2011, 
Quesada et al 2012, Wang et al 2011). These genes both function upstream 
in the NFκB pathway, therefore their disruption leads to constitutive 
activation of NFκB (Puente et al 2011, Rossi, Fangazio, et al 2012). Despite 
this, BIRC3 is associated with a poor TTFT (Baliakas, Hadzidimitriou, et al 
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2015), shorter OS than that seen in wild-type patients (Nadeu et al 2016). It  
is highly correlated with UM-IgHV whereas MYD88 mutations are 
exclusively found in M-IgHV (Baliakas, Hadzidimitriou, et al 2015, Landau et 
al 2015, Puente et al 2011, Wang et al 2011) and have not been shown to 
have a negative impact on OS (Puente et al 2011). 
 
Several other genes have been reported to be recurrently mutated in CLL, 
albeit at very low incidences. These include the DNA repair genes SAM 
domain and HD domain 1 (SAMHD1), protection of telomeres 1 (POT1) and 
chromodomain helicase DNA binding protein 2 (CHD2), all found at 
frequencies of around 3% (Clifford et al 2014, Landau et al 2015, Quesada 
et al 2012, Wang et al 2011). Also the oncogenes KRAS and BRAF have 
reported in 2% of CLL cases (Landau et al 2013, Zhang et al 2011). More 
recently, mutations in the ribosomal protein S15 (RPS15) gene were found 
at a high frequency in a cohort of patients who relapsed within 2 years of 
FCR treatment (Ljungström et al 2016). 
 
1.5 Risk stratification 
Despite the identification of a plethora of reportedly clinically significant 
markers, there is still great uncertainty when predicting the TTFT for many 
patients. Mutations affecting the TP53 gene have a well described 
correlation with short TTFT and chemo-refractoriness in the patients 
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harbouring them. However, there are a cohort of patients without these 
poor prognostic factors that will do badly.  
 
Table 1.3 Prognostic risk stratification as devised by Rossi, Rasi et al (2013) 
 Cytogenetics Molecular mutations 
High Risk del(17p) TP53 and/or BIRC3 
Intermediate Risk del(11q) NOTCH1 and/or SF3B1 
Low Risk tri(12) - 
Very Low Risk del(13q) - 
 
 
To address this issue, recently devised prognostic algorithms have 
incorporated genetic markers into their scoring  (Rossi, Rasi, et al 2013, The 
International CLL-IPI Working Group 2016). The model proposed by Rossi, 
Rasi, et al (2013) stratifies patients into four risk categories based on the 
presence or absence of certain molecular characteristics (Table 1.3). 
Application of this model to 1274 patients determined that the OS over 10 
years was 29.1% for the high-risk group, 37.1% for the intermediate group, 
57.3% for the low risk group and 69.3% for very low risk group. However, 
neither Jeromin et al (2014) or Baliakas, Hadzidimitriou, et al (2015) were 
able to discriminate between the high and intermediate risk categories for 
TTFT in their cohorts of 930 and 3490 patients, respectively. 
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Table 1.4. Prognostic risk stratification as devised by the Internal CLL-IPI Working Group (2016). Very 
high risk = 7–10, high risk = 4–6, intermediate risk = 2–3, low risk = 0–1. 
Factor Adverse Feature Assigned Score 
TP53  Mutated or deleted 4 
IgHV  Unmutated 2 
β2-microglobulin  >3.5mg/L 2 
Rai Stage 
Binet Stage 
I-VI 
B-C 
1 
Age >65 1 
 
 
The new prognostic index proposed by the International CLL-IPI Working 
Group (2016) also classifies patients into four groups.  However, TP53 and 
IgHV mutation status are the only molecular markers used. The index 
works by applying a prognostic scoring system (The International CLL-IPI 
Working Group 2016) to separate patients into very high risk (score 7–10), 
high risk (score 4–6), intermediate risk (score 2–3) or low risk (score 0–1). 
On a cohort of 1214 patients, the proportion of patients surviving over 5 
years was 23.2% for the very high-risk group, 63.3% for the low risk group, 
79.3% for the intermediate group, and 93.2% for low risk group. Three 
independent validation cohorts supported these results bringing the total 
number of patients tested to 1839. The index has been criticised for two 
reasons. Firstly, since the data are based on clinical trial patients they do 
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not consider ‘watch and wait’ patients.  Therefore, the results have a 
limited application in determining TTFT, which can be valuable in 
identifying patients at risk of rapid disease progression, particularly as 
many newly diagnosed patients are classified as Binet Stage A (Baliakas, 
Hadzidimitriou, et al 2015). Secondly, the clinical trials were performed 
prior to the introduction of chemo-immunotherapy and therefore may not 
be suited in determining OS in patients treated with these therapies. 
However, subsequent studies have validated the index for determining 
TTFT (Gentile, Shanafelt, et al 2016, Molica et al 2016) as well as OS in 
patients treated with chemo-immunotherapy (da Cunha-Bang et al 2016). 
 
1.6 Cancer as an Evolutionary Process 
The theory that all cancers arise from a single clone that has undergone 
progressive acquisition of somatic mutations that confer a survival 
advantage, was first postulated forty years ago (Nowell 1976). If this is the 
case, it would therefore follow that cancer is governed by the same tenants 
underlying evolutionary biology; that is, the generation of genetic 
variation, the influence of genetic drift, i.e. random life and death events 
and Darwinian selection, i.e. the survival of those with a fitness advantage.  
Genetic variation occurs within the tumour through the acquisition of a 
somatic mutation. The survival of this mutation relies firstly on genetic 
drift, as even beneficial mutations have been shown to die out before they 
have a chance to expand (Levy et al 2015). Should the mutation escape 
40 
 
extinction and provide a survival advantage to the tumour, it will then 
gradually increase in abundance and, since the acquisition of somatic 
mutations is a random event, a heterogeneous population of cancer cells is 
created.  Indeed, there are multiple studies which demonstrate intra-clonal 
heterogeneity across a variety of cancer types as well as providing evidence 
supporting cancer progression as an evolutionary process (Anderson et al 
2011, Awad et al 2013, Diaz Jr et al 2012, Gerlinger et al 2012, 2014, 
Landau et al 2015, Schuh et al 2012).  
 
Whilst the model of clonal evolution in cancer is now well accepted, the 
acquisition of recurrent mutations across inter-clonal samples is, at first, 
difficult to explain in the clonal evolution theory of cancer. If it is assumed 
that genetic variation is a random event, how then can the recurrence of 
specific mutations be explained?  It is known that most cancers have an 
elevated mutation rate (Jones et al 2008, Loeb et al 2003). In addition, the 
processes that have been found to be responsible for generating somatic 
mutations (Alexandrov et al 2013) are biased to targeting certain DNA 
sequence patterns (Table 1.5). For instance, the AID enzyme, that is 
essential in SHM, preferentially deaminases cytosine found in a 5’-WRCN-3’ 
sequence. Furthermore, it has been hypothesised that even with a slow 
mutation rate of 1 mutation per cell division, a tumour containing 1010 cells 
would have developed every point mutation at least once (Wang, Walters 
et al 2014). 
41 
 
 
Table 1.5. Summary of the DNA sequence motifs recognised by some of the common causes of 
somatic mutations. Adapted from Roberts and Gordenin (2014). AID, activation-induced cytidine 
deaminase; APOBEC, apolipoprotein B mRNA editing enzyme catalytic polypeptide-like; POLη, DNA 
polymerase η, ROS, reactive oxygen species, POLε, DNA polymerase ε. 
Cause of Mutation Sequence Motif Base Change 
APOBEC TCW C>K 
AID WRCN C>K 
POLη NTW T>N 
5-meCpG 
deamination 
NCG C>T 
ROS NCN C>A 
Tobacco NCN C>A 
POLε TCG C>T 
TCT C>A 
 
 
In contrast to the evolution theory of cancer development, some recent 
studies have suggested that mutations are acquired rapidly in a relatively 
few, or even a single, catastrophic event. This ‘Big Bang’ model of genomic 
derangement suggests that tumour subclones are all formed during the 
initiation of the cancer as opposed to from later clonal expansions. 
Furthermore, the  pervasiveness of these subclones is more dependent on  
when they occur during tumour development as opposed to being selected 
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for due to a survival advantage (Baca et al 2013, Gao et al 2016, Sottoriva 
et al 2015, Stephens et al 2011). 
 
1.6.1 Clonal Evolution and Tumour Heterogeneity in CLL  
CLL is a good model of disease evolution since most, if not all, patients 
have the pre-malignant disorder of monoclonal B-cell lymphocytosis (MBL) 
(Landgren et al 2009).  MBL is an asymptotic condition characterised by the 
clonal expansion of B-cells at a frequency of less than 5000 cells per cubic 
millilitre (Strati and Shanafelt 2015). MBL has been shown to have 
cytogenetic and molecular abnormalities that are thought to be early 
drivers of CLL pathogenesis (Landgren et al 2009, Ojha, Secreto et al 2014, 
Rasi et al 2012). However, since the level of MBL transformation to CLL is 
particularly low at a rate of 1.1% a year (Rawstron et al 2008b), yet the 
frequency of some CLL-like mutations such as the del13q are reported at 
around 50% (Henriques et al 2014, Morabito et al 2013), there must be 
addition factors driving the pathogenesis of CLL from a background of MBL. 
Tumour progression is further demonstrated in CLL through the 
development of Richter syndrome. Around 5% of CLL cases will transform 
into RS which has an incidence rate of 0.5% per year (Parikh et al 2013). In 
most cases of RS, the tumour is clonally related to the preceding CLL and 
transformation has taken place in a linear fashion. This is demonstrated 
through possession of the same IgH rearrangement and mutational status 
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(Rossi, Spina, et al 2012) as well as through maintenance of mutations 
present in the CLL clone (Chigrinova et al 2013, Fabbri et al 2013). 
 
Work performed by Campbell et al (2008) in the early days of NGS showed 
that ultra-deep sequencing analysis of the IgHV could be used to 
demonstrate intraclonal diversification. Furthermore, analysis of the 
phylogenetic relationship between the subclones as well as their evolution 
from the germline, indicated a complex model of tumour development 
whereby some subclones denoted intermediaries to the dominant clone, 
others signified divergent clones, whilst a proportion represented ongoing 
evolution. The presence of divergent clones detectable through NGS 
analysis of the IgHV was confirmed in a later study (Bashford-Rogers et al 
2013). 
 
Nowadays, intra-tumour heterogeneity is well reported in CLL through the 
use of NGS technologies, or the analysis of consecutive samples, or a 
combination of both (Knight et al 2012, Landau et al 2013, Schuh et al 
2012). Furthermore, these studies have demonstrated how these 
subclones can expand over time to become the major clone in response to 
external pressures, particularly since patients who have undergone 
treatment have a greater degree of clonal evolution (Landau et al 2013). 
This is supported by studies that have shown that the presence of 
subclonal mutations are associated with the same prognosis as clonal 
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mutations in certain genes such as TP53 (Rossi et al 2014) and NOTCH1 
(Nadeu et al 2016). 
 
1.6.2 The Leukaemic Stem Cell in CLL  
The cell of origin in CLL remains controversial. Since some CLL cells are 
known to have undergone SHM (Damle et al 1999, Hamblin et al 1999) and 
all have clonal IgHV rearrangements (Fais et al 1998), it was proposed that 
CLL cells derive from mature B-cells (Chiorazzi and Ferrarini 2003). Later it 
was found that CLL cells shared many features with marginal zone B- (MZB) 
cells (Chiorazzi and Ferrarini 2011). However, a more recent study found 
that CLL and MZB cells have distinct expression profiles and instead 
proposed a previously undefined mature CD5+ B-cell as the cell of origin 
(Seifert et al 2012). 
 
Relapsed CLL is known to have a distinct profile genetically to its diagnostic 
predecessor since mutations that enable the cell to survive treatment were 
able to expand whereas those with mutations susceptible to therapy died 
out (Schuh et al 2012, Stilgenbauer et al 2007). In spite of these transient 
changes, it is well accepted that the IgHV remains stable over the course of 
the disease, in that the V(D)J rearrangement does not change from 
diagnosis to relapse (Provan et al 1996). This suggests that the CLL and the 
subsequent relapse clone must have arisen from a B-cell population that 
has undergone V(D)J recombination, supporting the notion that the cell of 
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origin is a mature B-cell. Further corroboration is shown in cases that have 
transformed to RS as these have the same IgHV rearrangement as their CLL 
predecessor (Rossi, Spina, et al 2012). Moreover, it is now widely accepted 
that CLL develops from pre-malignant condition MBL. MBL has been shown 
to be oligo-clonal in terms of IgHV rearrangements in a high proportion of 
cases (Klinger et al 2015, Lanasa et al 2010), yet bi-clonal IgHV 
rearrangements are only reported in <5% of CLL cases (Plevova et al 2014, 
Rassenti and Kipps 1997, Visco et al 2013). This may suggest that a 
subclone of the MBL population acquires further mutations, potentially as 
an indirect result of antigen activation of the BCR, which instigates the 
transformation to CLL. 
 
Whilst these provide evidence for a mature B-cell as the normal 
counterpart for CLL, the origin of the leukaemic stem cell in CLL is yet to be 
elucidated. Certainly, the presence of oligo-clonal MBL suggest that the 
leukaemia initiating event must occur in an early progenitor B-cell, at least, 
and could be related to the normal ageing process that leads to B-cell 
oligoclonality in the age-matched healthy population (Gibson et al 2009). 
Recent data show that leukaemia inducing mutations, such as those in 
SF3B1, can be detected in the progenitor B-cells of patients with CLL 
(Damm et al 2014). Furthermore, studies in mice have shown that 
engrafting haemopoetic stem cells from patients with CLL into 
immunodeficient mice gives rise to clonal B-cells with V(D)J 
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rearrangements that are independent of the original clone (Kikushige et al 
2011).  
 
Nonetheless, an early B-cell as the CLL leukaemic stem cell would be 
expected to give rise to a proportion of CLL expressing multiple V(D)J 
rearrangements. Yet, using conventional methods, only 5% of CLL are 
reported to have bi-clonal IgHV rearrangements (Plevova et al 2014, 
Rassenti and Kipps 1997, Visco et al 2013). At such low frequencies, it is 
possible that these actually represent two lymphoproliferative diseases 
that have arisen independently, as opposed to one disorder possessing two 
IgHV rearrangements. Indeed, clonally unrelated RS was considered as a 
secondary disease that had arisen independently to the CLL due to the 
presence of genetic lesions different to their CLL counterparts (Rossi et al 
2011). However, further studies found that they possess the same V(D)J 
rearrangement suggesting that they arose as a result of branching 
evolution in the pre-CLL phase (Fabbri et al 2013). Identification of a sub-
clone within CLL possessing the same DJ rearrangement as the dominant 
clone but with a different V-gene would provide further evidence that the 
CLL derives from a haematopoietic stem cell. 
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1.7 Aims of thesis 
The primary aim of this thesis was to characterise the genomic complexity 
and molecular drivers of clonal expansion and maintenance of chronic 
lymphocytic leukaemia (CLL) in the context of clinical intervention.  More 
specifically, the objectives were to develop, validate and apply methods to 
identify and begin to functionally characterise the various genetic 
abnormalities within paired pre-treatment and relapse samples using (1) 
ultra-deep NGS sequencing of the IgHV and (2) genome wide array 
technology.  As a final step, the approach was applied to samples from 
large cohorts of patients with robust clinical outcome to determine the 
prognostic/predictive significance of these findings. 
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Chapter 2  Materials and Methods 
 
This chapter describes the protocols used in this work. Additional 
protocols, including primer sequences used for specific projects, are 
detailed in the relevant chapters and/or the appendices. 
 
2.1 Cell Preparation 
2.1.1 Ficoll Preparation of Peripheral Blood Mononuclear 
Cells 
Whole blood or bone marrow from EDTA tubes was transferred into 50ml 
centrifuge tubes. Phosphate buffered saline [PBS] (10010031, Life 
Technologies, Carlsbad, California, USA) with 1% fetal bovine serum [FBS] 
(10270-106, Life Technologies) was added at 2.5x volumes. 4ml of Ficoll 
(17-5442-02, GE Healthcare, Little Chalfont, Buckinghamshire, UK) was 
added to 15ml centrifuge tubes. 10ml of blood/PBS mix was carefully 
layered on top of the Ficoll. The tubes were centrifuged for 20mins at 400g 
at 4°C. The upper layer was removed and discarded, whilst the white cell 
fraction was transferred to a new 15ml tube. PBS was added to make a 
total volume of 14ml, then the tubes centrifuged for 5mins at 280g. The 
supernatant was removed and discarded and 500ul of RBC lysis solution 
(158904, Qiagen, Hilden, Germany) added. The tubes were incubated at 
room temperature for 10mins then made up to a volume of 10ml with 
Dulbecco's Modified Eagle Medium [DMEM] (11995-065, Life 
50 
 
Technologies). The tubes were centrifuged for 5mins at 280g and the 
supernatant removed and discarded. PBS was added to give a final 
concentration of 1x107 cells/ml. Cells were stored in 2ml cryogenic vials 
containing 1ml of cell preparation. 
 
2.1.2 Thawing Frozen Cells 
Thawing of frozen cells must be carried out in a timely manner to prevent 
cell death. Vials containing cells are agitated in a 37°C waterbath till 
thawed. Cells are then transferred dropwise to 15ml centrifuge tubes 
containing 10ml DMEM. The tubes are then centrifuged for 5mins at 180g 
and the supernatant removed. 1ml of PBS was then added.  
 
2.1.3 Isolating B-Cells 
B-cells were isolated using the EasySep Human CD19 selection kit (18054, 
Stem Cell Technologies, Vancouver, Canada). Equal amounts of peripheral 
blood and 1x EasySep RBC lysis buffer were mixed in a 14ml falcon tube. 
CD19 EasySep Positive Selection Cocktail was added to a final 
concentration of 25ul/ml and the tubes incubated at room temperature for 
15mins. EasySep Magnetic Nanoparticles were then added to a final 
concentration of 25ul/ml and the tubes incubated at room temperature for 
10mins. The samples were made up to 10ml with PBS containing 1% FBS 
and incubated at room temperature in the Big Easy EasySep Magnet 
(18001, Stem Cell Technologies) for 10mins. The supernatant was then 
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discarded by inverting the magnet. The remaining cells were pipette mixed 
with 10ml PBS with 1%FBS, then incubated for 5mins at room temperature 
in the magnet, before the supernatant was again discarded. This was 
repeat twice more and the remaining cells resuspended in 400ul of PBS 
with 1% FBS. 
 
2.2 Extraction of Genomic DNA 
The QIAamp DNA mini kit (51306, Qiagen) uses spin columns to isolate 
DNA. Unless otherwise stated, the reagents used for this protocol were 
provided in this kit. The sample is first lysed with buffers and enzymes that 
also stabilise the DNA and enhance its binding to the silica-gel membrane 
within the column. Wash buffers are used to remove impurities, and then 
the DNA is eluted into low-salt buffer (Buffer AE). 
 
Once thawed, cells were made up to 200ul with PBS in a 1.5ml 
microcentrifuge tube. 200ul of buffer AL and 20ul Qiagen protease was 
added and the tubes pulse-vortexed. The tubes were then incubated at 
56°C for 10mins. 200ul ethanol was added and the tubes pulse-vortexed. 
The mix was transferred to a QIAamp spin column and centrifuged at 
6000g for 1min. The spin column was then transferred to a clean 2ml 
collection tube and 500ul Buffer AW1 added. The column was centrifuged 
at 6000g for 1min and then transferred to a clean collection tube. 500ul 
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Buffer AW2 was added and the column centrifuged at 20,000g for 3min. 
The column was transferred to a new collection tube and centrifuged at 
20,000g for a further 1min. The column was then transferred to a 1.5ml 
microcentrifuge tube and 200ul Buffer AE added to the membrane. The 
column was incubated at room temperature for 1min then centrifuged at 
6000g for 1min. 
 
2.3 Extraction of RNA and cDNA preparation 
2.3.1 Preparation of cells for RNA extraction 
2.3.1.1 From Whole Blood 
Blood was transferred to 50ml tubes and made up to 50ml with RBC lysis 
solution. Tubes were rotary mixed at room temperature for 10mins then 
centrifuged at 1100g for 10mins. The supernatant was discarded then 20ml 
of RBC lysis solution added. Tubes were rotary mixed for 5mins then 
centrifuged as before and the supernatant was discarded. RBC lysis 
solution was added to give a maximum concentration of 3.5x107 cells/ml. 
The cell preparation was transferred to 1.5ml microcentrifuge tubes in 1ml 
volumes. The tubes were spun at 18,000g for 2mins then the supernatant 
discarded. 600ul of Buffer RLT (79216, Qiagen) containing 1% β-
mercaptoethanol (M3148, Sigma Aldrich, St. Louis, Missouri, USA) was then 
added and the cells homogenised with a 20-gauge needle. Samples were 
then either stored at -70°C or processed to the next step. 
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2.3.1.2 From Ficoll Preparations or Sorted Cells 
Both types of cell preparations have already undergone red cell lysis. 
Therefore, these cells start at the microcentrifuge tube stage and progress 
as described in section 2.3.1.1. 
 
2.3.2 RNA extraction using the QIAamp RNA Blood Mini Kit 
RNA extraction from the GTC lysate was performed using the QIAamp RNA 
Blood Mini Kit (52304, Qiagen). First, 600ul 70% ice-cold ethanol was 
added to the microcentrifuge tubes and the tubes pipette-mixed. The mix 
was transferred to a QIAamp spin column and centrifuged at 18,000g for 
15s. The spin column was then transferred to a clean 2ml collection tube 
and 700ul Buffer RW1 added. The column was centrifuged at 18,000g for 
15s and then transferred to a clean collection tube. 500ul Buffer RPE was 
added and the column centrifuged at 18,000g for 15secs. A further 500ul 
Buffer RPE was added and the tubes centrifuged for 2mins. The column 
was transferred to a new collection tube and centrifuged at 18,000g for a 
further 1min. The column was air-dried at room temperature for 5mins, 
then transferred to a 1.5ml microcentrifuge tube and 30ul molecular-grade 
water (W4502, Sigma Aldrich) added to the membrane. The column was 
incubated at room temperature for 2min then centrifuged at 18,000g for 
2min. 
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2.3.3 cDNA preparation 
6ul of RNA was transferred to a 0.5ml microcentrifuge tube and 2ul 5x Vilo, 
1ul 10X Superscript (11754250, Life Technologies) and 1ul molecular-grade 
water added. The tubes were then incubated at 25°C for 10mins, then 42°C 
for 60mins and finally the reaction terminated at 85°C for 5mins. The cDNA 
was then made up to a final volume of 50ul with molecular grade water. 
 
2.4 Nucleic Acid Assessment 
2.4.1 Nanodrop 
A Nanodrop 2000c UV-Vis spectrophotometer (ThermoFisher Scientific, 
Waltham, Massachusetts, USA) was used to determine nucleic acid 
concentration and purity. With the measurement arm raised, 1.5ul of test 
sample was pipetted onto the pedestal. The measurement arm was then 
closed so that the sample was held between the light source and the 
detector. The Nanodrop 2000 software package (v1.6.198) determines the 
measurement and record the results for each sample. Prior to analysis of 
the first sample, the baseline measurement is established by analysing 1ul 
of the solution used to re-suspend the DNA/cDNA/RNA sample. The sample 
pedestal is wiped clean with distilled water between each test sample. A 
260/280 ratio of ~1.8 was considered as ‘pure’ DNA and of ~2.0 as ‘pure’ 
RNA. 
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2.4.2 Qubit 
For some samples, a Qubit 2.0 Fluorometer (Thermo Fisher Scientific) was 
also used to quantify DNA specimens using the ds BR assay kit (Q32850, 
Thermo Fisher Scientific). Since this method can differentiate between DNA 
and other contaminates it is a more accurate methodology than 
spectrophotometric based methods. A working dilution of Qubit reagent 
was prepared by diluting the Qubit dsDNA reagent by a factor of 1:200 into 
Qubit dsDNA Buffer. To prepare the two standards, 10ul of each standard 
was diluted into 190ul of the Qubit working solution. The test samples 
were prepared by diluting 1ul of sample into 199ul of Qubit working 
solution. The tubes were then mixed by vortexing and left at room 
temperature for 2mins. The standards were measured first to generate a 
standard curve, against which each sample is measured. 
 
2.4.3 Bioanalyser  
Following amplification and cleaning, PCR product was assessed for purity 
using the Agilent High Sensitivity DNA Assay (5067-4626, Agilent 
Technologies, Santa Clara, California, USA) on the Agilent 2100 Bioanalyser.  
For each sample, 1ul of product was loaded into a single well of the chip 
and processed using a 2100 Bioanalyzer instrument (Agilent Technologies) 
as per the manufacturer’s instructions. 
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2.5 Polymerase Chain Reaction (PCR) 
Conventional PCR was employed to amplify regions of interest within the 
DNA. Unless otherwise stated, a standard 25ul reaction mix comprised of 
12.5ul Multiplex PCR MasterMix (206145, Qiagen), 1ul of forward and 
reverse primer (10uM of each primer) and 1ul of template DNA (25-
250ng/ul). Primers were designed using the Primer3 software 
(http://bioinfo.ut.ee/primer3-0.4.0/) using all the default settings except 
for adjusting the GC clamp to 1. The amplification conditions consisted of 
an initial denaturation step of 95°C for 10mins followed by 35 cycles of 
denaturation at 95°C for 30secs, primer annealing at 60°C for 1min and 
primer extension at 72°C for 2mins, followed by a final 10min extension at 
72°C. 
 
2.6 Sanger Sequencing  
2.6.1 PCR amplification of the IgHV locus using the 
InvivoScribe Somatic  
Samples were amplified using the IGH Somatic Hypermutation Assay v2.0 
(5-101-0041, Invivoscribe, San Diego, California, USA). 1ul of DNA/cDNA 
was added to 25ul of Hypermutation Mix 1 containing 0.1ul AmpliTaq Gold 
(N808-0241, Applied Biosystems, Foster City, California, USA). The 
amplification conditions consisted of an initial denaturation step of 95°C 
for 7mins followed by 35 cycles of denaturation at 95°C for 45secs, primer 
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annealing at 60°C for 45secs and primer extension at 72°C for 90secs, 
followed by a final 10min extension at 72°C. 
 
2.6.2 PCR clean-up using MicroClean 
Following amplification, equal volumes of PCR product and MicroClean 
reagent (2MCL50, Microzone Ltd, Heywards Heath, UK) were mixed by 
vortexing in a PCR plate and left at room temperature for 5mins. The plate 
was then centrifuged at 4700rpm for 40mins, and then spun inverted for 
60secs at 38rpm on a folded paper towel to remove the supernatant. The 
cleaned product was re-suspended in DNase free water up to half the 
volume of starting PCR product and allowed to stand for 10mins to re-
hydrate. 
 
2.6.3 Cycle sequencing 
A 10ul Sanger PCR mix comprised of 1x ready reaction premix, 1x BigDye 
sequencing buffer (4337456, Thermo Fisher Scientific), 30pmol of 
sequencing primer and 1ul of purified PCR product. The amplification 
conditions consisted of an initial denaturation step of 96°C for 1min 
followed by 25 cycles of 96°C for 10secs, 50°C for 5secs and 60°C for 4mins. 
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2.6.4 Ethanol precipitation 
5μl of freshly prepared 125mM EDTA (93302, Sigma Aldrich) and 60μl of 
cold 100% ethanol was added to each cycle sequencing reaction. The 
sample was vortex mixed and incubated at room temperature for 15mins. 
The plate was centrifuged at 3700rpm for 30mins at 4°C. The plate was 
then inverted to remove the supernatant and washed again in 60μl of ice 
cold 70% ethanol. The samples were centrifuged at 3500rpm for 15mins, 
the supernatant removed and the samples allowed to air-dry. The dried 
samples were re-suspended in 8.5μl of Hi-Di formamide (4311320, Thermo 
Fisher Scientific) prior to sequencing. 
 
2.6.5  Capillary electrophoresis and Data Analysis 
Samples underwent capillary electrophoresis on a 3130 Genetic Analyzer 
(Applied Biosystems).  Samples were run on a 96-well plate using the 
Sequencing Analysis Application. 
 
Following capillary electrophoresis, raw sequencing was first analysed 
using the sequencing analysis software (v5.4, Applied Biosystems), to 
generate quality values and basecalling data files. These output files can 
then be used for downstream analysis. IgHV SHM analysis was performed 
by importing a FASTA file into IMGT/VQUEST (Lefranc et al 2009). Variant 
identification was performed using Mutation Surveyor (SoftGenetics, State 
College, Pennsylvania, USA). This software takes analysed ABI files and 
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performs a direct base-to-base comparison against a FASTA file of the wild-
type sequence.  
 
2.7 Next Generation Sequencing 
2.7.1 AMPure clean-up 
Following amplification, the libraries were purified to select amplicons for 
re-sequencing, and remove excess reaction components that could 
interfere with the downstream processes. Purification is performed using 
magnetic beads which will bind and elute DNA using specific buffers.  
 
PCR products were made up to 25ul using elution buffer (19086, Qiagen) in 
a 96-well microplate.  25ul of AMPure XP Beads (A63882, Beckman Coulter, 
High Wycombe, UK) were added to each sample and vortex mixed at 
1800RPM for 2mins. The samples were incubated at room temperature for 
10mins then the plate was placed onto a magnetic stand for 2mins. The 
supernatant was removed using a multi-channel pipette and the samples 
washed twice in freshly-prepared 80% ethanol. The plate was air-dried for 
10mins then the dried samples were resuspended in 25ul of elution buffer. 
 
2.7.2 Nextera 
Amplified cleaned PCR products were tagged with the Index 1 (i7) and 
Index 2 (i5) adapters and sequences required for cluster formation for 
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MiSeq sequencing using the Nextera XT DNA library kit (FC-131-1096, 
Illumina, San Diego, California, USA). The i7 and i5 tags uniquely barcode 
the sequences from individual samples so that they can be identified post 
sequencing. A 50ul Nextera mix contained 2ul of cleaned PCR product, 15ul 
of Nextera PCR Mastermix (NPM), 5ul i5 tag and 5ul i7 tag. The 
amplification conditions consisted of an initial step of 92°C for 3min 
followed by 95°C for 30sec then 5 cycles of 95°C for 10secs, 55°C for 30secs 
and 72°C for 30secs and a final extension of 72°C for 5mins. The samples 
were then cleaned again using the AmpPure technique. 
 
2.7.3 KapaQuant 
Once cleaned, the labelled PCR products were quantified using the Kapa 
Library Quantification kit (KK4835, KapaBiosystems, Woburn, 
Massachusetts, USA).  A 20ul reaction mix consisted of 12ul KAPASYBR Fast 
qPCR mix, 0.4ul low Rox and 4ul of standard or 1:1000 diluted PCR product. 
PCR was performed in the 7500 Real-Time PCR System (Applied 
Biosystems). The amplification conditions consisted of an initial 
denaturation step of 95°C for 5mins followed by 35 cycles of denaturation 
at 95°C for 30secs and primer annealing at 60°C for 45secs. Absolute 
quantification for each sample was determined against the standard curve 
using the KAPA Library Quantification Data Analysis Template. 
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2.7.4 MiSeq Preparation and Loading 
Samples underwent next generation sequencing using the either the MiSeq 
Reagent Kit v2 300-cycle kit (MS-102-2002, Illumina) or the MiSeq Reagent 
v3 600-cycle kit (MS-102-3003, Illumina) on the MiSeq Instrument 
(Illumina). Cleaned PCR products were quantified using the Qubit BR assay 
kit (Section 2.4.2), then normalised to 4nM. 2ml of each normalised 
product was then pooled, and then requantified using the Qubit BR assay 
kit. 5ul of pooled product was added to 5ul of freshly prepared 0.2M NaOH 
then incubated at room temperature for 5mins, and then 990ul of HT1 
added. In a new microtube, this library was diluted to the required loading 
concentration with HT1 and 11.5pmol PhiX. 600ul of the final library was 
then loaded onto the cartridge. 
 
2.7.5 Analysis of the IgHV locus using the LymphoTrack® IGH 
Somatic Hypermutation Assay Panel  
1.25ul of template cDNA/DNA (25-250ng/ul) was amplified in a 12ul 
reaction mix comprised of 11.25ul LymphoTrack IGH SHM Leader PCR 
MasterMix (71210069, Invivoscribe) and 0.1ul AmpliTaq Gold (Thermo 
Fisher Scientific). The amplification conditions consisted of an initial 
denaturation step of 95°C for 7mins followed by 33 cycles of denaturation 
at 95°C for 45secs, primer annealing at 60°C for 45secs and primer 
extension at 72°C for 90secs, followed by a final 10min extension at 72°C. 
Next the PCR products were purified and quantified as previously described 
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(Sections 2.7.1 and 2.4.2 respectively) and then analysed using the MiSeq 
Reagent v3 600-cycle kit (Section 2.7.4) to generate FASTQ data.  
 
The FASTQ data generated by the MiSeq was analysed using the 
LymphoTrack IGHV SHM Software (Invivoscribe). First, data was analysed 
using the LymphoTrack_IGH_SHM_MiSeq_1.0 software to generate a 
fastq_read_summary file. This file was then visualised using the 
LymphoTrack_IGH_SHM_Visualization.xlsm macro file on Excel.  Reads that 
were out of frame or that contained stop codons were discounted from the 
analysis. Sequences were also analysed using IMGT HighV-Quest (Alamyar 
et al 2012). 
 
2.7.6 Targeted Next Generation Sequencing using the 
Illumina TruSeq Custom Amplicon assay 
A TruSeq Custom Amplicon assay (TSCA) (Illumina) was used to analyse 
genes which had been reported as recurrently mutated in CLL. The libraries 
were prepared using the TSCA kit (FC-130-1001, Illumina). Unless otherwise 
stated, the reagents used for this protocol were provided in this kit. First 
the oligos were hybridised to the sample template by adding 5ul of TSCA 
mastermix to 10ul of DNA (150-250ng) and 35ul of OHS2. This was then 
heated to 95°C then left to cool to 40°C for ~90mins. Unbound oligos were 
then removed by washing twice with SW1 and once with UB1 in a filter 
plate. The products were then extended and ligated by adding 45ul of 
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ELM4 to each sample and incubating at 37°C for 45mins. Next 25ul of 
freshly prepared 50nM NaOH was added and the samples incubated at 
room temperature for 5mins. 20ul of this product was added to a PCR 
mastermix consisting of 4ul i5 tag, 4ul i7 tag, 21.6ul PMM2 and 0.4ul TDP1. 
The amplification conditions consisted of an initial denaturation step of 
95°C for 3mins followed by 25 cycles of denaturation at 95°C for 30secs, 
primer annealing at 66°C for 30secs and primer extension at 72°C for 
60secs, followed by a final 5min extension at 72°C. PCR products were 
purified and quantified as previously described (Sections 1.7.1 and 1.4.2 
respectively) and then analysed using the MiSeq Reagent v2 300-cycle kit 
(Section 1.7.4). 
 
The variant calling file (VCF) generated by the MiSeq was analysed in 
VariantStudio v2.2 (Illumina). Variants were filtered to remove those with 
less than 10 reads, those with a variant allele frequency (VAF) of less than 
5%, as well as those with no consequence. Variants which had been 
validated in dbSNP (v138) were assumed to be germline and were also 
excluded from the analysis. 
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2.8 Single Nucleotide Polymorphism Array 
2.8.1 Illumina Genome-wide SNP Platform hybridisations 
Single Nucleotide Polymorphism (SNP) arrays were used to detect copy 
number alterations (CNAs). Initial arrays were performed using 1M-Duo 
SNP chips (WG-311-1102, Illumina); however, due to product 
discontinuation, subsequent samples were analysed using HumanOmni1-
Quad SNP chips (WG-311-1110, Illumina). Unless otherwise stated, the 
reagents used for this protocol were provided in these kits. 
 
250ng of DNA was denatured by adding 0.1M NaOH and incubating at 
room temperature for 10mins. Next the denatured DNA underwent whole-
genome amplified by adding 68ul MA2 and 75ul MSM to each sample, and 
then incubating for 20-24hrs at 37°C. The amplified samples were then 
enzymatically fragmented by adding 50ul FMS and incubating at 37°C for 
1hr. Next, the fragmented samples were precipitated by adding 100ul PMS 
and incubating at 37°C for 5mins, then adding 300ul isopropanol (I9516, 
Sigma Aldrich), mixing well, incubating at 4°C for 30mins and then 
centrifuging at 4700rpm for 20mins, before removing the supernatant. The 
pellets were left to air-dry for 1hr, then resuspended in 46ul of RA1 by 
incubating at 48°C for 1hr. Samples were hybridized onto the BeadChips by 
rocking in a hybridisation oven at 48˚C for 16-24hrs and then the 
BeadChips were washed in PB1. The hybridised primers were extended 
with labeled nucleotides and then stained. Finally, the BeadChips were 
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coated with XC4 and then analysed on the iScan (Illumina). The data was 
processed using GenomeStudioV2009.2 (Illumina) to generate a txt file.  
 
2.8.2 Data Analysis with Biodiscovery Nexus 
The txt file generated by GenomeStudio was analysed using Nexus 8 
Discovery Edition (BioDiscovery, El Segundo, California, USA) with the 
following settings (SNPRank Segmentation): Significance Threshold 1x 10- 
5; Max Contiguous Probe Spacing (Kbp) 1000.0; Min number of probes per 
segment 5; High Gain 0.6; Gain 0.2; Loss -0.2; Big Loss -1.0; 3:1 sex 
chromosome gain 1.2; Homozygous Frequency threshold 0.95; 
Homozygous Value Threshold 0.8; Heterozygous Imbalance Threshold 0.4; 
Minimum LOH Length (Kb) 20; percentage outliers to remove 3%. All Nexus 
processed plots were also inspected visually to scan for changes not 
identified using these analysis settings. 
 
2.9 Data Analysis 
TFS and OS distributions were plotted using Kaplan–Meier estimates and 
were compared using the log-rank test. TFS and OS were calculated from 
the time of diagnosis until the date of first treatment and the date of 
death, respectively. All deaths included in this analysis were CLL-related. 
When the death was CLL-unrelated, the death event was not included in 
the OS analysis. All tests were two-sided. An affect was considered 
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statistically significant at P<0.05. All analyses were performed with 
Graphpad Prism 5.0 software (La Jolla, California, USA), IBM SPSS 13.0 
software (Chicago, Illinois, USA) or Microsoft Excel (Richmond, Washington, 
USA). 
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Chapter 3  Using Next Generation 
Sequencing for Analysis of the 
Immunoglobulin Heavy Chain Locus 
 
3.1 Introduction 
It is widely accepted that the mutational status of the IgHV gene is 
independently prognostically significant in CLL (Damle et al 1999, Hamblin 
et al 1999).  Current practice is to determine the mutational status using 
SSeq (Ghia et al 2007). SSeq presents challenges when analysing the IgHV 
region, however, as it only enables analysis of the dominant clone unless 
further manipulation is performed such as gel extraction or cloning. In 
addition, SSeq analysis of the IgHV region has a reported failure rate of up 
to 20% (Burger et al 2014). 
 
NGS has the capacity to analyse multiple sequences simultaneously so it is 
highly suited to analysing samples with sub-clonal populations. Campbell et 
al (2008) and Bashford-Rogers et al (2013) have both previously 
demonstrated that it is possible to detect sub-clones in CLL through the 
analysis of the IgHV region. However, neither study investigated the 
significance of these subclones in terms of correlation with disease 
progression or pathogenesis. As discussed previously, CLL is widely thought 
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of as a monoclonal disorder in terms of IgHV, that solely affects mature B-
cells. However, if it were possible to identify IgHV subclones from different 
Vh families this would suggest that the pre-leukaemic stem cell would be 
pre-B in origin, if not earlier. Therefore, the aim of the study in this chapter 
was to develop and validate an NGS method to analyse the IgHV region. 
Three methods were used; an in-house assay on the Roche 454 platform, 
an in-house assay on the Illumina MiSeq platform and the Invivoscribe 
Lymphotrack IGH Somatic Hypermutation Assay. 
  
70 
 
3.2 Materials and Methods 
3.2.1 Patient Samples 
3.2.1.1 In-house Assays  
Unsorted cells from 15 patients with CLL were used in these studies (From 
population C, Appendix 2). For the 454 analysis, DNA was extracted as 
previously described (Section 2.2) and for the MiSeq analysis cDNA was 
extracted as previously described (Section 2.3). In addition, cDNA from 2 
non-CLL patients was used to illustrate the normal B-cell repertoire.  
 
3.2.1.2 Invivoscribe IGH Somatic Hypermutation Assay 
For this study cDNA was extracted from CD19+ purified cells from a cohort 
of 270 patients (Population A, Appendix 2)  
 
3.2.2 Sanger Sequencing 
Samples were amplified and analysed using the InvivoScribe Somatic 
Hypermutation Kit V2.0 as described previously (Section 2.6.1). 
 
3.2.3 454 Analysis 
3.2.3.1 Sample Preparation and Running 
The clone-specific VDJ rearrangement in the IgHV was amplified using the 
specific Vh family primers (GS FLX primers, Appendix 1) in a 50ul mix 
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containing 25ul Phusion PCR Buffer (M0532S, NEB), 1ul of forward and 
reverse primer (10uM of each primer) and 1ul DNA extracted from 
sequential samples taken at diagnosis, post first treatment and at 
subsequent relapse on 3 CLL patients with an unmutated IgHV and 1 
patient with a hypermutated IgHV.  The amplification conditions consisted 
of an initial denaturation step of 94°C for 3min followed by 30 cycles of 
94°C for 30secs, 60°C for 45sec and 72°C for 1mins, followed by a final 
7min extension at 72°C. PCR product was then cleaned using the AmpPure 
method (Section 2.7.1) and quantified using the Bioanalyser (Section 2.4.3). 
These products were sequenced on a 454-FLX (Roche Diagnostics, Basel, 
Switzerland).   
 
3.2.3.2 Data Analysis 
Resulting sequences were analysed using a Perl script. The primers were 
removed and reads of less than 200bp were eliminated from the analysis.  
The reads were then grouped in Excel to identify recurrent sequences. 
Reads with less than 100 copies were discarded from the analysis. The 
remaining reads were then visualised in Jalview (Waterhouse et al 2009) to 
identify differences between the sequences. 
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3.2.4 Illumina MiSeq 
3.2.4.1 In House Assay 
3.2.4.1.1 Sample Preparation 
1ul of cDNA from 10 patients with CLL and 2 non-CLL patients was 
amplified for each Vh family individually using the MiSeq Leader and JH 
primers (Appendix 1) in a 25ul mix containing 5ul Hotstart HiFidelity PCR 
Buffer and 0.1ul HiFidelity polymerase (202602, Qiagen), 1ul of forward 
and reverse primer (10uM of each primer). The amplification conditions 
consisted of an initial denaturation step of 95°C for 5mins followed by 35 
cycles of 94°C for 15secs, 57°C for 1min and 72°C for 2mins, followed by a 
final 10min extension at 72°C. PCR product was then cleaned using 
AmpPure (Section 2.7.1).The product was then quantified using the Qubit 
(Section 2.4.2) and 2ul of each Vh product pooled for each sample giving 12 
pooled samples. These were tagged using the Nextera protocol (Section 
2.7.2), then cleaned again using the AmpPure method. The cleaned 
products were then quantified using the KapaQuant kit (Section 2.7.3). 
From this a 10pMol library with 10% PhiX was prepared and loaded onto 
the Illumina MiSeq (Section 2.7.4) 
 
3.2.4.1.2 Data Analysis 
The FASTA files generated from the run were paired together using FLASH 
(Magoč and Salzberg 2011) and the primer sequences removed using 
Cutadapt (Martin 2011). Files were then uploaded to Galaxy 
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(https://usegalaxy.org/) and collapsed to count recurring reads. The 
collapsed reads were then exported as a FASTA file which was uploaded to 
IMGT HighV-Quest (Alamyar et al 2012) online analysis tools to enable 
identification of the IGH rearrangement. This analysis produces a 
compressed folder comprising of several txt files. The 1_Summary file was 
then analysed using Excel to generate a csv file. Bubble plots were 
generated with the csv file using the ggplot2 package (Wickham 2009) in R-
Studio (RStudio Team 2015). 
 
3.2.4.2 Invivoscribe LymphoTrack IGH Somatic Hypermutation 
Assay  
Samples were amplified using the LymphoTrack IGH Somatic 
Hypermutation Assay, loaded onto the MiSeq and analysed using the 
LymphoTrack IGHV SHM Software (Section 2.7.5). 
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3.3 Results 
3.3.1 454 Analysis 
3.3.1.1 Concordance with Sanger sequencing 
To determine whether NGS would be appropriate for investigating the IgHV 
region, DNA from five patients was analysed using NGS on the 454 platform 
and compared to the gold-standard method of SSeq. Comparison of the 
dominant clone identified by NGS in the diagnostic sample showed that the 
sequence was identical to the one determined by SSeq (Table 3.1). 
 
3.3.1.2 Sub-clonal Analysis 
Sub-clonal analysis was performed on four of the five patients. Since this 
analysis only used the VH-family specific primer the subclones all contained 
the same V-, J- and D-genes (known as clonotype) as the major clone. 
Subclones with reads of over 100 copies in at least one sample (diagnosis, 
post-treatment or relapse) were visually assessed in Jalview (Waterhouse 
et al 2009) for differences. For CLL044 and CLL063, six subclones were 
identified, for CLL056 seven subclones were detected and for CLL003 21 
subclones were found (Figure 3.1 Figure 3.2, Table 3.2). Of the 36 sub-
clones identified over the four samples, 33 were caused by indels (92%). 
Two of the remaining three sub-clones were the result of transition 
mutations, a C to T mutation in CLL056 and a G to A mutation in CLL003. 
The final sub-clone, in CLL003, had both a transition and an indel mutation. 
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Table 3.1. Comparison summary of SSeq and the dominant clone identified using NGS from the 454. 
Sequences obtained from both techniques were analysed using the IMGT V-Quest tool to determine 
V-gene, V-gene identity to germline, J-gene, J-gene identity to germline and D-gene.  
Sample Method V-gene V-gene 
Identity 
to 
Germline 
J-gene J-gene 
Identity 
to 
Germline 
D-gene 
 
 
CLL003 SSeq IGHV1-
69*01   
219/219 
nt 
IGHJ6*02  43/47 nt IGHD3-
3*01  
NGS IGHV1-
69*01   
219/219 
nt 
IGHJ6*02  43/47 nt IGHD3-
3*01  
CLL044 
 
SSeq IGHV3-
30*03 
206/223 
nt 
IGHJ4*02 23/31 nt IGHD6-
13*01  
NGS IGHV3-
30*03 
206/223 
nt 
IGHJ4*02 23/31 nt IGHD6-
13*01  
CLL056 
 
SSeq IGHV3-
48*03 
221/223 
nt 
IGHJ4*02  26/31 nt IGHD6-
6*01  
NGS IGHV3-
48*03 
221/223 
nt 
IGHJ4*02  26/31 nt IGHD6-
6*01  
L13 
 
SSeq IGHV3-
72 
220/224 
nt 
IGHJ6*02 40/46 nt IGHD2-
2*02 
NGS IGHV3-
72 
220/224 
nt 
IGHJ6*02 40/46 nt IGHD2-
2*02  
CLL063 
 
SSeq IGHV3-
21*01 
218/223 
nt 
IGHJ6*02 31/36 nt IGHD2-
15*01  
NGS IGHV3-
21*01 
218/223 
nt 
IGHJ6*02 31/36 nt IGHD2-
15*01  
 
 
3.3.1.3 Clones remain stable over time 
Sequential samples taken at post-treatment and subsequent relapse was 
available on four patients. To determine the clone stability over time DNA 
from these samples was analysed on the 454 platform. The technical 
results of this analysis are summarised in Table 3.2. Analysis of the 
sequential data showed that all sub-clones were present at all the time-
points. For three of the four samples, CLL044, CLL063 and CLL056, the 
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clones remained stable over time, with the major clone making up at least 
90% of the reads in each sample (Figure 3.1). In CLL056, the most dominant 
subclone occupied a maximum of 1.3% of the reads with the remaining 
subclones each having less than 1% individually and collectively they 
represented 1.7%, 1.4% and 1.7% of the analysed reads at diagnosis, post-
treatment and relapse, respectively. The subclones in CLL063 were a 
greater proportion of the analysed reads with a combined average of 5.8%. 
As with CLL056, there was a more dominant subclone which in this case, 
appeared to be expanding at relapse. CLL044 was the only M sample in this 
cohort. For this patient, the most dominant subclone occupied an average 
of 5.9% of the reads, although this clone appeared to be marginally 
growing out at relapse. The other subclones detected in this patient are 
consistent at diagnosis and relapse, collectively representing 1.3% of the 
reads in both cases, although there was a slight expansion in these clones 
post-treatment to around 4%. 
 
Table 3.2 Technical result summary of sequential samples on the 454 platform 
 CLL003 CLL063 CLL056 CLL044 
No. of reads 
over 250bp 
/ total 
number of 
reads 
 
% reads 
used in 
analysis 
Diagnosis 
38659 / 
43669 
88% 
28624 / 
41262 
69% 
34571 / 
41098 
84% 
16089 / 
27556 
58% 
Post-
treatment 
34702 / 
44030 
79% 
27532 / 
35188 
78% 
34851 / 
38018 
92% 
28329 / 
33076 
84% 
Relapse 
46815 / 
55045 
85% 
25867 / 
34941 
74% 
31915 / 
39370 
81% 
13156 / 
27556 
48% 
No. of recurrent clones 
in over 100 reads 21 6 7 6 
 
Figure 3.1 The different subclones detected in a.CLL044, b.CLL063 and c.CLL056 over the 3 time-points 
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Figure 3.2 The different subclones detected in CLL003 over the 3 time-point 
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One patient, CLL003, however, had fluctuating levels of sub-clones as 
illustrated by the IgHV region (Figure 3.2). At diagnosis, the major clone 
occupied just 55% of the total reads. This clone expanded following 
treatment and at relapse to about 75% of the reads. The most dominant 
subclone at diagnosis represented 39% of the total reads. However, this 
dramatically decreased post-treatment with an 80-fold reduction to just 
0.49%. At relapse, this clone had begun to expand again having increased 
to 13% of the reads. 
 
3.3.2 MiSeq Analysis using an in-house assay 
3.3.2.1 Concordance with Sanger sequencing 
To determine whether the MiSeq NGS platform would also be appropriate 
for investigating the IgHV locus, MiSeq analysis of the IgHV region was 
performed on cDNA from 10 patients and compared to SSeq. As with the 
454 platform, all rearrangements found by SSeq were also detectable by 
MiSeq NGS (Table 3.3). The average number of reads obtained for the 
dominant clone was 170,761 (range 3,342-661,730). 
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Table 3.3. Concordance between MiSeq and SSeq for 10 patients. In each case the sequences 
obtained from the SSeq and the MiSeq conveyed identical VH gene and the % homology to the 
germline (as determined using the IMGT/ Vquest tool). UM unmutated, M mutated 
 
MiSeq Sanger   
IgHV 
status Pt No VH Gene 
% 
homolog
y  VH Gene 
% 
homolog
y 
CLL129-Abs V1-69 100 V1-69 100 UM 
CLL130_Abs V1-69 100 V1-69 100 UM 
L43_Abs V1-69 99.65 V1-69 99 UM 
L49_abs V3-23 98.26 V3-23 98.26 UM 
L74_Abs V3-23 97.22 V3-23 97.22 M 
L76_abs V3-23 96.18 V3-23 96.2 M 
RA_Abs V3-48 96.53 V3-48 96 UM 
L48_Abs V3-13 96.14 V3-13 95.5 M 
TM_Abs V3-9 93.06 V3-9 93.4 UM 
 
3.3.2.2 Sub-clonal Analysis 
The work on the 454 had shown that frequency of subclones of the same 
clonotype as the major clone remained stable over time suggesting that 
VDJ recombination was either an early event in the leukogenesis of CLL or 
preceded the development of CLL. To determine whether VDJ 
recombination was an early event, different clonotype subclones other 
than the one detected in the major clone were analysed.  Since the 454 
study showed that a VDJ rearrangement could have several subclones 
which differed by a few bases, recurrent reads were further grouped 
together, following the IGMT/HighV-Quest analysis, if they were deemed 
identical through possession of the same clonotype (VDJ rearrangememt), 
regardless of SHM or productivity. Subsequently, the major clone (as 
defined by SSeq) was found to represent a median of 90.0% (range 60.7-
98.8) of the total reads (Figure 3.3) and in five of the nine samples this 
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accounted for over 90% of the total reads compared to the minor clones 
which made up less than 2% (Table 3.4).  
 
In four samples, the major clone comprised less than 90% of the reads. For 
three of these samples, the minor clones represented an average 18.8% 
(range 10.1-39.3) of the total reads (Figure 3.3f-h). Further analysis of the 
subclones identified in TM found the 2nd most frequent read, a V3-13, J4, 
D6-19 clonotype, was detected in 1% of the total reads. A V3-13, J4, D6-19 
clonotype was also found in CLL130 composed of 1.4% of the total reads 
and L74 was found to have a V3-21, J6, D5-24 clonotype that comprised 
1.2% of the total reads. 
 
 
 
Table 3.4. Summary of Subclone Analysis from the Miseq. Fasta files were analysed using the IMGT HighVquest online tool to identify the V,D, and J genes as well as the productivity of the 
rearrangement. To determine the number and % of reads representing the dominant clones reads that had the same VDJ rearrangement as the dominant clone regardless of SHM or 
productivity were grouped together. Minor clones were defined as any read that differed by at least 1 gene (V, D or J). The number of copies of the minor clone was defined as the number of 
unique reads that differed from the VDJ rearrangement found in the dominant clone  
Sample Total No. of 
Reads 
No. of Unique 
Reads 
No. of Reads 
Representing 
Dominant 
Clone 
% Reads 
Representing 
Dominant 
Clone 
No. of Reads 
Representing 
Minor Clones 
% Reads 
Representing 
Minor Clones 
No. of Reads 
Representing 
Productive 
Minor Clones 
Range in the 
No. of Copies 
of the Minor 
Clones (min 
to max) 
CLL129 33704 16137 32604 96.7 294 0.9 211 1-8 
CLL130 3805 254 3342 87.8 401 10.5 305 1-24 
L43 191914 65976 181142 94.4 2283 1.2 1519 1-87 
L48 669631 192511 661730 98.8 746 0.1 346 1-11 
L49 154352 64813 138856 90.0 1695 1.1 1283 1-99 
L74 104359 55939 77070 73.9 15921 15.3 13711 1-399 
L76 261387 143129 158635 60.7 102752 39.3 65928 1-9005 
RA 190607 77256 184565 96.8 3083 1.6 2395 1-142 
TM 9830 7088 8091 82.3 996 10.1 773 1-11 
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Figure 3.3. The dominant clone represents an average of 90% of the reads in samples with one major 
clone. The bubbleplots show the frequency of the different clonotypes found in 8 of the CLL samples. 
a.RA, b.L49, c. L43, d.L48, e.CLL129, f.L74, g.TM, h. CLL130. The V-gene is plotted along the X-axis, 
the D-gene along the Y-axis and the J-gene is represented by the colour of the bubble. The size of the 
bubble reflects the frequency of the clonotype. These 8 samples were all found to be IgHV-
monoclonal as the major clone represents an average of 90% of the reads (range 74-99). 
 
 
In one sample, L76, it was possible to detect a second clonotype comprised 
of a V1-69, a J6 and a D3-3 with 100% homology to the germline V1-69 
gene, indicating that this was an UM subclone. This subclone represented 
28% of the total reads for this patient (Figure 3.4a). The major clone 
identified by SSeq was a M V3-23 gene alongside a J4 and D6-6 
rearrangement. The major clone would be correlated with good prognosis, 
whereas the minor clone would be associated with a poorer outcome. Both 
clones can be visualised on agarose gel electrophoresis of the IgHV, 
amplified using the individual VH leader primers (Fais et al 1998) (Figure 
3.4b).  
 
3.3.2.3 The B-cell repertoire 
In each CLL sample, it was possible to observe VDJ clonotypes other than 
the major clone that had been identified using SSeq. To determine whether 
these rearrangements represented the normal background B-cell 
repertoire, cDNA from two aged-matched healthy controls underwent IgHV 
analysis on the MiSeq using the in-house assay. C1 generated a total of 
401,090 reads and C2 produced 17,569 reads. Of these reads 78% and 87% 
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respectively were unique. In comparison, an average of 42% of the total 
reads were unique for the nine CLL samples. 
 
 
Figure 3.4. Subclonality in L76. a. The bubble-plot shows both the VH3-23, J4, D6-6 clonotype (blue) 
as well as the V1-69, J6, D3-3 clonotype (pink).  b. Electrophoresis on 3% agarose gel of IgH amplified 
using the specific VH leader primer for VH1, VH2 and VH3. There are 2 leader primers for VH3; VH3a 
and VH3b. 
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Figure 3.5. Repertoire of the VDJ rearrangement in samples of 2 healthy age-matched controls. Both 
C1 (a) and C2 (b) show a polyclonal picture.  
 
The frequency of the different VDJ clonotypes in these samples was 
variable. In C1, the most abundant rearrangements were a V3-9, J6, D3-3 
rearrangement, a V3-21, J6, D6-13 rearrangement and a V3-48, J6, D2-2 
rearrangement (Figure 3.5a). These represented 1.7%, 1.0% and 0.99% of 
the total reads, respectively. There appeared to be only one dominantly 
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recurring clonotype in C2 which was composed of a V1-46, J4, D5-24 
rearrangement that comprised 3.1% of the total reads (Figure 3.5b). 
 
3.3.3 MiSeq Analysis using the Invivoscribe Lymphotrack 
SHM Kit 
The Invivoscribe Lymphotrack SHM kit is a commercially available kit that 
uses a single multiplex PCR mastermix. It therefore has a shorter 
processing pipeline than the in-house methodology as it does not require 
the Nextera tagging step or the Kapa quantification step. Furthermore, the 
kit is supplied with a built-in analysis software which enables rapid analysis 
of the NGS data obtained from the MiSeq.  
 
3.3.3.1 Concordance with Sanger sequencing 
To determine whether the Invivoscribe Lymphotrack SHM kit was suitable 
for NGS IgHV analysis, it was used on cDNA from 270 patients with CLL and 
compared to SSeq. As with the both the 454 platform and the in-house 
MiSeq assay, all rearrangements found by SSeq were also detectable using 
the Invivoscribe kit and bioinformatics pipeline.  Previous analysis using 
SSeq had identified that 50.0% (135/270) of patients were IgHV M, 38.5% 
(104/270) were UM and 11.5% (31/270) were believed to be polyclonal as 
SSeq was inconclusive due to the appearance of more than one sequencing 
read. In comparison, NGS could identify productive clonotypes in all 
patients. For samples with conclusive SSeq results, the concordance 
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between SSeq and NGS for the major clone was 98.3% (235/239); 87.9% 
(210/239) had identical results and 10.5% (25/239) had the same clonotype 
however the percentage homology to the germ-line differed slightly with a 
median error of 0.6% (range, 0.2 -1.6). For the remaining 1.7% (4/239), 
SSeq detected another clone which was less abundant by NGS, but still 
detectable. 
 
3.3.3.2 Sub-clonal Analysis 
The subclonal analysis using the Invivoscribe kit focussed solely on the first 
200 most abundant reads (MARs). This was primarily because these were 
the sequences presented by the Lymphotrack software but also because 
the analysis of the healthy age-matched controls in section 1.3.2.3 showed 
that normal B-cells could comprise up to 3.1% of the total reads and the 
200 MARs accounted for an average of 24% of the total reads (range 5-
50.4), therefore suggesting that any low level clonotypes represented CLL 
subclones as opposed to the normal B-cell background. 
 
Analysis of the 200 MARs found that 76.3% (206/270) had only one 
clonotype. Interestingly, in addition to the 11.5% (31/270) patients found 
to be polyclonal by SSeq analysis, a further 33 patients were found to have 
more than one productive VDJ rearrangement. This meant that 23.7% 
(64/270) of this patient cohort had multiple productive clonotypes. To 
verify the presence of these subclones, five patients with subclones of 
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different Vh families underwent IgHV PCR amplification using individual 
and specific VH family primer. For each patient, the NGS-predicted VH 
family amplification was always observed even when the subclone was 
present at a low frequency (<5% of the MARs) (Figure 3.6). This suggested 
that the subclones identified in this patient cohort were not a 
bioinformatic artefact. 
 
 
Figure 3.6. NGS can detect multiple specific VH family rearrangements. Electrophoresis on 2% 
agarose gel of IgHV amplified using specific VH leader primer for 5 subclonal representative patients. 
NGS clone frequencies are also provided. Even low frequency clones (<5%) are confirmed by 
electrophoresis. Beta globin was used as endogenous control. All: multiplex including all VH primers 
as positive control. NTC: no template control. 
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3.4 Discussion 
The IGH locus undergoes VDJ rearrangement during B-cell development to 
produce a rearrangement that is unique to the cell. In mature B-cell 
neoplasms, such as CLL, the locus therefore provides a marker of clonality. 
Previous studies have found the level of SHM that the rearrangement has 
undergone to be an independent marker of prognosis (Damle et al 1999, T 
J Hamblin et al 1999).  Additionally, it is well known that there is a bias 
amongst the VDJ rearrangements found in patients with CLL as 
stereotyping can be demonstrated in over a third of patients in their CDR3 
(Section 1.2) (Agathangelidis et al 2012, 2014). Correlation of this 
stereotyping to clinical data has enabled recurrent subsets which share 
clinical and biological features to be identified (Bomben et al 2009, Rossi 
and Gaidano 2010). This strongly implies that CLL may be antigen driven 
and, therefore, further analysis of the IgHV locus may elucidate the 
pathogenesis of CLL and potentially be beneficial in determining patient 
outcome. The aim of the study described in this chapter was to determine 
if NGS could be utilised to interrogate the IgHV locus, particularly for 
detecting subclones. It further sought to identify the best platform and 
method for NGS interrogation of the IgHV locus.  
 
3.4.1 Use of the two NGS Platforms 
The amplified size of the rearranged VDJ can vary depending on the 
components of the rearrangement and the primers used to amplify the 
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product. Both DNA and cDNA amplified using the FR1 primers will produce 
a fragment of 310-360bp (van Dongen et al 2003), whereas use of the 
leader primers will generate a 410-490 fragment for cDNA and a 500-570bp 
product for DNA (Szankasi and Bahler 2010). Leader primers tend to be the 
first option for IgHV analysis as the whole of the gene is amplified, enabling 
total interrogation of the locus (Ghia et al 2007).  These primers, however, 
can be problematic as the larger fragment can cause reduced PCR 
efficiency, particularly when using DNA. This may also present a challenge 
for certain NGS platforms.  The FR1 primers, in contrast, are more robust 
but as they are located within the IgHV gene it is not possible to obtain the 
full sequence; therefore, percent homology to the germline is estimated 
(Langerak 2009). Both the FR1 and the leader primers were used in this 
study.   
 
Two NGS platforms were utilised; the Roche 454-FLX and the Illumina 
MiSeq. The 454-FLX was the original instrument of choice as it was the only 
platform at the time that was capable of analysing reads of up 400bp. The 
results obtained from the 454 were consistent with the SSeq 
demonstrating that it would have been suitable for IgHV analysis. However, 
whilst the 454 was capable of both forward and reverse sequencing it did 
not, at that time, perform paired-end sequencing and therefore, there was 
no confirmation of the individual sequences. This can be beneficial 
particularly at the end of the reads when the reagents are nearing 
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exhaustion and the quality of the data decreases, especially for this 
analysis whereby single base differences may represent a true subclone or 
a sequencing artefact.  
 
Developments in the Illumina Miseq chemistry meant that it became 
possible to perform 300-cycle pair-end sequencing enabling 600bp 
sequencing. The added advantage of this system was that as the 
sequencing was paired-end, the forward reaction would sequence one-way 
then the reverse would start at the other end of the fragment and 
sequence back towards the start. This meant that a fragment of 500bp 
would have an overlap of 100bp in the middle, enabling confirmation of 
base changes in this region of the sequencing. Since the overlapping region 
was the end of the fragment to be sequenced in both directions, this was 
the area most prone to sequencing errors caused by the exhaustion of the 
reagents. Double confirmation of base-changes in the region provided 
assurance as to its reliability. 
 
Irrespective of the advantages associated with either platform, results 
obtained from both the Roche 454 and the Illumina MiSeq were consistent 
with the traditional gold-standard method of SSeq, showing that either was 
suitable for this type of analysis.  
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3.4.2 Comparison of methodologies 
The methods used in this study included two in-house designed assays and 
one commercial kit. The kit was released after the development of the two 
in-house assays and offered a more rapid sequencing procedure as well as 
having the additional benefit of an analysis software. This was a significant 
advantage since the 454 methodology relied heavily on bioinformatic 
support which was not readily available at the time of the study, whilst the 
bioinformatics analysis of the in-house MiSeq assay used multiple 
command-line software tools that were not designed specifically for that 
type of investigation, resulting in a time-consuming bioinformatic analysis. 
In comparison, the software provided with the Invivoscribe kit was easy 
and relatively quick to use. Furthermore, the software produced multiple 
graphics to aid in the interpretation of the data. 
 
The Invivoscribe kit also offered a more rapid PCR processing pipeline in 
comparison to the in-house MiSeq assay. Whilst the method used for the 
in-house MiSeq assay controlled for PCR bias through the amplification of 
each VH-family independently, it also created a more timely and 
complicated process as each sample had eight PCR mixes (one for each VH-
family and a NTC). This meant that it was difficult to process large numbers 
of samples, limiting the potential usefulness of this assay. 
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Therefore, the Invivoscribe Lymphotrack Kit was chosen as the most 
suitable assay due to its simple processing and user friendly bioinformatics. 
 
3.4.3 Subclonal Analysis 
3.4.3.1 454 
Using the VH family specific primers, it was possible to identify subclones in 
all the samples using the 454 platform. Reads of less than 250bp and 
recurrent reads under 100 copies, unless present in sample from a 
different time-point, were excluded from this analysis. Reads of less than 
250bp were discounted as they would not enable complete examination of 
the IgHV region as well as the possibility that they were the result of 
sequenced primer dimerisation. Reads with less than 100 copies were also 
omitted on the assumption that they may be the result of polymerase 
errors. 
 
NGS sequencing analysis of sub-clonal populations can present some 
problems in regards to what represents a true sequencing variant and what 
is artefact generated during the initial amplification stage or during 
sequencing. The Phusion Taq used for the 454 sequencing has a reported 
error rate of 5.5x10-7 mutations/bp amplified (Li et al 2006), although 
McInerney et al (2014) found the error rate to be 2.6x10-6. In their study, 
McInerney et al found both transition and indel mutation polymerase 
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errors when using the Phusion Taq but no transversions. This is comparable 
with the subclones identified in this study, so it is possible that the 
differences are the result of polymerase errors in the initial amplification. 
However, using a 30 cycle PCR to generate a 300bp product would mean 
0.4% of reads would have an error. This study produced an average of 
38400 reads per sample equating to just 154 reads with polymerase 
mutations.  
 
Most of the subclones detected were caused by indel mutations (92%). The 
pyrosequencing chemistry utilised by the 454 is prone to indel errors in 
homopolymer tracts (Wang et al 2007).  Boyd et al (2009), Bashford-Rogers 
et al (2013) and Campbell et al (2008) all report errors to be at a higher 
rate than other types of sequencing error and that they are inserted at 
either the beginning or the end of short (>4bp) homopolymer runs 
(Campbell et al). A further consequence of these particular artefacts is the 
erroneous insertion of the homopolymer nucleotide at its next genuine 
occurrence following the tract. To overcome this problem, they discounted 
indels from their analysis, suggesting that the resulting frameshift would 
produce a non-functioning protein. It is possible that the indels detected in 
the subclones in this chapter are the result of sequencing artefacts. 
However, these subclones were reproducible as they were recurrent in all 
three samples from the same patient, albeit at differing proportions in 
some instances. 
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Of the four patients who had sequential samples, three demonstrated 
relatively constant subclonal frequencies over the three time-points. 
CLL003 however had fluctuating sub-clonal fractions. This patient had a 
rapidly progressing disease and died within three years of diagnosis. 
Therefore, this may account for the change in the clones over time. 
Furthermore, this patient subsequently went on to have whole genome 
sequencing on sequential samples which showed a very similar picture 
(Schuh et al 2012). Therefore, it is possible that the IgHV analysis may 
represent a surrogate measurement for the subclonal dynamics identified 
in this patient.  
 
3.4.3.2 MiSeq 
Both the in-house methodology and the Invivoscribe Lymphotrack kit used 
the leader primers to amplify cDNA to enable detection of the whole of the 
IgHV region that was expressed by the CLL cells. Focussing the analysis 
solely on expressed IgHV rearrangements prevented non-functioning 
unproductive rearrangements from inappropriately skewing the data. 
 
The in-house methodology used all the VH family primers together, as 
opposed to the family-specific primer used in the 454 study. This approach 
enabled detection of a second VDJ rearrangement in one patient. In this 
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instance the major clone defined by SSeq identified a M rearrangement 
which would conventionally be associated with good prognosis. However, 
NGS further identified an UM minor clone. Bi-clonal productive 
rearrangements of the IgHV locus have previously been reported (Kern et 
al 2014, Plevova et al 2014) with one study reporting that patients carrying 
rearrangements of discordant mutational status had shorter TFS and OS 
then patients with two hypermutated rearrangements (Visco et al 2013). 
Current guidelines however recommend that it is not possible to offer a 
conclusive clinical interpretation of the result (Langerak et al 2011). 
 
The release of the Invivoscribe Lymphotrack kit meant that it was possible 
to perform IgHV-NGS on a larger cohort pf patients. Analysis of 270 
patients with CLL found that the number of patients with multiple 
productive rearrangements was 24%. This is higher than has been found in 
previous studies where the percentage of CLL patients with more than one 
IgHV clone has been reported in <5% of CLL cases (Plevova et al 2014, 
Rassenti and Kipps 1997, Visco et al 2013). Since these other studies used 
SSeq, the increased sensitivity of NGS and its ability to amplify and 
sequence mixtures of DNA templates more reliably compared to SSeq, 
could provide an explanation for the detection of a larger number of 
subclonal IgHV patients. However, it is also possible that these subclones 
could represent the normal polyclonal B-cell background.  
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3.4.4 Conclusions 
The work in this chapter has demonstrated that NGS is, in principle, highly 
suited to analysis of the IgH, particularly for detection of subclones. Whilst 
all three methodologies were comparable with the current gold standard 
of SSeq, the Invivoscribe Lymphotrack Kit was shown to be superior in 
terms of sample processing and bioinformatic analysis. The discovery that 
around a quarter of CLL cases have multiple productive VDJ clonotypes 
provides evidence for a leukaemia initiating event that takes place prior to 
recombination. However, further work needs to be done to establish the 
sensitivity and false positive rate for sub-clonal detection using NGS as well 
as determining the clinical implications of these IgHV subclones within a 
CLL patient cohort. 
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Chapter 4  Subclonal IgHV rearrangements 
are clinically relevant in chronic lymphocytic 
leukaemia 
 
4.1 Introduction 
The work described in the previous chapter found that patients with 
subclonal IgHV rearrangements occurred at a higher frequency then has 
been previously described (Plevova et al 2014, Rassenti and Kipps 1997, 
Visco et al 2013), yet the clinical relevance of this is unclear. Whilst the 
identification of subclones that have different productive VDJ clonotypes 
would support a precursor B-cell as the leukaemic stem cell in CLL, it is also 
possible that these subclones are the part of the normal poly-clonal B-cell 
background. 
 
The work described in this chapter aimed to further investigate these IgHV 
subclones. This was done firstly by analysing the normal B-cell repertoire to 
establish if the subclones are background normal B-cells. Secondly, it was 
determined if these clones had any effect on prognosis. 
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4.2 Materials and Methods 
4.2.1 Patient Samples 
Population A used cDNA from a cohort of 270 unselected patients 
(Appendix 2). Population B used gDNA from a cohort of 227 pre-treatment 
CLL patients enrolled into two UK based FCR clinical trials (appendix 2). As a 
control, cDNA was extracted from purified B-cells taken from 10 age-
matched controls (Table 4.1). 
 
Table 4.1. Summary of healthy age-matched controls 
Sample Age (years) CD19+ cells (%) 
AMCONTROL1 77 92.2 
AMCONTROL2 86 92.3 
AMCONTROL3 80 94.6 
AMCONTROL4 90 97.4 
AMCONTROL5 75 96.9 
AMCONTROL6 71 92.3 
AMCONTROL7 75 98.3 
AMCONTROL8 59 97.2 
AMCONTROL9 62 97.7 
AMCONTROL10 61 97.3 
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4.2.2 Invivoscribe LymphoTrack IGH Somatic Hypermutation 
Assay  
Samples were amplified using the LymphoTrack IGH Somatic 
Hypermutation Assay, loaded onto the MiSeq and analysed using the 
LymphoTrack IGHV SHM Software (Section 2.7.6)  
 
4.2.3 Targeted NGS and SNP Array Analysis  
DNA from population B was analysed using SNP arrays (Section 2.8) and a 
targeted TSCA panel (Section 2.7.6 and Appendix 3). 
 
4.2.4 Statistical Analysis 
All analyses were performed with Graphpad Prism 5.0 software or IBM 
SPSS 13.0 software (Section 2.9) 
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4.3 Results 
4.3.1 Factors effecting the detection of subclones 
 
4.3.1.1 The normal polyclonal background B-cell repertoire  
To assess the diversity of the normal B-cell repertoire, cDNA from 10 
healthy age-matched volunteers was analysed using the Invivoscribe NGS 
IGH kit. The analysis was limited to the first 200 most abundant reads 
(MARs) to mimic the analysis of the CLL samples. Polyclonality was 
demonstrated in all cases with the healthy controls expressing a median of 
46.5 (range 28-53) different V-genes in the 200 MARs. These V-genes were 
found in combination with different J-genes as is demonstrated through 
the detection of multiple VJ clonotypes (Figure 4.1). The most common VJ 
clonotype comprised an average of 25% of the 200 MARs (range 7.6-49.9). 
Since, typically, most pre-treated CLL peripheral blood samples contain 
over 90% CLL cells (Ternynck et al 1974), polyclonal B-cell contamination 
would be found in less than 0.4% of the total reads. However, to ensure 
that subclones were real, CLL samples were only considered as subclonal if 
the minor clone represented over 2.5% of the 200 MARs. 
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Figure 4.1.  NGS IgHV profiles of B cell from healthy donors. Panels 1 to 10 represent the NGS IgHV 
profile of 10 purified B cells samples from healthy age-matched donors. The graphs are calculated by 
the lymphtrack software (Invivoscribe). 
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4.3.1.2 Effect of using cDNA or DNA on IgHV subclonal detection 
 
Figure 4.2. There is good concordance between cDNA and gDNA in the detection of subclones 
although cDNA is superior in detecting low level clones. NGS IgHV analysis of cDNA and gDNA from 8 
patients. Black dots are productive rearrangements and orange dots are unproductive 
rearrangements. R2=0.70, p<0.0001 
 
To determine the effect of using cDNA versus gDNA, cDNA and gDNA 
samples from eight patients were analysed in parallel (Figure 4.2). Whilst 
the data showed a significant correlation (R2=0.70, p<0.0001) and overall, 
using the 2.5% cutoff, the concordance between cDNA and gDNA was 87% 
(20/23), there were some discrepancies. Firstly, three subclones that were 
detected using cDNA were found below the 2.5% cutoff in gDNA and would 
therefore been discounted from the analysis. Also, in one instance, two 
unproductive rearrangements were detected at a lower frequency using 
cDNA compared to gDNA.  
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4.3.1.3 Normal B-cell contamination into CLL samples does not 
introduce false subclones  
Since it was demonstrated that cDNA can detect more subclones than 
gDNA, and it is widely accepted that CLL cells have a decreased expression 
of Ig in comparison to normal B-cells (Batata and Shen 1992, Ludescher et 
al 1992, Merson and Brochier 1988, Ternynck et al 1974), it is possible that 
by using cDNA the impact of the background B-cells may be artificially 
elevated and cause the detection of false subclones. To investigate this 
further, cDNA from purified B-cells taken from three healthy controls was 
serially diluted into cDNA from one clonal and from one subclonal CLL 
sample (Figure 4.3). In both incidences, the normal B-cell contamination 
polyclonal was undetectable in the first 200 MARs even at a 50:50 dilution 
ratio and with all normal B-cell clonotypes considered. This suggests that 
the subclones detected in the CLL samples are not the background normal 
B-cells and provides additional support for the 2.5% cutoff for the 
detection of subclones. 
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Figure 4.3. Polyclonal background B-cells are undetectable in CLL samples. Monoclonal (a) and 
biclonal (b) CLL cDNA (blue) was serially contaminated with cDNA from purified normal B cells 
(green). The frequency of each clonotype was calculated for the 200 most abundant clones. 
Polyclonal B-cells were not detectable in CLL samples with up to 50% normal B-cell contamination. 
 
 
4.3.1.4 Effect of multiplex PCR versus singleplex PCR on IgHV 
subclonal detection 
To determine if using a multiplex PCR mix, as provided in the Invivoscribe 
kit, could influence the detection of small subclones that would possibly 
not be detected by a normalized PCR approach through amplification bias, 
each of the seven Vh-leader forward primers were amplified with the 
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consensus JH reverse primer in individual and separate PCR reactions for 
six patients with CLL. Following amplification, the seven reactions were 
normalised, pooled and sequenced by NGS. In parallel, the samples were 
also analysed using the Invivoscribe kit.  23 different clonotypes were 
detected in total amongst the six patients and, whilst some clonotypes 
were detected in the individual reaction but not in the multiplexed reaction 
and vice versa, these were all below the 2.5% background cut-off. 
Importantly, the frequency of major clonotypes between individual 
reaction and multiplex PCR were significantly correlated with a R² of 0.9992 
(Figure 4.4). 
 
 
Figure 4.4. There is significant concordance between singleplex and multiplex PCR amplification of 
the IgHV locus. cDNA from 6 patients was amplified in 7 individual reactions for each of the Vh-family 
leader primers prior to NGS and compared to results obtained using the Invivoscribe kit. R2= 0.9992, 
p<0.0001. 
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4.3.2 NGS identifies five prognostically significant subgroups 
in an unselected patient cohort (Population A) 
NGS analysis of the IgHV locus in a cohort of 270 unselected patients 
(population A) found that 23.7% (64/270) had multiple productive 
rearrangements. Of these 64, 65.6% (42/64) had two subclones, 18.8% 
(12/64) had three subclones and 15.6% (10/64) had four or more 
subclones. The median frequency of the second, third and fourth most 
abundant clones was 10.3% (range 2.5-50%), 3.7% (range 2.5-25.2%) and 
6.5% (range 2.5-15.5%) respectively. 
 
Since NGS could identify different subclones in some patients, five different 
categories were created: patients with (i) multiple M clones (MultiM), (ii) 1 
M clone, (iii) a mix of M-UM clones, (iv) 1 UM clone (+subset #2 VH3-21), 
(v) multiple UM (Multi-UM) clones. SSeq had previously identified 135 M 
patients with a TFS of 131 months, 102 UM patients with a median TFS of 
33 months and 31 polyclonal patients with a median TFS of over 280 
months. Using the new NGS classification the SSeq-M patients could be 
further divided into three subgroups with a median TFS of >280 (MultiM), 
131 (M), 56 (Mix) months (P=0.0037), the SSeq-UM patients into three 
subgroups with a median TFS of 94 (Mix), 29 (UM), and 40 (Multi-UM) 
month (P=0.0049) and the polyclonal patients, previously inconclusive by 
SSeq, into three subgroups with a median TFS of >280 (Multi-M), 111 (M), 
and 4 months (Multi-UM) (P=0.0167) (Figure 4.5). 
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Figure 4.5. NGS-IgHV refines SSeq classification. TFS according to IgHV mutational status determined 
by SSeq, was plotted with Kaplan-Meier methods for all patients. NGS-IgHV classification was after 
applied to M patients by SSeq (a), to UM patients by SSeq (b) and to polyclonal patients inconclusive 
by SSeq (c) in terms of TFS. Difference between curves was assessed with the log rank test and 
median survival for each subgroup of patients was provided. 
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Figure 4.6. NGS-IgHV defines 5 different prognostic subgroups. TFS (a) and OS (b), according to NGS-
IgHV classification, were plotted with Kaplan-Meier methods. Difference between curves was 
assessed with the log rank test and median survival for each subgroup of patients was provided. 
 
Applying the NGS-IgHV classification to the whole cohort identified five 
subgroups with median TFS of >280 (Multi-M), 131 (M), 94 (Mix), 29 (UM), 
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19 (Multi-UM) months (P<0.0001) and a median OS of >397, 292, 196, 137, 
94 months (P<0.0001) (Figure 4.6).  
 
Table 4.2. Number of deaths in Binet Stage A patients.  
 No of Patients No of deaths % 
Multi-M 25 0 0 
M 98 9 9.2 
Mix 27 5 18.5 
UM 41 11 26.8 
Multi-UM 4 1 25 
 
 
Since Binet Stage A patients account for over 80% of new diagnoses  
(Baliakas, Hadzidimitriou, et al 2015), the model was applied to Binet Stage 
A patients only. In Population A, Stage A patients represented 72.6% 
(196/270) of the total patients.  The model was found to be a significant 
prognostic marker of TFS and OS for these patients (p<0.001) (Figure 4.7) 
although the median OS for the UM group was higher at 311 months than 
for both the Mix (196 months) and M (292 months) groups despite the UM 
group having a higher death rate (Table 4.2). This is most likely due to the 
low number of deaths in the Binet Stage A cohort; 13.3% (26/196) versus 
23.0% across the cohort (62/270). 
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Figure 4.7.  NGS-IgHV defines 5 different prognostic subgroups in Binet Stage A patients. TFS (a) and 
OS (b), according to NGS-IgHV classification, were plotted with Kaplan-Meier methods. Difference 
between curves was assessed with the log rank test and median survival for each subgroup. 
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Table 4.3. Predictive value of NGS-IgHV. PPV positive predictive value, NPV negative predictive value. 
* patient with at least a follow up of 2 years or receiving a treatment within 2 years after diagnosis. 
** patients with at least a follow up of 10 years or died within 10 years after diagnosis 
Treatment Prediction 
  No of 
Patients* 
% *Treated 
within 4 
years of 
diagnosis 
Untreated 
4 years 
after 
diagnosis 
PPV 
% 
NPV
% 
Sseq M 107 49 23 84   79 
  UM 90 41 62 28 69   
  Polyclonal 20 9 5 15 undetermined 
NGS Multi-M 19 9 1 18   95 
  1M 97 45 21 76   78 
  Mix M-UM 17 8 7 10 undetermined 
  1UM 79 36 56 23 71   
  Multi-UM 5 2 4 1 80   
  
 
 
 
 
  
 
   
Survival Prediction 
  No of 
Patients** 
% Deceased 
within 10 
years of 
diagnosis 
Alive 10 
years after 
diagnosis 
PPV 
% 
NPV 
% 
Sseq M 56 44 8 48   86 
  UM 58 46 31 27 53   
  Polyclonal 12 10 3 9 undetermined 
NGS Multi- M 9 7 0 9   100 
  1M 55 44 8 47   85 
  Mix M-UM 8 6 3 5 undetermined 
  1UM 52 41 29 23 56  
  Multi-UM 2 2 2 0 75  
 
 
 
115 
 
To determine the predictive power of the NGS-IgHV classification the 
positive predicative value (PPV) and negative predictive value (NPV) were 
calculated for both the NGS-IgHV and SSeq-IgHV subgroups. NGS-IgHV had 
a PPV of treatment initiation within 4 years of diagnosis, of 80% in patients 
with multiple UM clones and a NPV of 95% in patient with multiple M 
clones, compared to a PPV of 69% for SSeq-UM and a NPV of 79% for SSeq-
M. NGS-IgHV could also predict an OS of less than 10 years from diagnosis 
with a PPV of 75% for multiple UM and a NPV of 100% for multiple M 
subgroups compared with 53% for SSeq-UM and 86% for SSeq-M. For 
patients with only one clone (M or UM), similar PPV and NPV were 
observed between SSeq and NGS (Table 4.3).  
 
4.3.3 IgHV by NGS defines a very poor prognostic subgroup 
in a treatment-selected cohort (Population B) 
To validate the NGS-IgHV model, it was applied to a homogeneous clinical 
trial population, composed of 227 patients treated with FCR-based regimen 
(population B). In this cohort, NGS identifies productive clonal 
rearrangements in 99.1% of patients (225/227). The number of multiple 
rearrangements detected was less than population A at 11.5% (26/227).  
Furthermore, since population B is solely composed of patients that had 
received treatment, this introduced a bias in the patient population and 
therefore the five NGS-IgHV categories were not confirmed in this clinical 
trial population. This is unsurprising given that the frequency of multi-M 
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patients decreased from 10% in population A to just 3% in population B, 
whilst the frequency of Multi-UM patients increased from 2% to 9%. 
Indeed, the great majority of Multi-M patients in population A (90%) never 
required treatment and were therefore, by definition, would have been 
excluded from this clinical trial population.   
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Figure 4.8. NGS-IgHV defines a poor prognostic subgroup in a treatment selected clinical trial cohort. 
Difference between curves was assessed using an univariate analysis using with the log rank test and 
median survival for each subgroup of patients is provided. 
 
 
Despite this patient bias, it was possible to observe that Multi-UM patients 
had a far worse prognosis in terms of TFS compared to the rest of 
population B as these patients had a median TFS of just 2 months 
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(p=0.0016) (Figure 4.8). Additionally, the Multi-UM patients had a higher 
rate of progression compared to the rest of population B at 30.8% (4/13) 
compared to 21.9% (46/210) within 5 years of treatment, although neither 
group had reached its median progression free survival (PFS) at the time of 
writing. 
 
4.3.4 NGS-IgHV is an independent prognostic marker  
To compare how the NGS-IgHV model compared with other prognostic 
models described in Sections 1.5, a Cox regression analysis was used in 
Population A to determine the hazard ratios (HR). The presence of a 17p 
deletion was binarised (1); Binet stage A, B and C were named 0, 0.5 and 1, 
respectively; Döhner cytogenetic classification was named as 0, 0.25, 0.5, 
0.75, and 1 for 13q del, normal karyotype, trisomy 12, 11q del and 17p del, 
respectively, the CLL-IPI groups low risk, moderate risk, high risk and very 
high risk were called 0, 0.33, 0.66 and 1, respectively; and for NGS-IgHV, 
the five categories – (i) Multi-M; (ii) M; (iii) Mix M-UM; (iv) UM (+VH3-21), 
(V) Multi-UM - were named as 0, 0.25, 0.5, 0.75 and 1, respectively. Using 
this type of naming meant that the HR represents the hazard ratio between 
the very favourable prognosis group and the very unfavourable prognosis 
group whilst considering the intermediate groups in an ordinal manner.  A 
univariate Cox regression analysis (n=167) found that NGS-IgHV mutational 
status was the only significant HR compared to all tested factors for TFS 
(7.845, 95% CI 2.73 – 22.539, P<0.0001) (Table 4.4). 
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Table 4.4. Univariate Cox regression for Population A for TFS. HR hazard ratio, CI confidence interval. 
Binet stage calculated according to Binet et al. (1981), Döhner classified according to Döhner et al 
(2000) and CLL-IPI calculated according to The International CLL-IPI Working Group (2016). 
 P Value HR 95% CI 
Lower Higher 
Döhner 0.836 0.921 0.424 2.003 
NGS IgHV <0.0001 7.845 2.731 22.539 
Binet 0.124 1.639 0.874 3.074 
CLL-IPI 0.146 2.659 0.712 9.928 
del17p 0.229 1.898 0.668 5.393 
 
 
In a multivariate stepwise analysis (n=167) of these models, both IgHV 
mutational status by NGS (P<0.0001) and the CLL-IPI model (P<0.0001) 
were selected as independent and significant predictors of TFS (Table 4.5). 
None of these models were found to be significant for OS but this is most 
likely due to the small population size. 
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Table 4.5. Multivariate Cox regression for Population A for TFS. HR hazard ratio, CI confidence 
interval. Binet stage calculated according to Binet et al. (1981), Döhner classified according to 
Döhner et al (2000) and CLL-IPI calculated according to The International CLL-IPI Working Group 
(2016). 
  P Value HR 95% CI 
Lower Higher 
Step 1. Döhner 0.836 0.921 0.424 2.003 
 NGS IgHV <0.0001 7.845 2.731 22.539 
 Binet 0.124 1.639 0.874 3.074 
 CLL-IPI 0.146 2.659 0.712 9.928 
 del17p 0.229 1.898 0.668 5.393 
Step 2. NGS IgHV <0.0001 7.693 2.716 21.790 
 Binet 0.110 1.658 0.892 3.082 
 CLL-IPI 0.149 2.634 0.706 9.821 
 del17p 0.205 1.798 0.725 4.455 
Step 3. NGS IgHV <0.0001 5.755 2.285 14.494 
 Binet 0.229 1.428 0.799 2.551 
 CLL-IPI 0.004 4.488 1.615 12.473 
Step 4. NGS IgHV <0.0001 5.642 2.286 13.925 
 CLL-IPI <0.0001 6.215 2.681 14.409 
 
 
For 204 patients of Population B, a Cox regression multivariate analysis was 
performed. For this analysis, factors were binarised as either ‘having’ (1) or 
‘not having’ (0), except for SSeq-IgHV which was named as 0 for M and 1 
for UM. The factors included in the regression were mutation analysis by 
targeted NGS of commonly the mutated genes TP53, ATM, NOTCH1, SF3B1, 
and BIRC3; SNP array detection of the common cytogenetic abnormalities 
deletions 17p, 11q, 13q and trisomy 12; SSeq- IgHV and NGS-IgHV Multi-
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UM (1) or not (0). For this analysis, TP53 mutation and 17p deletion were 
merged, as were ATM mutation and 11q deletion. Only the presence of a 
multi-UM was found to be an independent and significant predictor of TFS 
(P<0.0001) (Table 4.6).  
   
Table 4.6. Multivariate Cox regression for Population B. HR hazard ratio, CI confidence interval. 
  P Value HR 95% CI 
Lower Higher 
Step 1 TP53 Mut/Del 0.499 1.197 0.710 2.019 
 ATM Mut/Del 0.155 1.275 0.912 1.781 
 BIRC3 Mut 0.664 0.882 0.500 1.555 
 Tri12 0.409 1.209 0.771 1.896 
 NOTCH1 Mut 0.882 1.032 0.684 1.556 
 SF3B1 Mut 0.655 1.084 0.762 1.543 
 Del13q 0.336 0.857 0.626 1.173 
 MultiUM <0.0001 3.086 1.671 5.696 
Step 2 TP53 Mut/Del 0.501 1.197 0.710 2.018 
 ATM Mut/Del 0.157 1.273 0.911 1.778 
 BIRC3 Mut 0.679 0.889 0.510 1.550 
 Tri12 0.411 1.207 0.770 1.893 
 SF3B1 Mut 0.660 1.082 0.761 1.540 
 Del13q 0.309 0.853 0.627 1.159 
 MultiUM <0.0001 3.101 1.685 5.704 
Step 3 TP53 Mut/Del 0.491 1.202 0.713 2.026 
 ATM Mut/Del 0.171 1.261 0.905 1.756 
 Tri12 0.461 1.176 0.764 1.812 
 SF3B1 Mut 0.643 1.087 0.764 1.545 
 Del13q 0.287 0.847 0.624 1.149 
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 MultiUM <0.0001 3.102 1.686 5.706 
Step 4 TP53 Mut/Del 0.533 1.178 0.703 1.974 
 ATM Mut/Del 0.175 1.258 0.903 1.751 
 Tri12 0.522 1.146 0.755 1.739 
 Del13q 0.256 0.839 0.620 1.136 
 MultiUM <0.0001 3.104 1.688 5.709 
Step 5 ATM Mut/Del 0.200 1.238 0.893 1.717 
 Tri12 0.578 1.124 0.745 1.697 
 Del13q 0.266 0.843 0.623 1.140 
 MultiUM <0.0001 3.118 1.695 5.734 
Step 6 ATM Mut/Del 0.240 1.206 0.882 1.649 
 Del13q 0.163 0.818 0.616 1.085 
 MultiUM <0.0001 3.042 1.665 5.559 
Step 7 Del13q 0.129 0.804 0.607 1.065 
 MultiUM <0.0001 3.051 1.670 5.571 
Step 8 MultiUM <0.0001 3.185 1.748 5.803 
 
 
To determine if there was any correlation between the five NGS-IgHV 
categories and other recurrent genetic abnormalities in CLL, a heatmap 
association chart was plotted for 204 patients in population B (Figure 4.9). 
Visual inspection of this heatmap shows no obvious associations between 
the five NGS-IgHV subgroups and other common genetic abnormalities.
 
 
 
Figure 4.9. NGS-IgHV is independent from other prognostic markers. Heatmap showing the distribution of recurrent genetic abnormalities in the different NGS-IgHV subgroups. 
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4.3.5 IgHV subclones are phylogenetically unrelated 
Since multiple studies have demonstrated that clones from independent 
CLL patients displayed similar, or even identical, CDR3 amino acid regions, 
the frequency of stereotyped receptors in the 358 productive sequences 
obtained from population A were investigated. Using previously described 
methods  (Bomben et al 2009), 36.9% (132/358) of sequences were found 
to have over 70% of identity when all the sequences were considered, 
which is in line with previous reports (Agathangelidis et al 2012). However, 
since more than one sequence was analysed per patient due to the 
presence of subclones, 47.8% (129/270) of patients had at least one 
stereotyped clone. This value decreases to 37.8% (102/270) of patients 
when the analysis is performed using only the major clone. In population B, 
33.5% (90/269) of sequences were identified as having greater than 70% 
identity and 37.8% (85/225) of patients had at least one stereotyped 
receptor.   
 
When both populations were combined subclonal patients constituted 
18.1% (90/497) of the total cohort. Of these patients, only 13.3% (12/89) 
expressed two subclones containing the same VH family gene. In these 
cases, the clonotypes had different D and J genes (Figure 4.10) suggesting 
that the clones had arisen independently, during recombination. 
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Figure 4.10. Circos plot visualization of V to D and V to J associations in the 12 patients expressing 
subclonal IgHV rearrangements from the same VH family. 
 
Further stereotyping analysis of the intra-clonal sequences identified that 
only 6.7% (6/90) of subclonal patients expressed related CDR3s, as defined 
as greater than 70% identity. Interestingly, one of these patients with intra-
clonal similarity, had 100% CDR3 AA sequence homology despite both 
subclones expressing completely different VH-family genes (Table 4.7). 
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Table 4.7. ADM304 with 100% intra-clonal CDR3-AA sequence homology. Freq – frequency, CDR3 – 
complementary determining region 3, AA – amino acid 
 Freq 
(%) 
V- 
gene 
J-
gene 
D- 
gene 
CDR3 AA seq 
ADM304 95.8 IGHV3-33 IGHJ6 IGHD3-16 RDLGSDVRLYYYYGM
DVW 
 3.0 IGHV1-3 IGHJ6 IGHD3-16 RDLGSDVRLYYYYGM
DVW 
 
 
4.3.6 Subclonal analysis using NGS-IgHV shows an evolving 
picture 
Work described in the Chapter 3 suggested that the IgHV remained stable 
between diagnosis and relapse. To investigate this further, 31 samples 
were screened at diagnosis and relapse (Table 4.8). Of the 31 patients, four 
had subclones at diagnosis (13%), which is in keeping with population B, 
since all the patients in this cohort have also undergone treatment. Of 
these four, two were multi-UM and two were mixed. At relapse, three had 
lost their subclones and one had detectable subclones although the clonal 
burden had reduced from 17.8% to 2.6%. Two patients had acquired 
subclones at relapse (CLL082 and CLL156) which were not detectable in the 
200 MARs. Interestingly analysis of all the unique reads in the diagnosis 
sample showed that for CLL156 (reads=140,168) the subclones were 
present at diagnosis but were below the 2.5% threshold, whilst for CLL082 
(reads=109,804) the subclone was undetectable in the diagnostic sample.
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Table 4.8. NGS-IgHV analysis of diagnosis-relapse pairs. UM – unmutated, M -mutated, Freq - 
frequency 
 DIAGNOSIS RELAPSE 
Sample V-gene IgHV 
Status 
Freq (%) V-gene IgHV 
Status 
Freq (%) 
ARR002 IGHV3-21 UM 100 IGHV3-21 UM 100 
CLL003 IGHV1-69 UM 100 IGHV1-69 UM 100 
CLL023 IGHV3-9 UM 100 IGHV3-9 UM 100 
CLL044 IGHV3-30 M 100 IGHV3-30 M 100 
CLL050 IGHV3-30 UM 100 IGHV3-30 UM 100 
CLL056 IGHV3-48 UM 100 IGHV3-48 UM 100 
CLL063 IGHV3-21 UM 100 IGHV3-21 UM 100 
CLL079 IGHV5-51 UM 84.2 IGHV5-51 UM 97.3 
 IGHV3-48 UM 17.8 IGHV3-48 UM 2.6 
CLL080 IGHV3-49 M 100 IGHV3-49 M 100 
CLL081 IGHV1-24 UM 100 IGHV1-24 M 100 
CLL082 IGHV4-34 M 100 IGHV4-34 M 87.3 
 - - - IGHV1-18 UM 12.7 
CLL083 IGHV1-18 UM 100 IGHV1-18 UM 100 
CLL084 IGHV1-46 UM 100 IGHV1-46 UM 100 
CLL085 IGHV3-15 UM 94.0 IGHV3-15 UM 100 
 IGHV5-51 UM 6.0 - - - 
CLL086 IGHV3-23 UM 100 IGHV3-23 UM 100 
CLL087 IGHV4-31 UM 100 IGHV4-31 UM 100 
CLL088 IGHV4-34 M 92.2 IGHV4-34 M 100 
 IGHV3-15 UM 5.6 - - - 
CLL089 IGHV3-48 UM 94.6 IGHV3-48 UM 97.6 
 IGHV3-30 M 2.9 - - - 
CLL090 IGHV3-30 M 100 IGHV3-30 M 100 
CLL091 IGHV1-6 M 100 IGHV1-6 M 100 
CLL092 IGHV1-69 UM 100 IGHV1-69 UM 100 
CLL094 IGHV1-2 UM 100 IGHV1-2 UM 100 
CLL096 IGHV4-34 M 100 IGHV4-34 M 100 
CLL098 IGHV4-4 UM 100 IGHV4-4 UM 100 
CLL099 IGHV3-33 UM 1001 IGHV3-33 UM 100 
CLL103 IGHV3-11 UM 100 IGHV3-11 UM 100 
CLL106 IGHV1-2 UM 100 IGHV1-2 UM 100 
CLL107 IGHV1-2 UM 100 IGHV1-2 UM 100 
CLL108 IGHV1-69 UM 100 IGHV1-69 UM 100 
CLL145 IGHV3-23 M 100 IGHV3-23 M 100 
CLL156 IGHV1-24 UM 100 IGHV1-24 UM 59.5 
 - - - IGHV3-23 UM 24.6 
 - - - IGHV3-30 M 9.1 
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4.4 Discussion 
The identification of subclones containing different productive VDJ 
clonotypes provides strong evidence that the leukaemia initiating event in 
CLL occurs early in B-cell development before the cell undergoes VDJ 
recombination. This suggests that a precursor B-cell is the leukaemic stem 
cell in CLL. Prior to the work described in this chapter, the percentage of 
CLL cases with more than one IgHV clone had been reported as relatively 
rare at a frequency of less than 5% (Plevova et al 2014, Rassenti and Kipps 
1997, Visco et al 2013). In contrast, by using NGS, this study reports a 
frequency five times higher, at 24%, in an unselected patient cohort.  
 
4.4.1 NGS-IgHV classification refines the SSeq-IgHV 
prognostic subgroups 
In this study, it was shown that IgHV-NGS could stratify patients into five 
different categories, with respect to TFS and OS, in an unselected CLL 
population. Patients with multi-M rearrangements had the best prognosis, 
even compared to patients with only one M clone. This is in line with Visco 
et al. (2013) who observed that biclonally M patients had a significantly 
lower CD38, more favourable cytogenetic lesions and a more indolent 
clinical course with the longest TTFT. Similarly, they found multi-UM to 
have a short TTFT. In contrast to the work described in this chapter, they 
reported that patients with mixed IgHV rearrangements had the worst 
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prognosis, although this might be due to the decreased sensitivity of the 
techniques used. 
 
The new NGS-IgHV classification can precisely classify patients with 
multiple IgHV rearrangements for which SSeq is inconclusive and improved 
prognostication for 92 out of 270 patients. Importantly, the poor prognosis 
of multiple UM patients detected by NGS-IgHV could be confirmed in an 
independent clinical trial population and showed a very short median TFS 
of 2 months. The presence of multiple IgHV re-arrangements was the 
strongest independent prognostic indicator in regression analysis of 11 
different variables including important driver mutations.  
 
4.4.2 IgHV subclones detected by NGS provide evidence for 
a precursor B-cell as the leukaemic stem in CLL 
The ability of NGS to detect a higher frequency of subclones in comparison 
to SSeq is unsurprising. NGS has a far greater sensitivity than SSeq which is 
often reported at around 20% (Tsiatis et al 2010). Furthermore, since NGS 
sequences each amplicon individually it is possible for the separate 
subclones to be detected as well as preventing larger subclones from 
masking the presence of smaller ones. 
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Since NGS has been shown to detect low level IgHV subclones at 
frequencies of down to 0.02% (Campbell et al 2008), it is necessary to 
exclude the normal B-cell background as the origin of these minor 
subclones. This was done by limiting the analysis to the first 200 MARs and 
further restricted by using a 2.5% cutoff for the classification of a subclone. 
Confirmation of the rationality of these restrictions was demonstrated 
through a series of validation experiments. Of interest, the comparison of 
gDNA and cDNA showed some differences. Firstly, that gDNA detected 
more unproductive subclones. This observation is not unexpected, 
however, as it is compatible with the instability of unproductive 
rearrangement at the RNA level (Ghia et al 2007, Langerak et al 2011). 
Secondly that cDNA had a far greater sensitivity for productive subclonal 
detection. This may in part explain the difference in the frequency of 
subclonal detection between Population A and B, since it suggests that 
gDNA subclones may be discarded as the normal B-cell background.  
 
 Several reports have previously described the presence of multiple CLL 
clones (Blachly et al 2015, Kriangkum et al 2015, Plevova et al 2014) as well 
as multiple clones with a discordant IgHV mutational status (Langerak et al 
2011, Visco et al 2013). The presence of multiple productive 
rearrangements in one quarter of CLL patients could be explained by a lack 
of allelic exclusion (Rassenti and Kipps 1997), which would suggest that 
both rearrangements are actually present in the same cell. However, a 
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recent study using single cell sequencing demonstrated that there was only 
one productive IgHV clonotype per cell (Kriangkum et al 2015). 
Furthermore, the study in this chapter has demonstrated incidences of 
three or more clonotypes. Taken together, this suggests that multiple 
rearrangements correspond to multiple leukemic subclones as was 
previously assumed (Plevova et al 2014, Visco et al 2013), implying that the 
leukemia-initiating events occur prior to IgHV re-arrangement in an 
unrearranged early B cell progenitor.  
 
4.4.3 Stereotypy analysis suggests that the IgHV subclones 
are phylogenetically unrelated 
Interclonal stereotyping of the CDR3 has been reported in a third of CLL 
cases (Agathangelidis et al 2012, Darzentas et al 2009, Stamatopoulos et al 
2007), leading to the theory that CLL pathogenesis is driven through the 
activation of the BCR by a common antigen or superantigen. Conversely, 
stereotyping analysis of the intraclonal CDR3s of subclonal IgHV patients in 
this study showed that, in most cases, there was no phylogenetic 
relationship. This contradicts this theory, since it would be expected that 
different clones in a given patient would have similar CDR3 region, if the 
leukemic clones emerged in response to a single common extracellular 
antigen. However recent work shows that Ig-BCRs of unrelated clonotypes 
may recognize common epitopes that were unpredictable from the 
molecular features of the Ig-BCR, including the CDR3 composition and 
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length (Mimmi et al 2016). Further in-depth studies of the hematopoietic 
stem cell and early B cell progenitor compartments in these patients will be 
required to confirm these observations.  
 
4.4.4 Conclusions 
In conclusion, the incidence of cases with multiple productive IgHV 
subclonal rearrangements is higher than previously reported at 24.4%. 
These subclones are likely to significantly contribute to the biological 
heterogeneity of this disease and point towards leukemia-initiating events 
that pre-date IgHV rearrangement. From a practical perspective, NGS-IgHV 
resolves the diagnostic uncertainties in a significant number of patients, 
enables the detection of small subclones and refines the previous SSeq-
based IgHV prognostic classification system. Finally, a new NGS-IgHV 
classification with five different clinically relevant prognostic categories has 
been proposed. 
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Chapter 5  Whole genome analysis using 
Single Nucleotide Polymorphism arrays 
 
5.1 Introduction 
The work described in the previous chapter demonstrated that the 
incidence of patients with multiple productive IgHV rearrangements is 
much higher than previously reported. Firstly, this finding implies potential 
biological heterogeneity of CLL, but it is not known whether the different 
IgHV subclones are also genetically and functionally different. Secondly, it 
suggests that leukaemia-initiating events are likely to occur prior to VDJ 
recombination in an early B-cell leukaemic progenitor. However, it does 
not provide a mechanism for leukaemogenesis per se. Thirdly, similar to 
the IgHV mutation status (Damle et al 1999, Hamblin et al 1999), the new 
NGS-IgHV classification of CLL patients was also of independent prognostic 
significance, and there was no association between the five NGS-IgHV 
categories and the common chromosomal aberrations detected in CLL, 
which have also been linked to prognosis (Dohner et al 1995, Gonzalez et al 
2011, Landau et al 2013, Zenz et al 2010, Austen et al 2007, Hurtado et al 
2015, Lozano-Santos et al 2016, Skowronska et al 2012, Jethwa et al 2013, 
Nadeu et al 2016, Wang et al 2011).  
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Using conventional cytogenetics, the incidence of a chromosomal 
abnormality in CLL is around 80% (Dohner et al 2000). However, through 
utilising both CGH and SNP array technology it has been possible to detect 
copy number alterations (CNA) in over 90% of cases (Gunn et al 2008, 
Gunnarsson et al 2011, Kay et al 2010, Ouillette, Collins, Shakhan, Li, Peres, 
et al 2011). Whilst CGH arrays have been reported to have a better CNA 
detection capacity than SNP arrays, particularly for small regions, this was 
done using relatively low resolution SNP arrays (<300K coverage) 
(Gunnarsson et al 2008). Furthermore, an additional benefit of SNP arrays 
over CGH arrays is the ability to detect copy neutral loss of heterozyogisty 
(cnLOH), which has been shown to be useful in identifying mutations in 
TP53 and ATM, which would have otherwise appeared normal using FISH 
or CGH array analysis (Edelmann et al 2013, Ouillette, Collins, Shakhan, Li, 
Peres, et al 2011). Therefore, a high resolution array with over one million 
SNP probes, would have a greater sensitivity than previous SNP arrays used 
to study CLL to date (Gunnarsson et al 2008, Pfeifer et al 2006) as well as 
the ability to detect cnLOH, making it an ideal tool for a systematic 
genome-wide analysis of recurrent chromosomal aberrations in CLL. The 
hypothesis was that these abnormalities may shed light on the molecular 
drivers of leukaemogenesis and relapse and identify additional novel 
predictors of response. 
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The work presented in the this chapter therefore aimed to: 
1. Describe the different CNAs in a cohort of patients before therapy 
and subsequent relapse and identify potential driver genes by MOR 
analysis. It was assumed that subclones containing driver mutations 
would be present at relapse whilst subclones with passenger 
mutations would decrease in number, or completely die out. 
2. Validate a selection of these in a larger cohort of clinically well 
annotated patients 
3. Correlate findings to clinical outcome  
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5.2 Materials and Methods 
5.2.1 Patient Samples 
The test project used gDNA from a pre-treatment cohort of 95 patients 
that were typical of that found in a tertiary referral centre with a high 
proportion of unmutated and treatment refractory cases (population C, 
Appendix 2). For 42 patients gDNA from subsequent relapse was also used. 
The validation project used gDNA from a cohort of 242 CLL patients 
enrolled into four UK based FCR clinical trials (population B and population 
D, appendix 2). All gDNA was extracted using the method described in 
section 2.2. 
 
5.2.2 Genome-wide SNP Platform hybridizations and analysis 
DNA was analysed using SNP arrays as previously described (Section 2.8) 
 
5.2.3 Sanger sequencing 
Sanger sequencing (Section 2.6) was performed on gDNA from 40 CLL 
patients using the ATG5 and BLIMP1 primers (Appendix 1). 
 
5.2.4 Targeted NGS gene panel 
DNA from 10 CLL patients was analysed using a TSCA (Section 2.7.6) CLL 
gene targeted NGS panel (Appendix 3) and the LymphoTrack IGH Somatic 
Hypermutation Assay (Section 2.7.5).   
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5.3 Results 
5.3.1 Common cytogenetic aberrations are recurrent within 
this cohort 
5.3.1.1 17p Deletions 
In the test cohort of 95 patients, 8.4% (8/95) were found to have a 17p 
deletion that removed the TP53 gene (Figure 5.1). One of these patients 
(CLL094) had a subclonal deletion that was found in approximately 40% of 
the sample. All the deletions removed the p-terminus of chromosome 17. 
The longest deletion was 22.7Mb in length and the shortest was 16.5Mb. In 
addition, a further four patients (4.2%) were found to have cnLOH over the 
TP53 gene, including one patient (CLL145) with a subclonal cnLOH in ~50% 
of the sample. As per the deletions, all the cnLOH affected the p-terminus 
of chromosome 17 with the length ranging from 8.1Mb to 21.1Mb. 
 
 
 
Figure 5.1. TP53 deletions are recurrent in CLL. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls from 12 patients with deletions/cnLOH of Chr17p. Red - CNA loss, orange - 
LOH; purple -  allelic imbalance. The grey line marks the location of the TP53 gene. 
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Figure 5.2. ATM deletions are recurrent in CLL. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls from 18 patients with deletions/cnLOH of Chr17p. Red - CNA loss, orange - LOH; 
purple - allelic imbalance. The grey line marks the location of the ATM gene.
135 
139 
 
5.3.1.2 11q Deletions 
In total, 18.9% (18/95) patients had an 11q abnormality over the ATM gene 
(Figure 5.2).  Of these 18 patients, 13 had a deletion and five had cnLOH. 
The size of the abnormalities ranged from 0.2Mb to 72.3Mb. Interestingly 
the smallest deletion (CLL073), although affecting three genes; C11orf65, 
NPAT and ATM, only completely removed ATM (Figure 5.3). 
 
 
 
Figure 5.3.The 11q deletion in CLL073 only completely removes the ATM gene. Nexus (BioDiscovery) 
image showing Illumina 1M- Duo data call for CLL073 at 11q22. Red - CNA loss. 
 
5.3.1.3 Trisomy 12 
13.7% (13/95) of patients had a trisomy 12. One additional patient (CLL 
108) had a partial trisomy 12 from 12p.12.2 to 12q21.31 that was 63.9Mb 
in size. Interestingly, the rest of chromosome 12 for this patient had cnLOH 
(Figure 5.4). Another patient (CLL189) also had a large region of cnLOH over 
chromosome 12 which covered from 12q13.11 to 12qter.  
 
 
  
Figure 5.4. Partial trisomy of chromosome 12 in CLL108. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for CLL108 at chromosome 12. Blue - CNA gain, orange - LOH; purple - 
allelic imbalance. 
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5.3.1.4 13q14 Deletions  
52.6% of patients (50/95) were found to have either cnLOH, a 
heterozygous or homozygous deletion at the 13q14 locus. The 
heterozygous deletion was the most common abnormality detected in 
66.0% (33/50) of this cohort. The size of the heterozygous deletion ranged 
from 0.6Mb to 78.8Mb in size, whereas the homozygous deletion which 
was identified in 28% (14/50) went from 0.15Mb to 2.6Mb. The remaining 
6% (3/50) had cnLOH ranging from 0.7Mb to 66.5Mb. Mosaicism was 
common, with 16% (8/50) of cases having a 13q14 deletion subclonal 
population, averaging 67.5% (range 30%-90%) of the total clone. 
 
The MOR for the 13q14 deletion was defined by two samples, CLL088 and 
MCLL100, and was 7364bp (0.007Mb) in length. This region contained just 
exon 2 of DLEU2. Mapping the MOR of the biallelic deletion was more 
complicated as two samples, CLL075 and MCLL148 had intermittent 
homozygous deletions. Therefore, two MOR regions were identified for the 
biallelic deletions. The first was a 0.11Mb region that was demarcated by 
CLL096 and CLL148. This area encompassed the first three exons of DLEU2. 
The second biallelic MOR was characterised by CLL075 and CLL105. This 
was 0.06Mb in length and contained exon 5 of DLEU1. Interestingly, 
miR15a and miR16-1 did not map to any of these MORs, although they 
were located about 9Kb (0.009Mb) downstream from the monoallelic 
MOR. 
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5.3.2 Large copy number alterations are recurrent in CLL 
Since other chromosomal abnormalities have been reported in CLL, 
additional recurrent genetic aberrations were investigated. Abnormalities 
were defined as recurrent if they were present in more than three samples 
(3% of the cohort) and further investigated if at least two of these samples 
had deletions or gains i.e. cnLOH was not examined in isolation. Using 
these criteria, abnormalities were identified on 2q, 6q, 8p, 9p, 10q, 18p, 
19p and 20q (Table 5.1). Whilst a recurrent deletion was identified on 22q, 
these were discounted as artefacts of Igλ rearrangement (Mraz et al 2013). 
 
5.3.2.1 Del(2q) 
There were two regions of interest on 2q, both of which were defined by 
deletions or cnLOH. The larger affected area was located at 2q22-2q24 
whereby two patients had a deletion (CLL068, CLL081) and two had cnLOH 
(CLL095, CLL103). The deletions were both smaller than the cnLOH at 
13.7Mb and 20.8Mb compared with 113.4Mb and 30.7Mb for the cnLOH. 
The two deletions defined the MOR as 11.3Mb in length (Figure 5.5a). 
There were many genes described within this area. 
 
The smaller region of interest on chromosome 2 was at 2q36 and affected 
four patients. There were two patients with deletions (CLL043, CLL112) and 
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two patients with cnLOH (CLL076, CLL095). The MOR was smaller at 
0.43Mb and contained the genes SP140L, SP100 and CAB39 (Figure 5.5b). 
 
Table 5.1. Summary of recurring copy number alterations in a pre-treatment CLL cohort (n=95). CNA 
– copy number alteration, MOR – minimally overlapping region, cnLOH – copy neutral loss of 
heterozygosity 
Chromosomal 
Region 
Type of 
CNA 
No of 
samples 
with CNA 
Size of 
MOR 
(Mb) 
No of 
genes 
in 
MOR 
  Genes  
17p 
 
Deletion/ 
cnLOH 
12 8.1 337   Many inc 
TP53 
11q 
 
Deletion/ 
cnLOH 
18 0.2 3   C11orf65, 
NPAT, ATM 
12 
 
Gain 15 63.9 803   Many 
13q14 Deletion/ 
cnLOH 
50 0.007 1   DLEU2 
2q22-2q24 
 
Deletion/ 
cnLOH 
4 11.3 56   Many 
2q36 
 
Deletion/ 
cnLOH 
4 0.4 4   SP140L, 
SP100, 
CAB39, 
LOC151475 
6q21 
 
Deletion/ 
cnLOH 
4 0.7 2   PRDM1, 
ATG5 
8p22p21.2 
 
Deletion/ 
cnLOH 
3 3.8 31   Many 
8p12 
 
Deletion/ 
cnLOH 
6 1.0 0   - 
9p23p22.3 
 
Deletion/ 
cnLOH 
5 2.3 9   MPDZ, 
NFIB, TYRP1 
+ 6 non-
protein 
coding 
10q24.32 Deletion/ 
cnLOH 
4 1.2 42   Many 
18p11.21 
 
Deletion/ 
cnLOH 
4 6.6 69   Many 
18p11.31 Deletion/ 
cnLOH 
4 4.0 83   Many 
19p13.2 
 
Gain 3 0.8 49   Many 
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Figure 5.5. Deletions at 2q. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for 4 patients at a. 2q22-2q24 and b. 2q36.The MOR boundary is indicated by the black lines. Red - 
CNA loss, orange – LOH 
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Figure 5.6. The MOR at 6q21 contains two genes; PRDM1 and ATG5. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for 4 patients at 6q21.The MOR boundary is indicated by 
the two black lines. Red - CNA loss, orange – LOH, green circle – PRMD1, blue circle – ATG5
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5.3.2.2 Del(6q) 
A recurrent deletion at 6q21 was identified in four patients in this cohort 
(4.2%). The deletions ranged in size from 5.9Mb to 87Mb with an average 
length of 41.9Mb. The MOR was 0.71Mb and defined by CLL061 and 
CLL095 (Figure 5.6). There are only two genes within this region; PR 
Domain 1 (PRDM1) and Autophagy related 5 (ATG5). PRMD1 is a regulator 
of plasma cell differentiation (Shapiro-Shelef et al 2003), whereas ATG5 is 
an important component of the autophagy pathway. Interestingly an 
additional patient, CLL083, had a small cnLOH over this site which was just 
under 0.5Mb (498,480bp). 
 
5.3.2.3  Del(8p) 
There are two regions of interest on 8p. The first at 8p22p21.2 was shown 
by deletions in 3 samples. The 3.8Mb MOR was defined solely by one 
sample, CLL078 (Figure 5.7a). 31 genes resided at this location including 
CCR4-NOT Transcription Complex Subunit 7 (CNOT7) which negatively 
regulates cell proliferation (Doidge et al 2012) and the tumour suppressor 
Platelet Derived Growth Factor Receptor Like (PDGFRL). The other location 
on chromosome 8 was at 8p12 and was found in two patients with 
deletions and four patients with cnLOH. The MOR was 1.0Mb in length and 
contained no genes although the gene Dual Specificity Phosphatase 26 
(DUPS26) was located just upstream (Figure 5.7b). This gene has been 
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shown to have a tumour suppressor role in certain cancers (Patterson et al 
2010). 
 
 
 
Figure 5.7. Deletions of 8p are recurrent in CLL.. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for a. 3 patients at 8p22p21.2 and b. 6 patients at 8p12.The MOR boundary is 
indicated by the black lines. Red - CNA loss, orange – LOH, green circle – PDGFRL, blue circle – CNOT7, orange circle – DUSP26 
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Figure 5.8. Deletions at 9p at recurrent in CLL. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for 4 patients at 9p23p22.3. The MOR boundary is indicated by the black lines. 
Red - CNA loss, orange – LOH, green circle – NFIK  
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5.3.2.4 Del(9p) 
A recurrent deletion was identified at 9p23p22.3. This deletion affected 
three patients and cnLOH was found in a further two patients (Figure 5.8). 
The MOR for this region was defined by two samples CLL043 and CLL105 
and was 2.3Mb in length. There were three protein coding genes in this 
region; Tyrosinase Related Protein 1 (TYRP1), Multiple PDZ Domain Protein 
(MPDZ) and Nuclear Factor IB (NFIB). 
 
5.3.2.5 Del(10q) 
Four patients were found to have a deletion on the 10q locus with a further 
patient having cnLOH. The size of the deletions ranged from 9.1Mb to 
1.2Mb, whilst the cnLOH was 2.2Mb in length. The MOR was defined by 
one patient, CLL041. The 1.2Mb region contained many genes including the 
transcription factor Nuclear Factor Kappa B Subunit 2 (NFKB2). 
 
5.3.2.6 Del(18p)  
The MOR at 18p was difficult to define since one sample (CLL106) had a 
split deletion, therefore two MORs were identified from the same three 
samples. The length of the first MOR was 6.5Mb and the second was 
4.3Mb. Both regions contain several genes (Figure 5.9). 
 
 
 
 
Figure 5.9. Two MORs can be defined at 18p. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for 3 patients at 18p. The first MOR boundary is indicated by the black lines and 
the second by the green lines. Red - CNA loss, orange – LOH. 
147 
 
 
Figure 5.10. Recurrent gain at 19p. Nexus (BioDiscovery) image showing Illumina 1M- Duo data calls for 3 patients at 19p. The first MOR boundary is indicated by the black lines. Blue - CNA 
gain, purple – allelic imbalance. 
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5.3.2.7 Gain(19p) 
A recurrent gain was identified in three patients on chromosome 19. One 
patient (CLL048) had trisomy 19, whereas two other patients had smaller 
gains that were 1.8Mb and 3.6Mb in length. The MOR for this region was 
0.8Mb and contained over 40 genes, including DNA methyltransferase 1 
(DNMT1) and autophagy related 4D cysteine peptidase (ATG4D) (Figure 
5.10). 
 
5.3.2.8 Other abnormalities 
Whilst other previously reported abnormalities were identifiable across the 
cohort, these did not fulfil the above stipulated criteria (Section 5.3.2) and 
were not therefore investigated in detail. Gain of 2p (Chapiro et al 2010) 
were found in two patients, for example, whilst the gain(8q) and trisomy 
18 (Edelmann et al 2013) were only detected in single patients. 
Additionally, large regions of cnLOH were observed at 20q (Clifford et al 
2014) in two patients. However as there was only one incidence of a 
deletion at this site, these were not evaluated further. 
 
5.3.3 Clinical significance of recurrent large copy number 
alterations is uncertain 
A comprehensive validation of these findings using a well-annotated pre-
treatment cohort of clinical trial patients (n=250) was performed as part of 
a separate project in the laboratory.  All the 14 CNAs identified in the test 
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cohort were found in this larger cohort except for the deletion at 8p12. Out 
of 250 patients, there were 49 incidences of these recurrent abnormalities 
found in 36 patients (14.4%). For five of the abnormalities, it was possible 
to further refine the MORs, in some cases substantially reducing the 
number of genes in the MOR (Table 5.2). 
  
Table 5.2. Summary of the recurrent CNA in a larger pre-treatment cohort. CNA – copy number 
alteration, MOR – minimally overlapping region. 
CNA No. of 
samples 
Refined 
MOR 
No. of genes 
in new MOR 
Genes  
Del(2q22-2q24)  1 Yes 8 ARHGAP15, 
GTDC1, TEX41, 
ZEB2 + others 
Del(2q36) 3 No 4 SP140L, SP100, 
CAB39, 
LOC151475 
Del(6q21) 
 
10 No 2 PRDM1, ATG5 
Del(8p22p21.2) 
 
4 No 31 Many 
Del(8p12) 
 
0 No 0 - 
Del(9p23p22.3) 
 
2 Yes 1 NFIB 
Del(10q24.32) 5 Yes 4 AS3MT, 
BORCS7, 
CNNM2, NT5C2 
Del(18p11.21) 
 
9 Yes 12 Many  
Del(18p11.31) 
 
8 Yes 25 Many 
Gain(19p13.2) 
 
7 No 49 Many 
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Analysis of the TFS in patients with recurrent CNAs found that patients with 
the del(6q21) (n=10) had the shortest median TFS of 10.6 months whilst 
patients with the gain(19p) (n=8) had the longest median TFS of 54.0 
months compared to 30.5 months for TP53-wildtype patients (n=213) and 
12.3 for TP53-mutated patients (n=21). However, this finding was not 
significant most likely due to the low frequency of the CNAs.  
 
5.3.4 Many pre-treatment abnormalities persist at relapse 
and other recurrent CNAs emerge  
To determine how these abnormalities had evolved at relapse, 42 relapse 
samples of the test cohort were analysed using SNP arrays. The results are 
summarised in Table 5.3. Of the 14 abnormalities identified in the pre-
treatment cohort, only the 10q deletion and the partial trisomy 12 were no 
longer present in the paired relapse sample. Validation of these findings in 
a well-annotated relapse/refractory cohort (n=67) of clinical trial patients 
confirmed all except for gain(19p) which was not detected in this cohort. 
As with the pre-treatment cohort the del(6q21) remained the most 
frequent CNA, after the common abnormalities, found in 9% (6/67) of 
these samples. 
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Table 5.3. Presence or loss of copy number alteration at relapse.  
Region Lost at relapse Retained at 
relapse 
Gained at 
relapse 
Del(17p) 
 
0 5 1 
Del(11q) 
 
0 8 1 
Tri(12) 1 (loss of partial 
trisomy) 
7 0 
Del(13q14) 
 
0 21 0 
Del(2q22-2q24)  
 
0 3 0 
Del(2q36) 
 
0 2 1 
Del(6q21) 
 
0 4 0 
Del(8p22p21.2) 
 
0 n/a 1 
Del(8p12) 
 
0 2 1 
Del(9p23p22.3) 
 
0 2 0 
Del(10q24.32) 
 
2 0 2 
Del(18p11.21) 
 
0 1 0 
Del(18p11.31) 
 
0 1 0 
Gain(19p13.2) 
 
0 1 1 
 
 
5.3.5 Further investigation of the del (6q) 
SNP array analysis of diagnosis/relapse pairs identified several CNAs that 
are recurrent in CLL and which persist at relapse, suggesting that they may 
be from the original leukaemic clone. Although multiple potentially 
interesting regions had been identified, the del(6q21) abnormality was 
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investigated further since, after the common abnormalities, it was the 
most frequent CNA found in 4.9% (20/411) of samples, it persisted at 
relapse and patients had a shorter TFS. 
 
The deletion at 6q in this cohort was found to contain just two genes; 
PRDM1 and ATG5. To determine if additional genetic abnormalities could 
be found in either gene, exon SSeq was performed on DNA from 40 
patients within this cohort including the four patients found to have the 6q 
deletion. However, no mutations were detected in either gene.  
 
5.3.6 Genes involved in autophagy are recurrently found in 
MORs in CLL 
Since SSeq did not identify any mutations in either ATG5 or PRDM1 in a 
cohort of 40 patients, nor was it possible to refine the MOR further by 
combining the data from all the studies (n=411), all MORs identified were 
interrogated by pathway analysis. Using a combination of the KEGG 
pathway database (Kanehisa et al 2016, Ogata et al 1999) and literature 
annotations, a number of other genes were classified as related to the 
autophagy processes (Table 5.4). 
  
 
 
Table 5.4. Summary of autophagy genes identified in recurrent MORs. Chr -chromosome, CNA – copy number alteration, MOR – minimally overlapping region. * Additional samples had 
trisomy 12 which affected this location. Others – uncharacterised genes 
Gene Chr Function in Autophagy Type of CNA No. of samples 
affected 
No. of genes 
in MOR 
Other genes in MOR 
ATG4D 19 Protein targeting / 
autophagosome formation 
Gain/ cnLOH 9 14 AP1M2, CDKN2D, DNM2, ILF3, KRI1, 
MIR1238, MIR638, QTRT1, S1PR5, 
SLC44A2 + others 
ATG5 6 Autophagosome formation Del/ cnLOH 13 2 PRDM1 
CAMKK2 12 Regulator of autophagy Del/ cnLOH* 6 3 ANAPC5, P2RX4 
CDKN1B 12 Regulator of autophagy Del/ cnLOH* 3 25 Many 
CDKN2A 9 Regulator of autophagy Del/ cnLOH 10 7 CDKN2B, MTAP, Mir_384 + others 
KBTBD6 13 Regulator of autophagy Del/ cnLOH 42 6 KBTBD7, Mir_324, MTRF1 + others 
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KBTBD7 13 Regulator of autophagy Del/ cnLOH 42 6 KBTBD6, Mir_324, MTRF1 + others 
NEK9 14 Autophagosome formation Del/ cnLOH 29 3 TMED10, ZC2HC1C 
PRKAG1 12 Regulator of autophagy Del/ cnLOH* 10 13 Many 
RB1 13 Regulator of autophagy Del/ cnLOH 121 3 LPAR6, RCBTB2 
SESN1 6 Regulator of autophagy Del/ cnLOH 21 3 ARMC2, CEP57L1 
STK4 20 Activation of LC3 Del/ cnLOH 10 21 Many 
STK7 
(PKN2) 
1 Regulator of autophagy cnLOH 7 2 GTF2B 
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5.3.7 Screening of relapse samples identifies mutations not 
present at diagnosis 
Analysis of the 42 paired samples showed that 40% (n=17) had no change 
in the subsequent relapse sample using SNP array analysis. Of these 
samples, there was sufficient DNA on nine to perform both a targeted NGS 
gene panel and the NGS-IgHV. 
 
Analysis of these nine samples showed that changes at relapse were 
detectable in seven (78%) (Table 5.5). For two samples (CLL87 and CLL103) 
there were no differences between the diagnostic and subsequent relapse 
sample. Both patients were UM and had trisomy 12. Of the seven patients 
with changes at relapse, three (CLL098, CLL99 and CLL102) had altered 
VAFs, implying a shift in the subclonal levels. The other four samples had 
either lost mutations and/or acquired novel variants suggesting that a 
subclone had either died out completely or a new subclone had been 
created.  At relapse, CLL088 had lost the IgHV3-15 subclone and gained an 
EGR2 variant, although further analysis showed that the EGR2 deletion was 
detectable in 1.9% of the reads in the diagnostic sample (depth = 529) and 
that the IGHV3-15 subclone was present in 0.0019% (5/267,440) of the 
relapse reads. CLL050 was similar in that the KRAS variant was also 
detectable in the diagnosis sample, at a VAF of 3.6%. In contrast, the 
IGHV3-30 subclone in CLL089 was completely absent at relapse (read depth 
= 24,770) and the emerging IGHV1-18 subclone in CLL082 was 
undetectable in the diagnostic sample even with a depth of 109,804 reads.
 
 
Table 5.5. Summary of differences at diagnosis and relapse exclusively of patients without noticeable difference by array  
 Diagnosis   Relapse Comments 
 
Sample Array IgHV NGS Panel   
CLL050 Del6q14, Del11q12, 
Del13q14 Tri7p21 
UM IGHV3-30 None detected 8.4% KRAS p.L19F  KRAS detectable 
in D at 3.6% 
CLL082 Del13q13 
HomDel13q14 
M IGHV4-34 None detected 12% UM IGHV1-18 - 
CLL087 Tri12, HomDelXp11 UM IGHV4-31 None detected No changes - 
CLL088 Del13q14 92.2% M IGHV4-34 
5.6% UM IGHV3-15 
None detected Loss of IGHV3-15  
Gain 5% EGR2 p.A304del 
EGR2 detectable 
in D at 1.9% 
CLL089 Tri1q21, Tri1q25 94.6% UM IGHV3-48 
2.9% M IGHV3-30 
18.3% XPO p.E571Q Loss of IGHV3-30 
XPO increased to 42.7% 
- 
CLL098 None detected UM IGHV4-4 7.9% NOTCH1 p.P2514Rfs*4 
10% NOTCH1 p.Q2406* 
NOTCH1 p.P2514Rfs*4 
decreased to 2.6% 
NOTCH1 p.Q2406* increased 
to 24.8% 
- 
CLL099 Tri1q21 UM IGHV3-33 18.1% RSP15 p.P131T RSP15 decreased to 2.2%  
CLL102 Tri12  40.3% IRF4 p.N102K IRF4 increased to 47.6%  
CLL103 Tri1q21, cnLOH2q22, 
cnLOH9p24, 
Tri10q26, 
cnLOH13q33, Tri12, 
Tri22q11 
UM IGHV3-11 29.7% NOTCH1 p.H2106Y 
 
No changes  
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5.4 Discussion 
The data in this chapter demonstrates the validity of using high-resolution 
SNP arrays to characterise and quantify copy-number aberrations in CLL. 
The analysis reveals several recurrent, and therefore non-random, CNAs 
within the cohort, some of which persist into relapse. Furthermore, the 
refining and characterisation of the MORs of these CNAs has enabled 
candidate genes and pathways involved in leukaemogenesis and disease 
progression to be identified.  
 
5.4.1 SNP arrays can detect CNAs and cnLOH in CLL 
The frequency of the common mutations detected in the test cohort was in 
keeping with previous studies, with the 13q14 deletion being the most 
common aberration detected in the test cohort, found in 52.6% of samples 
(Gunnarsson et al 2010, Ouillette, Collins, Shakhan, Li, Peres, et al 2011, 
Pfeifer et al 2006). MOR analysis of these regions were also consistent with 
previous studies with both the heterozygous and homozygous 13q14 
deletions containing part of the DLEU2 gene, as well as the 11q and 17p 
deletions MOR mapping to the ATM and TP53 genes, respectively 
(Edelmann et al 2013).  
 
Analysis of other recurrent abnormalities was limited to those present in at 
least three samples, with a CNA in at least two of the samples. cnLOH in 
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isolation was excluded since studies using paired tumour and germline 
DNA samples have found that cnLOH in the absence of an associated CNA 
are often germline in origin (Edelmann et al 2013, Pfeifer et al 2006). The 
CNAs detected in the test cohort using this criteria had all been previously 
reported (Dohner et al 2000, Edelmann et al 2013, Gunnarsson et al 2011, 
Ouillette, Collins, Shakhan, Li, Peres, et al 2011). However other recurrently 
reported abnormalities such as the gain(2p) and trisomy 18, were excluded 
as they were present at low frequencies in this cohort (<3%).  
 
Analysis of the MORs in an extended cohort of 411 samples identified 
several interesting genes that may have a role in leukaemogenesis. PRMD1 
and ATG5 were the only genes in the MOR at del(6q) whilst the MOR at 
2p36 contained the genes SP100 and SP140L, and NFIB was found to be the 
sole gene in the MOR of the del(9p) abnormality. NFIB is a transcription 
factor that has been reported to be an oncogene (Dooley et al 2011, Zhang 
et al 2015) and has been found to have a role in megakaryocyte 
differentiation (Lu Chen et al 2014, Rice et al 2011). SP100 and SP140L 
have previously been implicated in familial CLL (Di Bernardo et al 2008). 
Whilst these are all interesting genes for further investigation, the del(6q) 
was by far the most frequent CNA found in 4.9% (20/411) of samples, 
compared to 2.2% (9/411) for the del(2p36) and 1.9% (8/411) for the 
del(9p). 
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5.4.2 Genes required for leukaemogenesis are present in 
relapse samples 
To identify possible genetic drivers of tumour development and relapse, 
paired pre-treatment and relapse samples were analysed. Previous studies 
using paired samples have focussed on clonal evolution in the context of 
other clinical markers such as IgHV mutation status, as opposed to the 
implications of disease drivers (Gunnarsson et al 2010) or solely on the 
common abnormalities (Ouillette et al 2013). Therefore, this study 
concentrated on identifying genetic abnormalities that were present at 
relapse since, although it is possible that mutations that initiate 
leukaemogenesis may not be necessary for the subsequent relapse, if they 
were present in the pre-leukaemic clone it would be assumed that they 
would be present in all subclones and in the relapse sample. 
 
5.4.3 Screening of relapse samples identifies mutations not 
present at diagnosis 
Three of the nine samples that underwent a full screen of SNP array, 
targeted NGS and NGS-IgHV, were found to have acquired novel subclones 
as determined by the detection of a new variant. In two of these samples, 
deep sequencing analysis of the novel gene variants found that these were 
present at diagnosis suggesting that treatment had selected for them.  
Interestingly the third sample had gained a subclone with an UM IgHV 
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which was not detected at diagnosis. Attainment of an IgHV-UM subclone 
in a IgHV-M patient has previously been reported (Rose-Zerilli et al 2016); 
however in this case it was possible to detect other genetic lesions that 
were associated with the UM subclone in the diagnostic sample, suggesting 
that the UM subclone was present at diagnosis but undetectable using 
conventional SSeq methodology. In contrast, it was not possible to detect 
the emerging clone in the diagnostic sample in the study described in this 
chapter despite obtaining over 100,000 reads. Whilst it is well recognised 
that CLL samples can acquire novel variants through random mutagenesis 
(Amin et al 2016, Landau et al 2015, Ouillette et al 2013, Schuh et al 2012), 
the acquisition of previously undetectable IgHV subclone would support 
the theory that the susceptibility for a cell to progress to CLL is  present 
early in B-cell development (Kikushige et al 2011). 
 
5.4.4 Genes in the autophagy pathway are recurrently 
mutated using SNP array analysis 
The del(6q) has been recurrently reported in CLL (Dohner et al 2000, 
Gunnarsson et al 2011, Ouillette, Collins, Shakhan, Li, Peres, et al 2011, 
Stilgenbauer et al 1999) and was persistent in the relapse samples. The 
work described in this chapter refines, for the first time, the del(6q) MOR 
to the ATG5 and PRMD1 genes. PRDM1, as a B-cell regulator of 
differentiation, seemed the most likely target, especially since it has 
previously been reported to act as a tumour suppressor in other lymphoid 
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malignancies (Hangaishi and Kurokawa 2010).  However, downregulation of 
the autophagy pathway has also been implicated in the myeloid 
leukaemias (Watson et al 2011).  SSeq mutation screening of both genes 
did not reveal any variants in a cohort of 40 CLL patients, however genetic 
mutations in CLL are often described at a low frequency so it is possible 
that the sample size was too small. Nevertheless, WES of a cohort of 278 
patients only found one variant in PRDM1 and none in ATG5 (Landau et al 
2015). 
 
Extended analysis in a cohort of 411 patients was unable to further refine 
the del(6q) MOR. However, several key genes involved in the autophagy 
pathway were found to be located within recurrent CNAs, suggesting that 
the autophagic pathway may be altered in CLL cells. Furthermore, MYD88, 
which is mutated in around 5% of CLL cases (Puente et al 2011, Lili Wang et 
al 2011) has been shown to trigger autophagy as part of antigen 
presentation (Shi and Kehrl 2008). The expression of PRDM1, the other 
potential target of the del(6q), has been shown to be regulated in plasma 
cells through autophagy (Pengo et al 2013). Together, this suggests that 
autophagy may be a significant role in the pathogenesis of CLL. 
 
5.4.5 Conclusions 
In conclusion, the work described in this chapter provides further support 
for an early B-cell as the CLL leukaemic stem cell. Furthermore, the refining 
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of the del(6q) MOR and the identification of multiple autophagy genes in 
other MORs has elucidated a potential new mechanism for CLL 
pathogenesis through the autophagy pathway. Further work is necessary to 
determine the role of autophagy in CLL.  
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Chapter 6  Analysis of autophagy in B-CLL 
samples reveals increased autophagy activity 
when compared to normal age-matched B-
cells 
6.1 Introduction 
The work described in the previous chapter showed that in patients with 
CLL there are recurring abnormalities in genes involved in the autophagy 
process. Autophagy is a mechanism of degradation whereby redundant or 
defective cellular components are disassembled and recycled. Autophagy 
has been shown to have a dual role in cancer in that it can act both as a 
tumour suppressor and a tumour promoter. Impaired DNA repair because 
of the downregulation of autophagy can promote tumorigenesis. 
Conversely, an increase in autophagy activity can support tumour cells 
through the provision of energy and nutrients (Eskelinen 2011). 
 
Since the autophagy pathway interacts with many genes that have 
implications in CLL, it is therefore possible that autophagy may be involved 
in the pathogenesis of CLL. The aim of the study in this chapter was to 
further investigate the role of the autophagy process in CLL.   
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6.1.1 The Autophagy Pathway 
Macroautophagy (hereafter referred to as autophagy) is the highly-
conserved process of degradation of cytoplasmic components in a double 
membraned structure called the autophagosome. The autophagosome 
encapsulates superfluous proteins targeted for destruction, then fuses with 
the lysosome and degradation takes place. Basal autophagy plays an 
important role in maintaining normal cellular haemostasis through the 
disposal of misfolded or damaged proteins and organelles, and protein 
aggregates. Autophagy also acts as a survival mechanism and is up-
regulated in response to cellular stresses such as starvation, to provide 
additional nutrients through the recycling of cytosolic components. 
Additionally, autophagy has an immunological function through the 
elimination of microbes as well as a role in antigen presentation.  
 
6.1.1.1 Formation of the Autolysosome 
Autophagy is a multistep process. It starts with nucleation whereby the 
necessary factors are recruited to form the phagophore. Once formed, the 
phagophore is elongated to encapsulate the factors targeted for 
degradation. When the autophagosome has matured and sealed, it is then 
fused to the lysosome. The lysosomal components are sequestered to the 
now autolysosome and the elements within degraded (Figure 6.1) (Choi et 
al 2013). 
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Figure 6.1 The autophagy pathway.  Proteins targeted for degradation are encapsulated by the 
autophagosome, which then fuses to the lysosome. The lysosomal factors are released into the 
autolysosome and the proteins degraded. Adapted from Choi et al. ( 2013). 
 
6.1.1.1.1 Nucleation  
Classical induction of autophagy is signalled through the serine/ threonine 
kinase mTOR. m-TOR resides inside the mTORC1 complex, alongside raptor, 
mLST8, PRAS40 and deptor. When activated, the MTORC1 complex 
suppresses the ULK1 complex which is composed of ULK1/2, FIP200, ATG13 
and ATG101 (Hara et al 2008, Hosokawa, Hara, et al 2009, Hosokawa, 
Sasaki, et al 2009) as well as the beclin1 regulator, Ambra1 (Nazio et al 
2013). Upon detachment from MTORC1, ULK1 is activated and is able to 
autophosphorylate itself and phosphorylate FIP200 and ATG13 (Ganley et 
al 2009). Stimulation of the ULK complex initiates the nucleation process of 
autophagy by activating the PI3K complex. 
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In mammalian cells the PI3k complex is formed from the class III 
phosphoinositide 3-kinase Vps34 alongside p150 (Volinia et al 1995), 
Barkor (Sun et al 2008), and beclin1. Barkor and p150 act as chaperones 
directing the complex to the site of autophagosome production while 
Vsp34 produces phosphatidylinositol-3-phosphate (PI-3-P) which acts as a 
marker of the site. The complex recruits WIPI1 (Proikas-Cezanne et al 
2004), WIPI2 (Polson et al 2010) and DFCP1. DFCP1 is a key component of 
the omegasome (Axe et al 2008), a PI-3-P-enriched ER subdomain which 
acts as a conduit for the formation of the phagophore or isolation 
membrane (IM) as it is also known (Hayashi-Nishino et al 2009, Uemura et 
al 2014, Ylä-Anttila et al 2009). Although the site of autophagosome 
formation is yet to be elucidated, the most favoured model is that 
development takes place at the ER-mitochondria contact site (Anao et al 
2015, Hamasaki et al 2013). 
 
6.1.1.1.2 Expansion and Closure 
The formation and elongation of the phagophore requires two ubiquitin-
like systems. In the first system, the ATG16L complex is formed. The initial 
step in the production of the ATG16L complex is the activation of ATG12 by 
the E1 enzyme ATG7. This is then conjugated to ATG5 by the E2 enzyme 
ATG10 (Mizushima et al 1998). ATG16L then binds to ATG5, through its N-
terminal domain, and to other ATG12-ATG5-conjugated ATG16L through its 
coil-coiled region, to form a homo-oligomer (Mizushima et al 2003). The 
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complex is then recruited to the autophagosome formation site by WIPI2 
(Dooley et al 2014) where it acts as an E3 enzyme by recruiting and 
activating the LC3-conjugated E2-enzyme ATG3 (Fujita et al 2008, Sakoh-
Nakatogawa et al 2013).  
 
In the second system, the ATG8 homologues; the microtubule-associated 
protein light chain 3 (LC3) subfamilies, are conjugated to 
phosphatidylethanolamide (PE). ATG3, alongside ATG7, converts LC3-I to 
LC3-II (Kabeya et al 2004). The ATG16L complex also lipidates the other 
ATG8 homologues; the Golgi-associated ATPase enhancer of 16 kDa (GATE-
16)/γ-aminobutyric acid (GABA)-receptor- associated protein (GABARAP) 
subfamilies. The lipidated LC3s and GATE16/GABARAPs are then recruited 
to the phagophore membrane. Both subfamilies have been shown to be 
essential for the formation of the autophagosome with LC3s acting at the 
early stages of development and GATE16/GABARAPs having a role in 
phagophore maturation (Weidberg et al 2010). 
 
The phagophore membrane expands through the fusion of lipids which is 
mediated by LC3 through the facilitation of hemifusion events. This is when 
only the outer layer of two membranes fuse together. The lipids can be 
obtained from either the ER (Hayashi-Nishino et al 2009, Ylä-Anttila et al 
2009), the mitochondria (Hailey et al 2010), the cell membrane (Ravikumar 
et al 2010) and the Golgi via the ER-Golgi-intermediate complex (ERGIC) 
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(Ge et al 2013), or from a combination of these depending on the 
autophagy stimulus and availability of the organelles (Tooze and Yoshimori 
2010).   
 
The mechanisms surrounding autophagosome closure are still unknown 
however it is thought that the GABARAPs act to dissociate the ATG16L 
complex from the autophagosome (Weidberg et al 2010) as it is not found 
on mature autophagosomes (Mizushima et al 2003). Additionally it is 
known that both ATG2 and ATG9 are essential for sealing of the membrane 
and defects in either prevent the autophagosome from closing (Corcelle-
termeau et al 2016, Velikkakath et al 2012).  
 
6.1.1.1.3  Fusion 
Once sealed, the autophagosome needs to be transported to the 
microtubule organising centre (MTOC) where it is fused to the lysosome. 
To achieve this the autophagosome moves along microtubule tracks 
assisted by the small GTPase Rab7 and its effectors; Rab-interacting 
lysosomal protein (RILP) (Jordens et al 2001) and FYCO1 (Pankiv et al 2010). 
 
Fusion to the lysosome is co-ordinated by Rab GTPases, particularly Rab7, 
facilitated by PLEKHM1 which simultaneously binds Rab7, LC3 and the 
homotypic fusion and vacuolar protein sorting (HOPS) complex (McEwan et 
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al 2015). The HOPS complex, a multimer of six vacuolar protein sorting 
proteins (Balderhaar and Ungermann 2013), has two functions; firstly it 
acts as a tethering molecule to position the necessary compartments 
intended for fusion into close proximity and secondly it primes the SNARE 
proteins for fusion (Jiang et al 2014, Wartosch et al 2015). The 
autophagosome-bound SNARE protein STX17, in complex with the SNAP29 
SNARE and stabilised by Barkor (Diao et al 2015), attaches to the 
lysosomal-bound SNARE VAMP8 enabling fusion between the 
autophagosome and the lysosome (Itakura et al 2012) to produce the 
autolysosome.  
 
6.1.2 Role of Autophagy in Cancer 
6.1.2.1 Autophagy as a Tumour Suppressor 
Autophagy can act as a tumour suppressor by removing damaged proteins 
which can increase levels of oxidative stress leading to DNA damage. There 
is also cross-talk between autophagy with the apoptotic pathway. 
Autophagy has been shown to prime cells for programmed cell death 
(Young et al 2012) and may be used as an alternative death pathway for 
cells with impaired apoptosis (Y Zhao et al 2010). 
 
Deficiencies of key autophagy genes has been described in several tumours 
further implying a tumour suppressor role for autophagy. BECN1 which 
codes for beclin1, is recurrently mono-allelically deleted in several 
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carcinomas (Aita et al 1999) and loss of the up-regulators of BECN1, 
Ambra1 and UVRAG, have also been shown to increase proliferation in 
tumour cells (Fimia et al 2007, Liang et al 2006). Absence of  the ATG5 
protein is associated with shorter PFS in melanoma (He Liu et al 2013) and 
mouse knockouts for ATG5 and ATG7 have been shown to develop 
diseases symptomatic of myelodysplastic syndrome and acute myeloid 
leukaemia (Mortensen et al 2011).  
 
Deficiency in the autophagy process leads to an increase in defective 
proteins and organelles which can stimulate oxidative stress through the 
production of reactive oxygen species (ROS). Additionally a decrease in 
autophagy activity results in the build-up of p62/SQSTM1, an adaptor 
protein used to deliver damaged cellular components to the 
autophagosome for degradation (Pankiv et al 2007). Accumulation of p62 
has been shown to lead to the production of ROS which in turn causes DNA 
damage. Furthermore, increased p62 has also been linked to dysregulation 
of the NF-κB pathway (Mathew et al 2009). 
 
6.1.2.2 Autophagy as a Tumour Promoter 
Upregulation of autophagy can provide a survival mechanism for tumour 
cells. Indeed inhibition of autophagy has been demonstrated to increase 
chemosensitivity and cell death in many carcinomas (Koukourakis et al 
2015, Levy et al 2014, Ma et al 2011, Ojha, Singh et al 2014, Zhao et al 
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2014). Increased autophagy can also provide nutrients to sustain tumour 
survival particularly during periods of cellular stress (Guo et al 2011) and 
tumour cells have been shown to be dependent on autophagy for the 
removal of ROS (Yang et al 2011). 
 
Apoptosis and autophagy are activated by similar triggers and can be 
stimulated simultaneously, sequentially or independently. Autophagy has 
been shown to prevent tumour cells from undergoing apoptosis by  
degrading key apoptotic factors (Hou et al 2010, Wang et al 2015). 
Moreover the inhibition of autophagy has been shown to initiate apoptosis 
suggesting a tumour promoter role (Boya et al 2005). 
 
6.1.3 Autophagy in CLL 
The role of autophagy in CLL is largely unknown. It has been suggested that 
the basal autophagy level in primary CLL cells provides a survival 
mechanism against cell death (El-Khoury et al 2014). Up-regulation of 
autophagy in CLL in response to cellular stress has also previously been 
described and demonstrated to promote cell survival (Kovaleva et al 2012, 
Mahoney et al 2012). This is consistent with studies that demonstrate that 
the inhibition of autophagy decreases CLL cell viability (Amrein et al 2011, 
Mahoney et al 2013). Furthermore two studies have established that one 
mechanism of action of the histone deacetylase inhibitor drugs, which have 
been shown to cause cytotoxicity in CLL cells, is to block the autophagy 
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pathway (El-Khoury et al 2014, MacCallum et al 2013). In contrast, a recent 
study has shown that CLL cells with impaired autophagy have a marked 
resistance to fludarabine (Bologna et al 2016), although this contradicts a 
previous study which suggests that autophagy provides little protection 
from fludarabine (Mahoney et al 2012). 
 
Genes involved in the P13K complex such as BECN1 have been showed to 
have reduced expression levels in CLL when compared with normal B-cells 
(Kristensen et al 2015). Additionally, the whole genome screening 
approaches described in the previous chapter have identified recurrent 
mutations in key autophagy genes such as ATG5 and ATG4D. Together this 
data suggests that there may be a role for autophagy in CLL pathogenesis.  
  
 
179 
 
6.2 Materials and Methods 
6.2.1 Quantitative real-time PCR of autophagy genes 
cDNA from 11 CLL samples (from population C, Appendix 2) and from 
sorted B cells (Section 2.1.3) from healthy donors was used in this analysis. 
Real time PCR was performed using Applied Biosystems Taqman Gene 
Expression assay kits for ATG5 (Hs00169468_m1), Beclin1 
(Hs00186838_m1) and GAPDH (Hs99999905_m1). Samples of cDNA (2ul) 
were made up into 10ul reaction mixes using Taqman MasterMix 
(4304437, Thermo Fisher Scienitific) and the corresponding Taqman Gene 
Expression probe. Detection was performed using the Rotorgene 6000 
(Qiagen). The PCR cycling conditions started with a 2min incubation at 
50°C, then an initial denaturation of 95°C for 10mins followed by 50 cycles 
of 95°C for 15sec and 60°C for 1min. Quantification of the of the samples' 
transcripts was performed using the Comparative Quantification method of 
the Rotor Gene 6.0 software. In this method, the Ct is defined as the point 
at which the exponential phase of amplification begins and the reaction 
efficiency is calculated between this point and the maximum rate of 
exponential amplification. From this the level of individual transcripts 
relative to the reference sample can be calculated using the formula:  
Relative Quantity = EfficiencyReferenceCt-SampleCt 
From this the relative expression ratios of BECN1 and ATG5 to GAPDH for 
each sample can be determined (Mccurdy et al 2008).  
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6.2.2 Preparation of Cells for Autophagy Analysis 
Cells from 8 CLL patients (from population C, appendix 2) and 4 age-
matched healthy donors were collected and the PBMC isolated and stored 
(Section 2.1.1). FACS buffer contained PBS with 1% FBS (12003C, Sigma 
Aldrich) and 0.05% sodium azide (71289, Sigma Aldrich). Cells were thawed 
(Section 2.1.2), then incubated either in RPMI (11875-085, Thermo Fisher 
Scientific) with 10% FBS with or without 10ug/ml of each of the lysosomal 
inhibitors E64d (E8640, Sigma) and Pepstatin A (P5318, Sigma) or in HBSS 
(14060, Invitrogen) with or without E64D and Pepstatin A for 2hrs at 37°C. 
The cells were then harvested and immunolabelled with human anti-CD5 
(1:100 FACS buffer, PE, 561897, BD Biosciences, San Jose, California, USA) 
and anti-CD19 (1:100 FACS buffer, Pacific blue, MHCD1928, Invitrogen, 
Carlsbad, California, USA). To prepare the cells for autophagy analysis using 
the ImageStream (Amnis, Seattle, Washington, USA), the cells were stained 
with the lysosomal marker Lyso-ID Red (1:1000 assay buffer, ENZ-51005-
500, Enzo Life Sciences, Farmingdale, New York, USA) then incubated with 
fixative (00-8222-49, eBiosciences, San Diego, California, USA) and washed 
with permeabilisation buffer (008333-56, eBiosciences). A mouse anti-LC3 
(1:1000 permeabilisation buffer, 0231-100/LC3-5F10, Nanotools, Teningen, 
Germany) was then added followed by immunolabelling with either alexa 
fluor 488 goat anti-mouse IgG (H+L) (1:500 permeabilisation buffer, 
Invitrogen) or alexa fluor 546 goat anti-mouse IgG (H+L) (1:500 
permeabilisation buffer, Invitrogen). For the caspase-3 analysis, cells were 
immunolabelled with FITC-conjugated rabbit anti-active caspase-3 (1:20 
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FACS buffer, BD Biosciences), post permeablisation. A small fraction of 
each sample was separately stained with LIVE/DEAD (1:2000 PBS, 
Invitrogen). Cells were then resuspended in 50ul FACS buffer. 
 
6.2.3 Imagestream 
Samples were processed on the Amnis ImageStream using the integrated 
INSPIRE software. First, the ImageStream was calibrated using speed beads 
(400040, Amnis) according to the manufacturer’s instructions. Next 
unlabelled and single colour fluorescent controls for each of the antibodies 
were run and finally the experimental samples were processed last. 
Acquisition started once the core stream had stabilised. At least 20000 cells 
per sample were collected and the cell classifier field had the area lower 
limit set to 25. Each sample generated a raw data file.  
 
6.2.3.1 Imagestream Analysis 
Following image acquisition, cells were analysed using the IDEAS 6.1 
software package (Amnis). A compensation file was generated from the 
single colour control files. Doublet cells and out-of-focus cells were 
discarded by gating out bright field area vs aspect ratio and bright field 
gradient root mean square > 300 respectively. Cells were gated on CD19 
and CD5 double positives in the CLL samples and on the CD19 positives for 
the normal controls.  
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These subsets were then gated on LC3+Lyso+. Autophagy activity in this 
study was based on the co-localisation of LC3 and lysosome, which occurs 
during autolysosome formation. The autolysosome formation levels were 
calculated based on the percentage of co-localisation bright detail 
similarity (BDS) of LC3 and lysosome in the LC3+Lyso+ subset. BDS is derived 
from the log-transformed, non-mean normalised Pearson’s correlation 
coefficient (r) calculated from the pixel intensity of the fluorescence of the 
two markers of interest. The r value determines the similarity in the 
fluorescence of the two markers on a scale of 0 (no correlation) to 1 
(complete correlation).  Since r is a linear value it can lead to compression 
at the high end of the range. This is overcome by log-transforming the r 
value to give the BDS value (Beum et al. 2006; Phadwal et al. 2012). The 
BDS of LC3 and lysosome was ascertained for each sample analysed on the 
Imagestream and both the mean BDS and the percentage of cells gated as 
BDShi were used to establish the autophagy activity. A previous autophagy 
study using the Imagestream described bimodal histograms when analysing 
the BDS in the cells of interest, enabling the second peak to be termed 
BDShi (Phadwal et al. 2012). In contrast, the histograms obtained in this 
study had a more normal distribution pattern, therefore BDShi was defined 
as the region to the right of the curve. To enable comparison between 
samples the average of the peak for all the CLL samples was calculated as 
1.66. Cells with a BDS greater than this value were defined as BDShi and this 
was applied to all the samples analysed. Both the mean BDS and the 
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proportion of cells achieving BDShi were determined for all samples to 
determine the autophagy activity.  
6.2.4 Statistical Analysis 
Statistical analysis was performed using Graphpad Prism 5.0. p-values were 
calculated using 2-tailed independent sample t-test and 2-tailed Mann-
Whitney U test. 
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6.3 Results 
6.3.1 Quantitative PCR 
To determine if the copy number loss identified by the array over the ATG5 
gene had an effect, qPCR was used to quantify gene expression of the 
ATG5 transcript in 11 CLL samples and B-cells isolated from four healthy 
donors. One of the B-cell controls was used as a calibrator. Overall 
comparison showed there was no significant change in ATG5 expression 
levels when compared to GAPDH (Figure 6.2a). qPCR analysis of the BECN1 
transcript however, showed almost a 50% decrease in the level of 
expression when normalised to GAPDH (Figure 6.2b). 
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Figure 6.2. ATG5 and BECN1 expression ratio in normal B-cells and CLL cells. qPCR of cDNA from 11 
CLL samples and B-cells isolated from 4 healthy donors for a. ATG5 and b.BECN1 (mean ± SEM,  [t-
Test]),  ns – not significant  
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6.3.2 Analysis of the autophagy levels using the Amnis 
Imagestream 
The Amnis Imagestream is an imaging flow cytometer that enables the 
simultaneous assessment of morphological characteristics alongside 
fluorescence signals in large numbers of cells. Furthermore, the location 
and intensity of the fluorescence signals can be determined and quantified. 
It is highly suited for assessing autophagy levels in primary cells as it is able 
to calculate co-localisation of autophagosomal markers whilst identifying a 
subpopulation of cells by their surface markers (Figure 6.3a). Assessment of 
autophagy in this study is based on the co-localisation of LC3 and lysosome 
which characterises autolysosome formation (Figure 6.3b). In addition to 
analysing the basal autophagy levels, analysis of co-localisation in the 
presence of the lysosomal inhibitors E64D and Pepsatin A were also 
calculated. The inhibitors prevent the fusion of lysosome to the 
autophagosome and halts the autophagic process. This therefore implies 
the degree of autolysosomal formation at the period the inhibitors were 
added. 
 
 
 
 
Figure 6.3. ImageStream analysis of autophagy. a. ImageStream images of one cell for each channel. b. Analysis pathway for determining autophagy levels in CLL cells. Cells are first gated on 
CD5+CD19+ double positives. The co-localisation of lysosome and LC3 is then determined in this gated population. Finally, the distribution of co-localisation is demonstrated graphically. 
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Figure 6.4. CLL cells have a higher basal autophagy level than age-matched control B-cells.  
Autophagy levels in basal and basal + I from 8 CLL patients and 4 age-matched controls comparing a. 
Percentage of double positives with BDShi in (mean ± SEM, p=0.004 [Mann-Whitney Test]) b. Mean 
BDS (Mean ± SEM, *p=0.016, **p=0.004 [Mann-Whitney Test]). Overlay of BDS histograms from CLL 
(white) and normal B-cells (blue) under c. basal and d. basal + I conditions. 
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6.3.3 Basal autophagy levels are higher in CLL cells than age-
matched controls 
To assess the basal level of autophagy in CLL, primary cells from patients 
and healthy age-matched controls were immunostained with anti-CD5 and 
anti-CD19 and the level of autophagy activity established. The autophagy 
level of the normal B-cells was similar to what has been previously 
described (Phadwal et al 2012). Analysis of the %BDShi demonstrated that 
the CLL cells have nearly a six-fold increase in autophagy activity compared 
to the normal B-cells (Figure 6.4a). The increase in autophagy is further 
supported by analysis of the mean BDS which shows a 70% increase in the 
CLL cells. (Figure 6.4b) An overlay of the BDS histograms (Figure 6.4c and d) 
for the CLL cells (blue) and the normal B-cells (white) provided further 
evidence of the increase. 
 
6.3.4 CLL cells have increased autophagy levels upon 
induction 
Autophagy can be stimulated during cellular stress to provide nutrients and 
energy.  Therefore, cells were incubated in starvation buffer for 2hours 
prior to immunostaining to ascertain how the induction of autophagy 
activity in CLL cells compares to normal B-cells. Analysis of %BDShi showed 
that the CLL cells have nearly a 50% increase in induced autophagy activity 
compared to normal B-cells (Figure 6.5). Interestingly the data showed no 
difference between the induced and basal autophagy level in the CLL cells 
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(p=0.63) which differs from what has been previously reported (Kovaleva et 
al 2012). 
Figure 6.5. Induced autophagy levels are higher in CLL cells than in age-matched controls. Percentage 
of double positives with BDShi in induced and induced + I from 8 CLL patients and 4 age-matched 
controls Mean ± SEM, *p=0.012, *p=0.032 [Mann-Whitney Test]). 
 
6.3.5 Increased autophagy levels in CLL cells is not a feature 
of CD19+CD5+ cells 
CLL cells express CD19 and CD5 on their surface. Although CD19 is found on 
all mature B-cells (Nadler et al 1983, Wang et al 2012), CD5 is only 
expressed on B-1a cells which represent <20% of the B-cells compartment 
(Cabezudo et al 1997, Vuillier et al 1991). These cells have a different 
function to the CD19+CD5- cells, so it is possible that the increase in 
autophagy is a feature of the CD19+CD5+ phenotype. Therefore, the CD19+ 
B-cell cohort isolated from the age-matched controls was further 
delineated to the CD5+ fraction.  Analysis of the mean BDS in this subset 
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showed no significant difference in autophagy activity compared to the 
CD19+CD5- cohort (Figure 6.6). 
 
Figure 6.6. Basal autophagy level in the B-cell subsets of the age-matched controls. Mean BDS in 
basal and basal + inhibitors for all CD19+ cells and in the CD19+Cd5+ cohort (mean  SEM, p=0.86 and 
0.23 respectively [Mann-Whitney U Test]) ns – not significant 
 
6.3.6 Higher autophagy is not linked to cell death 
Since an increase in autophagy could be a response to increased cellular 
death, the level of caspase-3 was determined in the cells. For this, the CLL 
cells were identified solely with an anti-CD19 marker, and the autophagy 
activity and caspase-3 level determined. Analysis of the caspase-3 level in 
CLL cells with high and no autophagy were compared. No significant 
change in the caspase-3 level was detected in any of the three patient 
samples (p-value=0.7) (Figure 6.7). 
 
192 
 
 
Figure 6.7 The increase in autophagy activity in the CLL cells is not associated with cell death. a. BDS 
overlay demonstrating the cells define as high and low autophagy. b. Percentage of cells with 
caspase-3 activity in the high and low autophagy subsets (mean ± SEM, p=0.7 [Mann Whitney U 
Test]). 
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6.4 Discussion 
Since genes involved in the autophagy pathway were found to be 
recurrently mutated in patients with CLL it raises the question of a role for 
autophagy in the pathogenesis of CLL. This study has demonstrated that 
CLL cells have higher autophagy activity than normal age-matched B-cells 
and shown that this increase is neither a feature of B1-a cells or a response 
to an increase in apoptosis. 
 
6.4.1 CLL cells have a higher level of autophagy activity than 
B-cells from normal age-matched controls 
In this study, it has been demonstrated that CLL cells have a higher level of 
autophagy than B-cells from healthy age-matched controls. Normal CD19+ 
B-cells are known to have low or undetectable levels of basal autophagy 
(Lee & Sugden 2008; Phadwal et al. 2012). Furthermore, mature B-cell can 
exist in the absence of functioning autophagy as has been demonstrated by 
ATG5 knockout mice suggesting that autophagy is not essential for B-cell 
survival (Miller et al. 2008; Arnold et al. 2016). The increased autophagy 
seen in the CLL cells supports previous studies that have shown that CLL 
cells use autophagy as a survival mechanism (El-Khoury et al 2014, 
Kovaleva et al 2012, Mahoney et al 2012).  
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Accumulation of autolysosomes, as demonstrated by the co-localisation of 
LC3 and lysosome, can potentially be cause by either an overproduction of 
autophagosomes or by a deficiency in the downstream machinery of the 
autophagy pathway, and could therefore represent defective autophagy 
rather than a true increase in activity (Mizushima et al 2010). To overcome 
this potential problem, the study in this chapter also analysed co-
localisation in cells that have been treated with the lysosomal protease 
inhibitors Pepstain A and E64D. These inhibitors block the degradation of 
LC3-II causing an accumulation of autolysosomes (Tanida et al 2005). The 
increase in co-localisation in the CLL cells versus normal age-matched B-
cells was still detectable under these conditions suggesting that rise in the 
number of autolysosomes in the CLL cells was not caused by defective 
autophagy. 
 
6.4.2 Increased autophagy is not a feature of B1-a cells 
B-1a cells are found naturally in the B-cell component. It is estimated that 
CD5+ B-cells account for up 25% of the B-cell population (Cabezudo et al 
1997, Vuillier et al 1991). B1-a cells, in contrast to B2-cells, are involved in 
the innate immune response. Since B1-a cells differ in their functionality to 
B2 cells it may be that they also differ in their levels of autophagic activity. 
Indeed a key function of B-1a cells is to remove autoantigens (Botto and 
Walport 2002, Ehrenstein and Notley 2010, Kaveri et al 2012, Tsiantoulas 
et al 2012) and it is possible that autophagy is the mechanism by which this 
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is achieved. Furthermore ATG5 has been shown to be important in the 
maintaining B1-a cells in the peripheral blood although it is not essential 
for B2 cells (Miller et al 2008) implying that these subsets may have distinct 
autophagy activity.  
 
To determine if B1-a cells had an autophagy level that was different 
compared to the rest of the B-cell population, the B-cell compartment was 
further delineated into CD5+ and CD5- cells in the normal age-matched 
controls. Comparison of these subgroups yielded no significant difference 
suggesting that the increase in autophagy activity was not a feature of 
CD5+CD19+ cell types. 
 
6.4.3 Cells with high autophagy levels are not undergoing 
apoptosis 
There is a large amount of cross-talk between the regulators and 
components of the autophagy and apoptosis pathways as well as an 
overlap in the activation of both pathways  (Maiuri et al 2007). 
Consequently both processes are induced in response to the same stimuli 
(Marino et al 2014) and autophagy has been shown to be induced prior to 
apoptosis (Bhutia et al 2010). It is possible that the up-regulation of 
autophagy detected in the CLL cells in this study may be in response to 
apoptosis. Therefore, analysis of caspase-3 was done to exclude cell death 
as a reason for the increase in autophagy. Caspase-3 is activated early in 
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apoptosis and is therefore a marker of apoptosis. There was no increase in 
activated caspase-3 in the cells that had high levels of autophagy when 
compared to the cells with low levels of autophagy. This suggests that the 
increase in autophagy seen in the CLL cells was not a by-product of 
apoptosis. 
 
There is some evidence that autophagy may act as a second death 
pathway, ergo it is possible that the increase in autophagy in the CLL cells is 
caused by autophagic cell death. As the mechanism of autophagic cell 
death is not yet understood, it is not possible to exclude this as an option 
through this assay, as autophagic cell death is independent of caspase-3 
(Yang Liu et al 2013). However ATG5 and BECN1 expression has been found 
to be upregulated during autophagic cell death but not under autophagy 
survival conditions (Shimizu et al 2004) and since the work described in this 
chapter did not detect an increase in ATG5 expression in the CLL samples, it 
is likely that the CLL cells are not undergoing autophagic cell death.  
 
6.4.4 Conclusions 
In conclusion, the work in this chapter has shown that CLL cells have higher 
levels of autophagy activity when compared to normal age-matched B-
cells. The increase is not a feature of normal CD5+ B-cells and is also not in 
response to programmed cell death. This further supports the idea that CLL 
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cells use autophagy as a survival mechanism and that inhibition of 
autophagy may sensitise CLL to treatment. 
Chapter 7  Discussion 
7.1 Introduction 
Over the course of my thesis, the understanding of the molecular drivers of 
CLL pathogenesis has significantly increased due, mostly, to the increasing 
availability of NGS technologies. At the beginning of this work, CLL was 
thought to be a relatively stable disease originating in the secondary 
lymphoid organs. However, our work and that of others (Damm et al 2014, 
Kikushige et al 2011, Knight et al 2012, Landau et al 2015, Ouillette et al 
2013, Puente et al 2011, Schuh et al 2012, Zenz et al 2009), provides 
evidence that supports the presence of ongoing clonal evolution and of a 
pre-leukaemic stem cell that originates from an un-rearranged progenitor 
cell in the bone marrow. 
 
7.2 Summary of Findings 
My thesis aimed to characterise the genomic complexity of CLL. It sought 
to identify candidate molecular drivers responsible for clonal expansion 
and relapse following clinical intervention and to define predictors of poor 
outcome.  A range of techniques were utilised, including genome-wide SNP 
array as well as NGS of both the IgHV region and recurrently mutated 
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genes. Paired pre-treatment and relapse samples were used to allow the 
identification of emerging subclones. Finally, where possible, findings were 
correlated with clinical outcomes to determine prognostic significance or 
validated at protein level using flow cytometry. 
 
At the start of this thesis, in 2009, NGS technology was in its infancy. Three 
platforms were available, the Roche 454 GS Flx, the Illumina Genome 
Analyser and the Applied Biosystems SOLiD sequencer. Each were designed 
primarily for high-throughput large-scale sequencing (Mardis 2008).  Only 
the release of benchtop sequencers made NGS accessible to a wider user 
group, including routine diagnostic laboratories (Loman et al 2012). The 
work in Chapter 3 describes efforts to validate NGS for investigation of the 
IgHV region using these technologies.  At first the Roche 454 was the only 
platform with the capacity to perform 400bp sequencing, required to cover 
the whole of the IgHV. It was only replaced by the Illumina MiSeq when 
this platform could perform 600bp sequencing. 
 
Chapter 3 introduces the concept of IgHV subclones. The work by Campbell 
et al (2008) was the first to demonstrate ongoing clonal evolution in CLL 
through NGS analysis of the IgHV region using a VH-family specific primer. 
The work in Chapter 3 expands on this by utilising all the VH-primers to 
search for subclones with different VDJ rearrangements, the presence of 
which would indicate a pre-B cell leukaemic stem cell. The detection of two 
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productive VDJ rearrangements has previously been reported in CLL at low 
frequencies (Plevova et al 2014, Rassenti and Kipps 1997, Visco et al 2013). 
The work in this chapter found that by using NGS it was possible to detect 
multiple productive IgHV subclones in 24% of CLL patients. This finding 
provides evidence for leukaemia-initiating events that pre-date IgHV 
rearrangement. 
 
Chapter 4 sought to determine whether the IgHV subclones formed part of 
the CLL or whether these were contaminating B-cells from the normal 
polyclonal background. Through a series of validation experiments it was 
possible to show that these subclones were indeed part of the CLL.  
Furthermore, it was demonstrated that these subclones refined the 
previous SSeq-based IgHV prognostic classification system (Damle et al 
1999, Hamblin et al 1999).   
 
Chapter 5 used a cohort of 411 pre-treatment and relapse samples to 
detect recurrent genetic abnormalities. This work primarily used high 
resolution SNP array to screen for genome-wide copy number aberrations. 
At the time, NGS was not available and CGH- and SNP-array were the 
techniques of choice to screen for global changes in the genome. Prior to 
the start of this study there had been limited work in CLL performed using 
SNP-arrays (Gunnarsson et al 2008, Pfeifer et al 2006). This chapter 
expands on these studies by using high-resolution SNP arrays with over one 
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million probes, on a larger cohort of patients (411 versus 10 and 70, 
respectively). Furthermore, this work included paired diagnosis and relapse 
samples enabling, for the first time, clonal evolution to be demonstrated in 
CLL at a global level through the identification of emerging subclones 
(Knight et al 2012).  
 
Finally, the work in Chapter 6 showed that CLL cells had higher levels of 
autophagy when compared with normal B-cells from healthy age-matched 
controls. This work followed on from the observation in Chapter 5, that 
ATG5 was one of two genes in the MOR of the del(6q) and that autophagy 
related genes could be identified in other MORs that occurred recurrently 
in CLL. There have been limited studies investigating the role of autophagy 
in the pathogenesis of CLL. Whilst a few studies have suggested that CLL 
cells up-regulate autophagy in response to stress (Kovaleva et al 2012, 
Mahoney et al 2012) and that inhibition of autophagy decreases the 
viability of CLL cells (El-Khoury et al 2014, Mahoney et al 2013), to date 
there has been no work investigating the autophagy levels in CLL cells, 
compared with age-matched normal controls. 
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7.3 The relationship between aging and 
development of CLL 
Both Chapters 4 and 6 use CD19+ B-cells from age-matched healthy 
volunteers as controls. CD19 is a reliable hallmark of B-cells since it is 
expressed on the B-cell surface from the pro-B phase (Wang et al 2012).  
The control samples are acquired from age-matched volunteers since CLL is 
found predominately in the over 65 age-group (Cancer Research UK, 
2016b). Age-matched controls ensure, as far as possible, that any 
abnormalities are a characteristic of the CLL rather than of aging. Both 
autophagy and B-cells are known to be affected by the aging process. 
Autophagy levels are thought to decrease with age due to the altered 
expression and availability of its components (Carroll et al 2013, Phadwal 
et al 2012). Therefore, aged-matched controls are vital in differentiating 
between the effects of the CLL and the effects of aging. 
 
 Likewise, age is associated with a higher frequency of haematopoietic 
disorders. The incidence of clonal haematopoiesis of indeterminate 
potential (CHIP), an entity defined by the presence of somatically acquired 
mutations in blood cells, is around 10% in the over 60s (Genovese et al 
2014, Jaiswal et al 2014, Steensma et al 2015, Xie et al 2014). Monoclonal 
B cell lymphopoesis (MBL) has been reported in just under 20% of the 
healthy population aged over 70 (Almeida et al 2011). Similar to CHIP, MBL 
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is a relatively benign condition, although mutations found in some  
haematological malignancies have been reported in MBL (Ojha, Secreto et 
al 2014, Rawstron et al 2008b). The validation work in Chapter 4 provides 
further support for the presence of oligoclonal B cell populations in the 
over 70s since it was possible to identify low frequency clonal IgHV 
subclones in every normal control. It is important to stress that whilst these 
cells were CD19+, they were also CD5-. Therefore, these cells do not 
represent MBL, but are typical of age-related B-cell expansion (Gibson et al 
2009, Frasca and Blomberg 2009). However, whilst both CHIP and MBL are 
not uncommon, the incidence of transformation is relatively low at around 
1% per year (Genovese et al 2014, Jaiswal et al 2014, Rawstron et al 
2008b). Therefore, whilst these diseases represent a pre-leukaemic state, a 
second hit is required for transformation to CLL and this is likely to involve 
antigenic stimulation in the germinal centre.  
 
7.4 CLL as a subclonal disease 
CLL has traditionally been thought of as a monoclonal disease 
characterised by the presence of a single productive VDJ rearrangement. 
Although the detection of two productive rearrangements had been 
reported it was argued that only one would be transcribed, translated, and 
expressed on the cell surface (Rosenquist 2009). This was further 
supported by early work suggesting that the presence of two productive 
clones was, in most instances, caused by rearrangement of both alleles in 
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one cell due to a lack of allelic exclusion otherwise known as allelic 
inclusion (Langerak et al 2011, Rassenti and Kipps 1997). 
 
Whilst it was accepted that two rearrangements may represent a biclonal 
disease, this was thought to be rare since the clones were required to be 
both morphologically and phenotypically distinct in order to be classified as 
such (Sánchez et al 2002). Later work by Plevova et al (2014) found several 
incidences of  CLL with a homogeneous phenotype alongside multiple 
productive rearrangements. The group excluded allelic inclusion, through 
the detection of partial VJ rearrangements since this would suggest that 
full VDJ recombination had not taken place on both alleles. Single cell 
sequencing has been used more recently to show that there is only one 
productive rearrangement per cell (Kriangkum et al 2015). Therefore, it is 
highly likely that each rearrangement corresponds to an individual 
leukaemia subclone, that is, that the different rearrangements are present 
in different cells. 
 
The data presented in Chapters 3 and 4 demonstrate that the incidence of 
multiple productive rearrangements in CLL is far higher than previously 
reported (Plevova et al 2014, Rassenti and Kipps 1997, Visco et al 2013), 
suggesting that CLL, like other cancers and leukaemias, is a subclonal 
disease. Furthermore, the work in Chapter 5 provides further evidence of 
subclones through the detection of expanding mutations at relapse. 
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Indeed, the notion of subclones in CLL, as defined as by subclonal 
mutations and CNAs, is well supported by current literature (Amin et al 
2016, Grubor et al 2008, Jethwa et al 2013, Knight et al 2012, Landau et al 
2013, 2015, Ljungström et al 2016, Rasi et al 2016, Rossi et al 2014, Schuh 
et al 2012).  
 
It has been proposed that the presence of multiple productive 
rearrangements represents CLL co-existing alongside ongoing MBL with a 
CLL-phenotype (Plevova et al 2014). Both clonal and subclonal IgHV CLL-like 
MBL has been reported (Klinger et al 2015, Rawstron et al 2008a), so it is 
possible that there is underlying MBL in multiply productive CLL. Through 
ultra-deep targeted NGS, it was possible to quantify the IgHV subclones 
detected in Chapters 4 and 5.  A biclonal IgHV was detected in 65% of 
multiple productive CLL with an average frequency of 10% for the second 
clone. It is possible that this indicates CLL with a monoclonal MBL 
background. Likewise, three IgHV subclones were detected in 19%, and 
over four subclones were detected in 16% of multiply productive CLL 
patients, which may suggest CLL with an oligoclonal MBL background. It is 
difficult to distinguish subclonal CLL from monoclonal CLL with background 
MBL, since the discriminating factor between CLL and MBL diagnostically is 
their white cell count in the peripheral blood (Strati and Shanafelt 2015). 
However, there is evidence that MBL does not have stereotyped CDR3 
receptors (Dagklis et al 2008). Chapter 4 shows that some IgHV subclones 
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did demonstrate stereotyping which may favour a subclonal CLL model. 
Regardless of the origin of the subclones, their very presence is supportive 
of an IgHV subclonal disease, which contrasts with the traditional concept 
of a monoclonal disorder.  
 
7.5 The role of autophagy in CLL pathogenesis  
The work in Chapter 6 shows that CLL cells have altered autophagy when 
compared with normal B-cells.  The reason behind the investigation into 
autophagy was the finding that ATG5 is recurrently mono-allelically deleted 
in CLL.  It would be assumed that the deletion of one copy of the ATG5 
gene would result in some loss of expression, yet this was not seen using 
quantitative PCR. Furthermore, a functional loss of ATG5 would be 
predicted to reduce the level of autophagy, however, increased autophagy 
was reported even in the patient with the ATG5 deletion. SNPs in the ATG5 
gene and in its preceding intergenic region have been shown to increase 
ATG5 expression (Zhou et al 2011) therefore it is possible that the loss of 
the balancing SNP may cause upregulation of the ATG5 gene. However, this 
study did not find an increase in ATG5 expression in the CLL samples, 
although BECN1 expression was downregulated, a finding that has been 
previously reported (Kristensen et al 2015).  Therefore, it is worth noting 
that mRNA levels do not always correspond to protein activity (Vogel and 
Marcotte 2012) and that the expression levels of ATG5 and BECN1 may not 
affect autophagy activity in CLL.  
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On the other hand, it has been shown that autophagy can take place in 
mammalian cells in the absence of the ATG5 protein (Nishida et al 2009). 
Furthermore, inactivation of ATG5 was found to accelerate oncogenesis in 
mice, although it also decreased the level of progression (Rao et al 2014). 
This is in keeping with the dual role of autophagy in cancer, such that 
dysregulated autophagy can lead to tumourigenesis, yet functioning 
autophagy provides a survival advantage to cancers once they have 
developed. Whilst the absence of ATG5 and BECN1 may have implications 
for the development of CLL, it is not possible to explain the relationship, if 
any, between BECN1 expression levels and the increase in autophagy 
reported in Chapter 6. 
 
Normal B-cells have a low level of autophagy activity (Phadwal et al 2012). 
Although not essential for B-cell development, it has been shown that 
autophagy is required at a basal level to sustain B-cells long-term in the 
periphery (Arnold et al 2016, McLeod and He 2010, Miller et al 2008). B-
cells are known to use autophagy in the processing of antigens prior to 
their presentation to T-cells (Clark et al 2004, Schmid et al 2007, Watanabe 
and Tsubata 2009). Furthermore, antigen stimulation of the BCR has been 
shown to induce autophagy in B-cells (Watanabe et al 2008).  
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Chapter 6 found that CLL cells have a higher level of autophagy activity 
than their counterpart B-cells. Autophagy is known to provide a survival 
advantage to tumour cells through the provision of nutrients (Guo et al 
2011) and the prevention of apoptosis (Hou et al 2010, Wang et al 2015). 
Recent work suggests that autophagy may also play a role in disabling the 
anti-tumour immune response (Lévy et al 2015, Rao et al 2014, Wei and 
Guan 2012). Stimulation of the BCR has also been shown to induce 
autophagy in CLL cells (Smith et al 2015) and since it has been proposed 
that activation of the BCR may be the trigger in transitioning MBL to CLL 
(Sutton and Rosenquist 2014), it is possible that autophagy may be 
instrumental in this evolution. Indeed, UM-CLL has been reported to have 
higher autophagy activity than M-CLL (Smith et al 2015), providing further 
evidence that increased autophagy confers a survival advantage in CLL. 
 
7.6 Future work and directions 
Although my work has provided some insight into the genomic complexity 
of CLL, it also raises further questions for investigation. 
 
Firstly, it would be beneficial to confirm the IgHV prognostic classification 
system in an independent cohort. Whilst validation of this model in 
another clinical trial cohort may be subjected to the same issues of sample 
bias that was reported in population B in Chapter 4, examination of a well 
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annotated non-trial cohort would provide further support for this model. 
Additionally, since the ARCTIC and AdMIRe trial samples used for 
population B had limited follow-up, it would be worth re-evaluating the 
data in a further five years to ascertain if the model works for this cohort in 
terms of OS. Long-term follow-up of the CLL8 trial has shown that around 
50% of patients with M-CLL obtained a long-term PFS following FCR 
treatment (Stilgenbauer et al 2014). It would be very interesting to test this 
cohort for their NGS-IgHV status to see if they would fit the prognostic 
model, as well as potentially differentiating the long-term PFS M-CLL 
patients from the other M-CLL patients. 
 
The work performed in Chapters 3 and 4 used a 2.5% cut-off to distinguish 
between subclones and B-cell background. Early NGS work by Campbell et 
al (2008) reported subclones as low as 0.02% although they excluded B-cell 
background by solely interrogating the dominant clonal IgHV. The 
validation work in Chapter 4 shows that less than 0.4% of the reads would 
be normal B-cells, suggesting that a cutoff of 2.5% is very conservative. It 
also shows that using gDNA reduces the occurrence of IgHV subclones 
since they fall below the 2.5% cut-off. Therefore, it would be interesting to 
see if using a lower cut-off increases the frequency of IgHV subclonal CLL 
and the effect this would have on the NGS-IgHV prognostic model.  
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It would be interesting to correlate the IgHV subclones with other 
mutations and to analyse sequential samples to see how subclones evolve 
over time. Currently, it is difficult to use NGS to determine both IgHV 
mutation status and the presence of gene mutations simultaneously due to 
the different processing techniques involved. It may be possible to add 
IgHV to a TSCA panel, however I think that it will prove difficult to achieve 
acceptable sequencing coverage without compromising the integrity of the 
rest of the panel. Whilst it may be possible to use WGS for this, again I 
predict that there will be issues at the bioinformatics stage when piecing 
together the 100bp reads to obtain a full and accurate coverage of the 
IgHV. Additionally, WGS has an average depth of 75x, which would be 
insufficient for the detection of some IgHV subclones. It is possible that 
third generation sequencing technologies such as Nanopore technology 
may solve this problem since it is able to process large lengths of 
unfragmented DNA and may offer a real alternative to single cell 
sequencing (Jain et al 2016, Lu et al 2016).  
 
Finally, further work on the role of autophagy in CLL and MBL may provide 
valuable insight into the pathogenesis of CLL, as well as offering a target for 
treatment. Investigation of the link between BCR signalling and increased 
autophagy in CLL (Smith et al 2015) may elucidate whether autophagy is 
one survival mechanism by which CLL cells evade anticancer immune-
surveillance and persevere following treatment.  Indeed, inhibition of 
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autophagy in CLL has been recurrently shown to decrease the viability of 
CLL cells (Amrein et al 2011, Mahoney et al 2013). Furthermore, work on 
the activation of autophagy through BCR signalling may be instrumental in 
the determining how CLL may develop through antigen stimulation. 
 
7.7 Conclusion 
Overall this thesis has contributed to our knowledge of the genomic 
architecture of CLL through the utilisation of NGS and SNP array. CLL was 
found to harbour IgHV subclones that are likely to contribute to the 
biological heterogeneity of this disease and point towards leukaemia-
initiating events pre-dating IgHV rearrangement. Finally, CLL cells were 
found to carry chromosomal copy number changes that affected a number 
of autophagy-related genes which may provide an alternative mechanism 
whereby CLL cells become resistant to apoptosis. 
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Appendix 1 - Table of primers 
 
Primer Sequence (5’-3’) 
ATG5 Exon 1 (F) CTGGGTTAGGCAGAACACG 
ATG5 Exon 1 (R) ACAAGGTGGACACACACACG 
ATG5 Exon 2 (F) TGCAAGGATCTGACTAATGCTC 
ATG5 Exon 2 (R) CCCATTTGCCACAATCAATG 
ATG5 Exon 3 (F) AAGAACACGGCTGTTTTTCC 
ATG5 Exon 3 (R) TGCTTAATAATGCAGAAAAATTCAC 
ATG5 Exon 4 (F) TTAAAGCCCCTGACATTTGG 
ATG5 Exon 4 (R) AATGGGACGAAGGAGAAATG 
ATG5 Exon 5 (F) TTGAAAAACTGGGGGATATAGTTC 
ATG5 Exon 5 (R) AATCTGGGCACAGAGGCTAC 
ATG5 Exon 6 (F) TTTCATCTCTTCATGTGAGGTATTC 
ATG5 Exon 6 (R) TGTCTGAGGCTTTCATAAATGG 
ATG5 Exon 7 (F) AAAAGGCACCTAATGCCAAC 
ATG5 Exon 7 (R) GAAATGTTTTAATGTTGCTGATTG 
ATG5 Exon 8a (F) TTGTTGGGTTTCTTTCTTGG 
ATG5 Exon 8a 
(R) TTCGTTAAGGAAAGATGGGTTTAC 
ATG5 Exon 8b (F) TTGAACTTTAGCTCATGAAAGTGG 
ATG5 Exon 8b 
(R) TCAGTGAAAATCGCAAAAGG 
ATG5 Exon 8c (F) CGATCATGGTTTTAGATCCCATA 
ATG5 Exon 8c (R) TTTTAAATAAAGACGGACACAACA 
BLIMP1 exon 1 
(F) GCCGAGTGGCTAAGGAAATC 
BLIMP1 exon 1 
(R) GCAGAAGCATGTTTCTACTGC 
BLIMP1 exon 2 
(F) CATAGCCTCTCAGAAGGAGC  
BLIMP1 exon 2 
(R)  GTAGGGAGATTTGGCACCAG 
BLIMP1 exon 3 
(F) GGCATCATTAATGTCTGTTTACTTATC 
BLIMP1 exon 3 
(R)  CGCACCTTAGTCCCAGCTAC 
BLIMP1 exon 4 
(F) CTTACCTGTTTCCGCCCTG 
BLIMP1 exon 4 
(R) CAGCATGTCTGGACCAATCC 
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BLIMP1 exon 5a 
(F) CTAGCCCTCTGTGTAATCGC   
BLIMP1 exon 5a 
(R) GTTGTTGATGCCATTCATGC 
BLIMP1 exon 5b 
(F) AGTACGCTCACTACCCCAAGTTC 
BLIMP1 exon 5b 
(R) CTCACAGCCCCTTGGACTG 
BLIMP1 exon 6 
(F) GAGCCAGCTTGAGAGCAGAG 
BLIMP1 exon 6 
(R) TGGGAGGGTGACTCACAGAC 
BLIMP1 exon 7a 
(F) CCCGTTGGCAACTCTTAATC 
BLIMP1 exon 7a 
(R) GCCTTTGCCTTGTTCATGC 
BLIMP1 exon 7b 
(F) AAATGGTTTCCCCTCACCTC 
BLIMP1 exon 7b 
(R) TGGGGAAATTTTCGCAGTG 
BLIMP1 exon 7c 
(F) AGTCCTGTGGCCATTCAGAG 
BLIMP1 exon 7c 
(R) ACCGACGTGATTGTGAGGTC 
BLIMP1 exon 7d 
(F) TGAGCCAAGCCATGTAAAAG 
BLIMP1 exon 7d 
(R) TGGAGATGTCGCTCACTGAC 
Miseq Leader 
VH1 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATGGACTGGAC
CTGGAGG 
Miseq Leader 
VH2 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCACRCTCCTGCT
GCTGACCA 
Miseq Leader 
VH3a 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTGGGTTTTCC
TTGTTGC 
Miseq Leader 
VH3b 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATGGAGTTKGG
RCTGAGCTG 
Miseq Leader 
VH4 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTCCCAGATGG
GGTCCTG 
Miseq Leader 
VH5 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTCCTCCTGGCT
GTTCTCC 
Miseq Leader 
VH6 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGTCTCCTTCCT
CATCTTCC 
Miseq JH 
consensus  
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTTACCTGAGG
AGACGGTGACC 
GS FLX VH1-FR1 
(1)  
GCCTCCCTCGCGCCATCAGTCGTATGGCCTCAGTGAAGGT 
CTCCTGCAAG 
GS FLX VH2-FR1 
(1)  
GCCTCCCTCGCGCCATCAGTCGTATGTCTGGTCCTACGCT 
GGTGAAACCC 
GS FLX VH3-FR1 
(1)  
GCCTCCCTCGCGCCATCAGTCGTATCTGGGGGGTCCCTGA 
GACTCTCCTG 
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GS FLX VH4-FR1 
(1)  
GCCTCCCTCGCGCCATCAGTCGTATCTTCGGAGACCCTGT 
CCCTCACCTG 
GS FLX VH5-FR1 
(1)  
GCCTCCCTCGCGCCATCAGTCGTATCGGGGAGTCTCTGAA 
GATCTCCTGT 
GS FLX VH6-FR1 
(1) 
GCCTCCCTCGCGCCATCAGTCGTATTCGCAGACCCTCTCA 
CTCACCTGTG 
GS FLX JH 
Consensus (1)  
GCCTTGCCAGCCCGCTCAGTCGTATCTTACCTGAGGAGAC 
GGTGACC 
GS FLX VH1-FR1 
(2) 
GCCTCCCTCGCGCCATCAGTCGCGAGGCCTCAGTGAAGGT 
CTCCTGCAAG 
GS FLX VH2-FR1 
(2)  
GCCTCCCTCGCGCCATCAGTCGCGAGTCTGGTCCTACGCT 
GGTGAAACCC 
GS FLX VH3-FR1 
(2) 
GCCTCCCTCGCGCCATCAGTCGCGACTGGGGGGTCCCTGA 
GACTCTCCTG 
GS FLX VH4-FR1 
(2)  
GCCTCCCTCGCGCCATCAGTCGCGACTTCGGAGACCCTGT 
CCCTCACCTG 
GS FLX VH5-FR1 
(2)  
GCCTCCCTCGCGCCATCAGTCGCGACGGGGAGTCTCTGAA 
GATCTCCTGT 
GS FLX VH6-FR1 
(2)  
GCCTCCCTCGCGCCATCAGTCGCGATCGCAGACCCTCTCA 
CTCACCTGTG 
GS FLX JH 
Consensus (2)  
GCCTTGCCAGCCCGCTCAGTCGCGACTTACCTGAGGAGAC 
GGTGACC 
GS FLX VH1-FR1 
(3)  
GCCTCCCTCGCGCCATCAGACGTGCGGCCTCAGTGAAGGT 
CTCCTGCAAG 
GS FLX VH2-FR1 
(3)  
GCCTCCCTCGCGCCATCAGACGTGCGTCTGGTCCTACGCT 
GGTGAAACCC 
GS FLX VH3-FR1 
(3)  
GCCTCCCTCGCGCCATCAGACGTGCCTGGGGGGTCCCTGAGACTC
TCCTG 
GS FLX VH4-FR1 
(3)  
GCCTCCCTCGCGCCATCAGACGTGCCTTCGGAGACCCTGT 
CCCTCACCTG 
GS FLX VH5-FR1 
(3)  
GCCTCCCTCGCGCCATCAGACGTGCCGGGGAGTCTCTGAA 
GATCTCCTGT 
GS FLX VH6-FR1 
(3)  
GCCTCCCTCGCGCCATCAGACGTGCTCGCAGACCCTCTCA 
CTCACCTGTG 
GS FLX JH 
Consensus (3)  
GCCTTGCCAGCCCGCTCAGACGTGCCTTACCTGAGGAGAC 
GGTGACC 
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Appendix 2 – Patient Characteristics 
Population A  
A cohort of 270 unselected pre-treatment CLL patients. FCR - Fludarabine, 
cyclophosphamide and rituximab 
Characteristics Number of patients 
270 
Mean Age (years) 
 
63 (range 34-90) 
Gender  
Female 123 
Male 147 
Binet  
Stage A 195 
Stage B-C 75 
SSeq IgHV  
Unmutated 104 
Mutated 135 
Not known 31 
Treatment Status  
Required Treatment 122 
Did not require treatment 148 
Type of Treatment  
Chlorambucil alone/mini-CHOP/cyclophosphamid 50 
Fludarabine alone/cladribine/bendamustine/ 
fludarabine-cyclophosphamide 
25 
 Rituximab + bendamustine/chlorambucil/GA101/ 
CHOP/cyclophosphamide 
12 
FCR 
 
49 
Ibrutinib/lenalidomide/lumiliximab/alentuzumab 16 
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Population B 
 
A cohort of 250 pre-treatment CLL patients enrolled onto either the ARCTIC 
(Attenuated dose Rituximab with ChemoTherapy In CLL) or AdMIRe (Does the 
ADdition of Mitoxantrone Improve Response) trials. FCR - Fludarabine, 
cyclophosphamide and rituximab, FCMR - Fludarabine, cyclophosphamide, 
mitoxantrone and rituximab. 
 
Characteristics Number of patients 
250 
Mean Age (years) 
 
62 (range 33-80) 
Gender  
Female 68 
Male 182 
Binet  
Stage A 34 
Stage B-C 216 
SSeq IgHV  
Unmutated 120 
Mutated 92 
Not known 38 
TP53 status  
Mutated 20 
Not mutated 230 
Type of Treatment  
FCR 122 
FCMR 61 
 FCMminiR 53 
FCminiR/FCR 14 
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Population C 
A cohort of 94 unselected CLL patients. FC – Fludarabine and cyclophosphamide 
FCR - Fludarabine, cyclophosphamide and rituximab 
Characteristics Number of patients 
94 
Mean Age (years) 
 
67 (range 36-87) 
Gender  
Female 28 
Male 66 
Binet  
Stage A 19 
Stage B-C 
Not known 
36 
39 
SSeq IgHV  
Unmutated 33 
Mutated 22 
Not known 39 
TP53 status  
Mutated 17 
Not mutated 77 
Type of Treatment  
Chlorambucil 16 
Chlorambucil + rituximab/ofatumumab 3 
FC 12 
FCR 11 
Ofatumumab 1 
Alemtuzumab 1 
Chemotherapy refractory 18 
Unknown 15 
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Population D 
A cohort of 67 previously treated CLL patients enrolled in either the CLL201 trial (a 
randomized phase 2 trial of fludarabine, cyclophosphamide, and mitoxantrone 
with or without rituximab in previously treated CLL) or the CLL202 trial (a phase 2 
study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine 
refractory CLL). FCMR - Fludarabine, cyclophosphamide, mitoxantrone and 
rituximab, CamFlud – Combination alemtuzumab and fludarabine 
Characteristics Number of patients 
N=67 
Mean Age (years) 
 
64 (range 32-79) 
Gender  
Female 14 
Male 
Unknown 
53 
2 
Binet  
Stage A 9 
Stage B-C 
Not known 
28 
30 
SSeq IgHV  
Unmutated 20 
Mutated 14 
Not known 33 
TP53 status  
Mutated 19 
Not mutated 48 
No of Previous Treatments  
1 12 
>1 24 
Unknown 31 
Type of Treatment  
FCMR 19 
 FCMminiR 20 
CamFlud 29 
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Appendix 3 – NGS CLL panel 
The targeted TSCA NGS panel was designed by Pauline Robbe and Ruth Clifford 
and was designed to cover hotspots in the following genes: 
 
ATM 
BIRC3 
BCOR 
BRAF 
CDKN2A 
CHD2 
DDX3X 
EGR2 
FBXW7 
HIST1H1E 
IRF4 
ITPKB 
KLHL6 
KRAS 
MED12 
MYD88 
NOTCH1 
NRAS 
POT1 
PTEN 
RIPK1 
SAMHD1 
SF3B1 
TGIF1 
TP53 
XPO1 
ZFPM2 
ZMYM3 
 
